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Infection with high risk human papilloma viruses (HPVs) is directly associated with the 
occurrence and development of cervical cancer, however, currently there is no specific 
anti-HPV drug available for cancer treatment. Arsenic trioxide (ATO) has been shown 
to induce apoptosis in HPV-infected cervical cancer cells in vitro but its wider clinical 
applications have been compromised by its toxicity and poor pharmacokinetics. This 
research explores an optimized drug delivery system for ATO using liposomal 
nanotechnology with the aim of enhancing its potential as a cervical cancer treatment. 
The size and surface charge of liposomes were optimised and 100nm neutral liposomes 
demonstrated maximum stability, least intrinsic toxicity and highest loading efficiency 
among all the tested formulations. Furthermore, both free and chosen liposomal-ATO 
were exposed to two cervical cancer cell lines (HeLa and HT-3, with and without HPV) 
and control cells.  Liposomal-ATO was most effective in inducing toxic response in 
HPV+ ve HeLa cells, followed by HT-3 and control cells. These cells were then 
screened for different surface markers in order to identify the best ligand for selectively 
targeting HPV positive cells. Folate receptor (FR) was found as the most abundantly 
expressed receptor on HeLa cells, therefore, folic acid (FA) was chosen as the targeting 
ligand. FA-liposomal-ATO were synthesised by linking liposomal-ATO to FA using 
5000kDa PEG spacer, which was shown to be most efficient and specific in enhancing 
the cellular uptake of ATO in FR positive cells. Finally, FA-liposomal-ATO were 
examined for their effectiveness in reducing HPV oncogenes and the possible 
mechanisms. Results showed that FA-liposomal-ATO induced higher cell death in HPV 
cells than free ATO per unit arsenic and also demonstrated higher selectivity and 
efficiency in inducing cell apoptosis, downregulating oncogenes and upregulating the 
tumour suppressors in HPV positive cells. These findings provide a promising 
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Cervical cancer is responsible for 14% of all gynaecological related cancers in women 
(Lorusso et al., 2014). Although it is a theoretically preventable disease with effective 
screening programs in place for an early identification at its pre-cancerous stage, once 
the cancer progresses to metastatic or recurrent stage, the prognosis is appalling with 
one year survival rate between 15 and 20 percent and mortality rate reaches as high as 
50 percent (Lorusso et al., 2014). Moreover the lack of efficient screening programs or 
affordable treatment options in developing countries has resulted in cervical cancer 
being the most prevalent disease among women worldwide and with highest morbidity 
(Appleby et al., 2007). Cervical cancer is caused by an infection with HPV, its high risk 
types HPV-16 and HPV-18 accounting for 70% of all cervical cancers. Viral oncogenes 
E6 and E7 have been established to be the main contributors to the HPV induced 
cervical cancer as their protein products deregulate cell cycle machinery resulting in 
uncontrolled proliferation (Schiffman et al., 2007).  
 
During the early stages of invasive cancer, the most common treatment is surgery with 
chemoradiotherapy. This combination treatment of pelvic irradiation accompanied with 
weekly dose of cisplatin has the potential to treat 80-90% of women, albeit with some 
serious side effects (Ordikhani et al., 2016). Along with the debilitating effects of 
radiation, patients taking cisplatin suffers from the usual limitations of 
chemotherapeutic drugs including development of tumour resistance, bone marrow 
depression and haematological toxicity which leads to neutropenia, thrombocytopenia, 
neurotoxicity, nephrotoxicity and anaemia (Ordikhani et al., 2016). This necessitates the 
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need to explore the efficacy of other drugs to treat cervical cancer and a means of 
increasing their therapeutic index in vivo by delivering the drug specifically to the target 
cells sparing normal cells.  
 
As HPV has been established as the causal agent of cervical cancer, our main aim was 
to specifically explore an anti-HPV agent (Schiffman et al., 2007). Among the drugs, it 
has been reported that ATO downregulates HPV E6 oncoprotein and reduces survival of 
HPV-18 HeLa cells (Wen et al, 2012). ATO is a broad spectrum anti-cancer drug with 
its therapeutic applications dating back to more than 2400 years when it was used in 
traditional Chinese medicine (Evens, Tallman and Gartenhaus, 2004). Discovery of its 
anti-leukemic properties is fairly recent which was initiated by a group of Chinese 
physicians from Harbin Medical University and Shanghai Second Medical University. 
Through careful clinical trials, they tested its effectiveness on patients of acute 
promyelocytic leukemia (APL). The highly positive results, duplicated with the success 
in United States, led to the approval of ATO by Food and Drug Administration (FDA) 
as the front line therapy for APL in 2000 (Antman, 2001). Similar clinical successes 
were subsequently translated for other haematological malignancies. However, when its 
efficacy was tested for solid tumours, ATO did not exhibit appreciable clinical success 
on human patients. Rapid clearance of arsenic and its products from the blood by 
reticuloendothelial system limits the therapeutic dose reaching the tumour site
 
(Swindell 
et al., 2013). Escalating arsenic dosage could not be an alternative as it led to systemic 
toxicities such as long term memory damage, liver failure, cardiac failure and peripheral 
neuropathy
 
(Swindell et al., 2013). Hence, to utilise its considerable anti-cancer 
properties for solid tumours, specifically cervical cancer, it was crucial to increase the 
drug’s therapeutic index while sparing the surrounding healthy tissues from arsenic 
toxicity. Such an alluring goal seemed possible with the application of nanotechnology 
in the field of drug delivery.   
 
Nanotechnology based drug delivery systems can specifically target cancer cells while 
avoiding direct contact with their healthy neighbours. In addition, they can prevent 
rapid clearance of the drug from the body and hence considerably increase the drug’s 
therapeutic index (Bosch et al., 2002; Ordikhani et al., 2016). Among the many 
nanocarriers discovered till date, the oldest and most commonly employed nanoparticles 
are liposomes. Liposomes are spherical vesicles of phospholipid bilayer with an 
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aqueous core; the core can encapsulate water soluble drugs and the bilayer has the 
potential to entrap lipid soluble drugs (Narisawa‐Saito et al., 2007). Achieved with the 
capacity to passively target tumour tissue and ease of surface modification where 
ligands can be attached complimentary to cancer cell specific receptors on their surface, 
liposomes can prove to be the ideal candidates to entrap anti-cancer drugs and target 
tumour tissue (Doorbar, 2005).  
 
In this study, I have applied nanoparticulate formation process to encapsulate ATO in 
robust, pH responsive, targeted liposomes to deliver ATO specifically to HPV infected 
cervical cancer cells in vitro. The specificity and efficacy of the formulated nano-carrier 
on target cells have been examined and compared with the free drug. Additionally, by 
elucidating the molecular mechanism involved behind the action of ATO delivered via 
these different routes, the best delivery method has been selected for ATO to target 














1.2 LITERATURE REVIEW 
 
 




Cervical cancer is the second most common cancer among women worldwide (Bosch et 
al., 2002). It was responsible for half a million reported incidence cases and 266,000 
consequent deaths worldwide in 2012 (Ferlay et al., 2015). Although this cancer can 
potentially be prevented by efficient routine screening programs and treatment of pre-
cancerous lesions, it is still the most prevalent female cancer in developing countries, 
where 80% of the cases occur (International Collaboration of Epidemiological Studies 
of Cervical Cancer, 2006). The principle cause of this high mortality is attributed to the 
lack of screening and available treatment options in low-resource countries along with 
extremely low survival rates of women diagnosed with advanced cancer (Ordikhani et 
al., 2016).   
During the 1990’s, it was established with undisputed epidemiological studies, 
augmented by molecular technology, that cervical cancer is caused by an infection of 
certain mucosatropic strains of HPV (Bosch et al., 2002; Walboomers et al., 1999). This 
association was assessed under all sets of causality criteria and the presence of 
universally consistent results eliminated alternative hypothesis for aetiology of cervical 
cancer (Bosch et al., 2002; Walboomers et al., 1999). This proved to be a major 
discovery as HPV was proposed to be the first ever described “essential cause” of 
human cancer and its association as significant as that between Hepatitis B or C virus 
infection with the risk of liver cancer or cigarette smoking with lung cancer 
development (Bosch et al., 2002). Clinical and epidemiological investigations imply 
cervical cancer to exhibit the profile of a sexually transmitted disease (STD) where the 
cancer develops several years after HPV infection (Bosch et al., 2002).   
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Owing to its principle role in virtually all cases of cervical cancer, HPV is now 
essentially regarded as its necessary though insufficient cause (Schiffman et al., 2011). 
Over the decades, many factors were attributed to the aetiology of cervical cancer 
including infectious agents for STD such as syphilis, gonorrhoea and type-2 herpes 
simplex virus (Bosch et al., 2002). The establishment of HPV as the necessary cause of 
cervical cancer eliminated their possibility of being causal agents along with certain 
previously ill-defined behavioural and demographic factors including low socio-
economic status of women, smoking, multi-parity and use of oral contraceptives, which 
are now recognised as pertinent co-factors that may be relevant only in the presence of 
HPV DNA (Bosch et al., 2002; International Collaboration of Epidemiological Studies 
of Cervical Cancer, 2006; Smith et al., 2003).  
 
1.2.1.2 Human papilloma virus 
 
HPV primarily infects epithelial cells and can be responsible for a variety of epithelial 
lesions including common warts, genital condyloma, verrucas and laryngeal papillomas 
(Doorbar, 2007). The HPV family includes more than 100 HPV types and 40 of them 
can infect the cervix (Doorbar, 2007). Most of them belong to alpha and beta genus with 
the two groups having noticeably different biology and life cycle patterns (Bosch et al. 
2002; Doorbar, 2007). Of them, the alpha PVs infect humans and primates and are 
divided into cutaneous and mucosal types (Doorbar et al., 2012). These mucosal types 
are further subdivided into high risk and low risk types according to their presence in 
the malignant lesions of cervix, with the high risk types linked to almost 95% of 
cervical cancer cases (Bosch et al. 2002; Doorbar, 2007; Munoz et al., 2003; Narisawa-
Saito and Kiyono, 2007). HPV-16 and HPV-18 account for 50% and 20% respectively 
of the viral types involved in invasive cancer (Doorbar, 2007). In addition to these, 
International Agency for Research on Cancer has classified HPV type- 31, 33, 35, 39, 
45, 51, 52, 56, 58 and 59 as human carcinogens (Bosch et al. 2002; Munoz et al., 2003). 
Fundamentally, all HPV types produce warty lesions but for them to progress into 
invasive cancer, infection with high risk HPV type is essential (Bosch et al. 2002). 
Substantial evidence suggests the involvement of HPV in considerable other cancers of 
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genital tract (such as penis, anal canal, vulva, vagina and perianal skin) and cancers of 
skin and oropharyngeal tract (Bosch et al. 2002). Continuous presence and expression 
of high-risk HPV is found to be essential for development, maintenance and progression 
of invasive cervical cancer (Bosch et al. 2002).  
 
1.2.1.3 Fundamentals of HPV virology 
 
HPV has a single stranded, circular DNA of 8000 base pairs encoding 8 genes E1, E2, 
E4-E7, L1 and L2 (Fig 1.2.1) (Schiffman et al., 2007). The E and L designation is 
according to their expression during the early or late stage of epithelium differentiation 
(Schiffman et al., 2007). L1and L2 proteins assemble to form icosahedral viral capsid 
whereas the early proteins are responsible for viral DNA replication and virus assembly 
(Doorbar, 2007; Munoz et al., 2006; Schiffman et al., 2007). There is an upstream 
regulatory region (URR) of around 1000bp separating both the gene sets which has 
binding sites for transcriptional activators and repressors, such as activating protein 1 
(AP 1) and nuclear factor 1 (NF 1), necessary for gene expression, replication and 






Fig 1.2.1: Schematic representation of HPV genome, displaying the arrangement of early and late (E and 
L) genes along with upstream regulatory region (Munoz et al., 2006). 
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The life cycle of HPV is perfectly adapted to its host cell biology (Narisawa-Saito and 
Kiyono, 2007). The basal layer of normal squamous epithelium divides like stem cells, 
where one of the daughter cells migrates upward and starts to undergo terminal 
differentiation (Narisawa-Saito and Kiyono, 2007). The other daughter stays in the basal 
layer and gives rise to a slow-cycling population (Narisawa-Saito and Kiyono, 2007). 
HPV virus establishes its infection at the basal layer of epithelium where it enters into 
the cells through micro-wounds (Munoz et al., 2006). Infecting an epithelial stem cell is 
hypothesised to be crucial for maintaining the infection (Doorbar, 2005). During the 
initial phase of HPV cell cycle, genome is maintained by expression of early proteins 
E1 and E2, in low episomal copy numbers, i.e. 25-50 genome copies per cell (Bosch et 
al. 2002; Munoz et al., 2006; Schiffman et al., 2007). As the basal epithelium 
differentiates and is propelled to the suprabasal compartment, there is a shift in the viral 
genome expression from early to late genes with viral life cycle subsequently going 
through successive stages of amplification, virus assembly and release (Schiffman et al., 
2007). The release of viral progenies into the environment re-initiating the infection 
makes use of the natural disintegration of epithelial cells at the superficial layers (Fig 











Fig 1.2.2: Infection of HPV virus and the role of the encoded genes in carcinogenesis. Initially, HPV 
infects basal cells of the tissue where replication of viral DNA takes place without the formation of 
virions. In the upper layer when the cells differentiate, capsid proteins formation co-ordinates with the 
viral genome replication leading to formation of virus particles that are released to infect new host cells 
(Narisawa-Saito and Kiyono, 2007). 
 
 
1.2.1.4 Carcinogenesis of HPV E6 and E7 oncoproteins 
 
The critical molecules responsible for HPV oncogenesis are viral proteins, E6 and E7 
(Schiffman et al., 2007). These viral proteins of the high risk types are capable of 
inactivating two key cell cycle regulatory molecules, namely p53 and retinoblastoma 
tumour suppressor protein (pRb) respectively, hence overcoming the safeguard arrest 
response (Bosch et al. 2002; Magaldi et al., 2012; Narisawa-Saito and Kiyono, 2007; 
Schiffman et al., 2007). Inactivation of p53 by E6 results in apoptosis inhibition and 
pRb deactivation by E7 abrogates cell cycle arrest (Schiffman et al., 2007). Together, 
they are known to cause polyploidy in cells and deregulation of genes responsible for 
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G2/M phase transition in cell cycle and consequent progression to mitosis (Fig 1.2.3) 





Fig 1.2.3: Carcinogenesis of E6 and E7 oncoproteins (Narisawa-Saito and Kiyono, 2007). 
 
 
The primary transforming activity of E7 lies in its binding to pRb and disrupting its 
association with E2F family of transcription factors (Doorbar, 2007). The E2F 
subsequently gets released and activates host cell and viral DNA synthesis (Bosch et al. 
2002). E7 also binds and activates cyclin complexes such as cyclin A and E which are 
responsible for cell cyclin progression (Bosch et al. 2002). Other molecules that E7 is 
known to associate with and inhibit are cyclin dependent kinase inhibitors p21 and p27 
which are known to stall the cells in a pre-S phase and hence prevent the E7 mediated 
cell proliferation (Doorbar, 2007). 
 
Another crucial cell cycle negative regulatory molecule is a tumour suppressor protein 
p53, which is activated upon phosphorylation by DNA damage sensing proteins (Bosch 
et al. 2002; Werness, Levine and Howley, 1990). Upon activation, it arrests the cell 
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cycle in G1-phase and DNA repair is induced (Narisawa-Saito and Kiyono, 2007). 
However on encountering heavy DNA damage, p53 may induce the cell apoptotic 
pathways (Bosch et al. 2002). E6 is responsible for the ubiquitin mediated proteasome 
dependent degradation of p53 and therefore, its deactivation compromises the cellular 
DNA damage response, causing secondary mutations to accumulate as a result 
(Doorbar, 2007). It also interferes with other pro-apoptotic proteins including pro-
caspase 8, Bak and FADD (Narisawa-Saito and Kiyono, 2007).  
 
Even in the absence of E7, E6 might mediate cell proliferation by binding to PDZ 
structural domain through its C-terminal leading to its degradation (Doorbar, 2007). 
Proteins in the PDZ domain are involved in a variety of cellular functions including 
cellular adhesion and cell signalling (Narisawa-Saito and Kiyono, 2007). This binding 
disrupts the normal cell to cell contact as a result of the loss of cell polarity, eventually 
leading to the development of metastatic tumours (Doorbar, 2007).  
 
Another important molecule which is activated by E6 and eventually plays a significant 
role in the immortalisation of HPV infected cells is telomerase (Bosch et al. 2002; 
Doorbar, 2007). Human telomerase is a ribonucleoprotein whose function is to stabilise 
telomere length and hence suppress senescence (ageing) (Narisawa-Saito and Kiyono, 
2007). Shortening of telomere below a certain critical length triggers cell death (Bosch 
et al. 2002). Since telomerase is not active in normal somatic cells, telomeres shorten 
with each cell generation and eventually senescence is induced due to incomplete 
lagging DNA strand synthesis and end-processing events (Narisawa-Saito and Kiyono, 
2007). E6 activates the catalytic subunit of telomerase hTERT (human telomerase 
reverse transcriptase) which induces the addition of hexamer repeats to the telomeric 
ends, henceforth maintaining and stabilising telomere length, causing the cells to 
continue dividing indefinitely (Bosch et al. 2002; Doorbar, 2007). 
 
There are several other cellular proteins which have been reported to be targets of HPV 
E6 and E7 oncoproteins including AP-1, p21, p27, p600, p300/CBP, Tyk 2, Bak, c-myc, 
hAda3, Mi2, MPP2, NuMa, Epoc-1 and TBP (Peralta-Zaragosa et al., 2012). Hence, 
apart from the cell cycle control deregulation and apoptosis inhibition, E6 and E7 exert 
their influence on immune response escape, angiogenesis associated and independent 
cell proliferation processes (Peralta-Zaragosa et al., 2012). Together, this results in HPV 
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effectively immortalising human keratinocytes and transforming them into malignant 
phenotypes (Peralta-Zaragosa et al., 2012).  
 
1.2.1.5 Development of cervical cancer 
 
Cervical cancer is primarily the culmination of decade long process which starts with an 
infection with carcinogenic HPV virus (Schiffman et al., 2011). The initial phase is 
referred to as Stage 0, when abnormal cells with potential to become cancerous can be 
found in the innermost lining of the cervix (also called cervical intraepithelial neoplasia 
CIN) (McConville, 2015). Left untreated it can progress to Stage 4, where cancer finally 
spreads to bladder or other parts of the body (McConville, 2015). In its final stages, it is 
marked by persistent high risk HPV type infection, upregulated viral gene expression 
leading to uncontrolled cell proliferation and poor DNA damage control with mutations 
accumulating in the infected cells (Doorbar et al., 2012).  
Cervical cancer develops while progressing through four primary stages: 1) HPV 
infection at the ring of squamous metaplastic epithelium referred to as the cervical 
transformation zone, 2) persistence of the infection, 3) progression of infected 
epithelium to precancer and 4) invasive cancer as the final stage (Schiffman et al., 
2007). The cervical transformation zone is the site where stratified non-keratinising 
squamous cells of ectocervix meet the columnar cells of endocervix (Doorbar, 2007). 
This is the most significant cytological and colposcopic site as it is highly susceptible 
for high risk HPV infections and is where more than 90% of genital neoplasia arise (Fig 








Fig 1.2.4: Life Cycle of High risk HPV (Doorbar, 2007). The six early open reading frames (E1, E2, E4, 
E5, E6 and E7) are expressed from early P97 (PE) or late P670 (PL) promoters during epithelial cell 
differentiation. The late open reading frames (L1 and L2) are also expressed from PL. This is followed 




At the site of erosion, the virions enter the basal and parabasal cells and viral DNA 
enters the cellular nuclei (Bosch et al., 2002). Molecular studies suggest that in many 
HPV associated cancers, there is an evidence of integration of HPV DNA into the 
cellular DNA (Bosch et al., 2002). In addition to the integrated form, HPV-16 can also 
be found episomally (Bosch et al., 2002; Cullen et al., 1991). Integration of viral DNA 
with cellular DNA results in constant levels of E6 and E7 proteins expressed via 
stabilisation of mRNA (Munoz et al., 2006). The consequence might be a deep-rooted 
presence of viral genome in the cells, the resulting infection persisting for even decades 
(Munoz et al., 2006; Schiffman et al., 2007). In such cases, it has an increased chance to 
develop into invasive cancer (Bosch et al. 2002). Although mostly, continued 
transcription of HPV oncogenes, instead of genome integration, is necessary for cancer 
development (Schiffman et al., 2007).  
 
Long persistent infection with high risk HPV types give rise to cervical dysplasia or 
CIN which develops into cervical cancer (Narisawa-Saito and Kiyono, 2007). CIN I and 
CIN II lesions exhibit mild and moderate dysplasia respectively where the viral DNA is 
mostly in the episomal conformation whereas CIN III lesions displaying severe 
dysplasia develop when HPV DNA integrates into host DNA and this stage might 
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represent carcinoma in situ (Narisawa-Saito and Kiyono, 2007; Peralta-Zaragosa et al., 
2012). 
 
Although there is a high risk of HPV infections in approximately 80% of productive 
women, most HPV infections clear within 1-2 years of exposure by cell mediated 
immunity (Schiffman et al., 2007). The persistence of infection decreases the 
probability of its subsequent clearance over a period of time and thereby, increases the 
risk of cancer development (Fig 1.2.5) (Schiffman et al., 2007). In-vitro experiments 
have revealed that as the HPV infection progresses to cervical neoplasia, there is a 
reduced ability in such women to mount a T-helper cell type immune response against 













The primary prevention of cervical cancer which could reduce incidence of the disease 
at population level could be in the form of health education programs promoting 
abstinence before marriage or stringent use of condom (Schiffman et al., 2007). 
However, the issue of practicality with such measures necessitate the importance of 
developing other techniques. In developed countries, there are currently two primary 
methods to prevent cervical cancer: 1, administration of HPV vaccines to prevent 
adolescent girls from getting infected and 2, screening for abnormal cells in cervix 
which can potentially be pre-cancerous (McConville, 2015).  
(i) Vaccines: A major breakthrough in formulating vaccines against HPV infection was 
the development of HPV L1 virus like particles (VLP) vaccines (Harro et al., 2001). 
When self-assembled L1 protein in non-infectious capsid containing no genomic 
material was injected intra-muscularly, it induced the formation of fifty times higher 
titres of neutralising antibody than in normal infection (Harro et al., 2001). This could 
lead to protection against subsequent infections (Soliman, Slomovitz and Wolf, 2004). 
Two VLP prophylactic vaccines, Gerdasil (Merck and Co, USA) and Cervarix 
(GlaxoSmithKline, Belgium) have been developed targeting HPV-16 and HPV-18 and 
are commercially available (Inglis, Shaw and Koenig, 2006). Apart from VLP based 
vaccines, other forms of HPV vaccines formulated and tested in clinical and preclinical 
trials are peptide based vaccines, proteins based vaccines, DNA based vaccines, cell 
based vaccines and vector based vaccines (Soliman, Slomovitz and Wolf, 2004). 
However, current HPV vaccines do not treat existing HPV infections or lesions 
(Schiffman et al., 2007). Moreover, the very high costs associated with the vaccines 
have precluded their introduction to low-resource countries (Arbyn et al., 2011).  
 
(ii) Screening: The various procedures employed for screening for HPV induced 
lesions are: direct visual inspection, visual inspection employing 3%-5% acetic acid, 
visual inspection using acetic acid and magnification, visual inspection using Lugol’s 
iodine, cervical cytology, HPV DNA screening and speculoscopy (Aggarwal, 2014). 
The two most commonly used screening procedures are described below.  
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Cervical cytology with Papanicolaou (Pap) Tests: The major screening target for 
cervical cancer is treatable CIN II or CIN III lesions, rather than invasive cancer where 
the morbidity is high and chances to succeed are low (Schiffman et al., 2011). In this 
approach, exfoliated cells are analysed for presence of any biomarkers suggesting an 
underlying risk of cancer (Schiffman et al., 2011). Unfortunately, the sensitivity of Pap 
test is as low as 50-60% with an implication that a single negative Pap test is not 
definitive in itself but requires repeated rounds of screening to detect developing CIN 
lesions (Schiffman et al., 2011). Despite this fact, a negative smear does indicate a 
substantially lowered risk of cervical cancer for multiple years (Gustaffson et al., 1997; 
Schiffman et al., 2011). These cytology based cervical cancer screening for detecting 
and treating pre-cancerous lesions at early stage have considerably reduced the 
incidence and mortality associated with this disease (Schiffman et al., 2007).  There is 
still an increasing demand to have stronger reassurance of safety when detecting the risk 
of cervical cancer, calling for other screening techniques (Schiffman et al., 2011).  
 
HPV DNA Screening: Screening for carcinogenic HPV DNA has proven to be more 
cost effective and sensitive in detecting pre-cancerous lesions than cytology-based 
methods where the results might be equivocal (Schiffman et al., 2007). Moreover, 
testing negative for HPV DNA is a conclusive evidence of no risk of developing 
cervical cancer (Schiffman et al., 2007). Currently there are two methods primarily 
employed to detect carcinogenic HPV: 1) genome amplification using polymerase chain 
reaction (HPV DNA Nested Polymerase Chain Reaction Detection Kit
TM
) and 2) 
hybridisation with signal amplification (Digene Hybrid Capture 2 High Risk HPV DNA 
Test
TM
; Cervista HPV HR Test
TM
) (Aggarwal, 2014; Schiffman et al., 2011). A major 
trade-off with HPV testing is while it has high sensitivity, it is limited on specificity 
(Aggarwal, 2014). It does not have the analytical specificity to decide which lesion 
would develop in cancer and which infection would regress taking its usual route 





1.2.1.7 Treatment:  
 
Cervical cancer is treated according to its stage of progression (Ordikhani et al., 2016). 
The women who are screened positive for pre-cancerous lesions have their entire 
transformation zone excised that is thought to contain CIN III lesions (Schiffman et al., 
2011). Usually, fertility sparing treatments such as cryotherapy and cone shaped 
excision are employed instead of hysterectomy (Schiffman et al., 2007). A small 
amount of cervical stroma is removed with loop electrosurgical excision procedure 
(LEEP) or large loop excision of the transformation zone (LLETZ) in an outpatient 
setting with local anaesthesia (Schiffman et al., 2007). In the situation where a larger 
tissue section has to be excised, cold knife cone is employed (Schiffman et al., 2007). In 
low-resources areas, cryotherapy is preferred as it does not require anaesthesia or 
electricity and the use of carbon dioxide instead of nitrous oxide can further reduce the 
expenses (Schiffman et al., 2007). However, blockage of equipment and poor depth of 
tissue necrosis are few of the technical issues that need to be addressed for this 
technique to be employed effectively (Schiffman et al., 2007).   Moreover, 
colposcopically guided biopsy and histological diagnosis suffer from poor performance 
as they typically concentrate on removing the most obvious lesion on visual inspection 
(Schiffman et al., 2011). This practice might fail to remove more than one third of the 
HPV positive CIN III lesion (Schiffman et al., 2011). Photodynamic therapy using 
photosensitising drug 5-aminolaevulinic acid was employed to treat cervical 
intraepithelial neoplasia in clinical trials; however it proved to be unsuccessful (Barnett 
et al., 2003).  
For the treatment of invasive cancers, radical hysterectomy has been the preferred 
treatment (Schiffman et al., 2007). However, for tumours smaller than 2cm size, two 
modalities are most commonly employed for younger women where future pregnancy is 
desired: radical vaginal trachelectomy with laparoscopic lymphadenectomy or sentinel 
lymph node biopsy and radical abdominal trachelectomy with pelvic lymphadenectomy 
(Downs, 2011; Schiffman et al., 2007). Early stage cancer is mostly treated with surgery 
and chemoradiotherapy which has the potential to cure 80-90% of women (Peralta-
Zaragosa et al., 2012). Initially, pelvic radiation was the standard treatment for 
advanced cancer as the principle cause of death among women was the uncontrolled 
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disease within the pelvis (Thomas, 1999). However, radiation dose was a severe 
limiting factor due to numerous late complications with this treatment (Thomas, 1999). 
For this reason, strategies involving combination therapy, particularly pelvic irradiation 
with concurrent chemotherapy was considered and that proved to be very effective for 
locally advanced stage cancer patients, with the mean survival rate increasing from 58 
percent to 73 percent (Ordikhani et al., 2016).  
Typically pelvic tumours are treated with weekly dose of cisplatin administered 
intravenously along with external beam irradiation and brachytherapy, the latter 
profiting from the easy accessibility of cervix where implants for brachytherapy can be 
placed non-invasively (Kang et al., 2015; McConville, 2015; Thomas, 1999). Among 
the chemotherapeutic drugs including cisplatin, paclitaxel, carboplatin, ifosfamide and 
toptecan employed for the treatment of advanced cervical tumour, cisplatin with 
response rate ranging from 20-30% and overall survival of 7 months, is documented to 
be the most active and effective drug (Downs Jr et al., 2011; Katanyoo et al., 2011; 
Leisching et al., 2015; Muderspach et al., 2001; Wang et al., 2015). Cisplatin is known 
to directly interact with DNA forming adducts, consequently inhibiting its transcription 
along with inducing oxidative stress and apoptosis in cancer cells (Ordikhani et al., 
2016). However, it suffers from the usual limitations of platinum containing 
chemotherapeutic drugs such as development of tumour resistance along with serious 
side effects, essentially bone marrow depression and haematological toxicity which 
leads to neutropenia, thrombocytopenia, neurotoxicity, nephrotoxicity and anaemia 
(Jones, 2009; Ordikhani et al., 2016).  
To increase the efficacy of the treatment, paclitaxel was used together with cisplatin and 
this combination treatment was better than the cisplatin monotherapy in terms of 
progression free survival and response rate (45-50%) although not overall survival 
(Cadron et al., 2007; Moore et al., 2004). When compared with other cisplatin 
combinations with Gemcitabine, Topotecan and Vinorelbine, none of them were as 
effective as the one with paclitaxel (Lorusso et al., 2014). However, prior to this could 
be routinely used as the new standard of care in advanced cervical cancer patients, the 
related toxicity and the discomfort associated with giving paclitaxel as a 24 h infusion 
made this combination impractical to be used as the cancer treatment (Lorusso et al., 
2014). Some studies suggested that in this context, carboplatin, with its better toxicity 
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profile, higher tolerance, and with the ability to administer it in outpatient settings, 
made this a suitable substitute to cisplatin in combination treatments (Lorusso et al., 
2014). Some studies have shown that cisplatin and gemtabicine acts synergistically on 
cancer cells both in vitro and in vivo and some demonstrate that combination of 
topotecan and cisplatin improves the overall survival to 9.4 months (Cadron et al., 
2007). However, the lack of detailed toxicity data, quality of life data and many other 
factors, which are still unknown issues, could affect the clinical outcomes of cervical 
patients (Lorusso et al., 2014). 
In cases where metastasis has not yet taken places, localised delivery of 
chemotherapeutic drugs holds several benefits such as less drug waste, diminished side 
effects and transport of high dose of drug at the active site of cervix (Ordikhani et al., 
2016). Localised delivery of chemotherapeutics is possible due to the accessible 
location of cervix through the vagina (Ordikhani et al., 2016). Different drug 
formulations, gels, fibres, rings and tablets, delivered through vagina to treat bacterial or 
fungal infections or STDs are also being studied to deliver chemotherapeutic drugs to 
the cervix (McConville, 2015; Ordikhani et al., 2016). Such a localised delivery system 
may help the patient to recover more quickly, have a better control over the dosage 
delivered and reduce the burden on hospitals and overall global healthcare costs 
(Ordikhani et al., 2016). When the cancer progresses to metastatic stage or becomes 
recurrent however, the survival rate becomes extremely low and is a major cause of 
high mortality (Peralta-Zaragosa et al., 2012). Therefore much effort is being directed 
on developing new drugs or searching for alternative approaches such as gene therapy 
or nanotechnology which would treat cervical cancer in cases where traditional 







1.2.1.8 Limitations:  
 
The incidence of procuring an HPV infection and consequent development into cervical 
cancer depends on the average societal age of first sexual intercourse and the efficiency 
of screening programs. The young age at death, where women are still raising their 
families, further accentuates the importance of detecting/ treating this disease 
(Schiffman et al., 2007).   
Among other cancers, the screening program for cervical cancer is most effective 
(International Collaboration of Epidemiological Studies of Cervical Cancer, 2006). 
However, cytology based cervical cancer screening requires skilled human resources, an 
infrastructure in place and quality assurance, which are mostly not available in 
developing countries (Arbyn et al., 2011). Due to this inadequate or non-existent 
screening and unaffordable or absent standard treatment options, the mortality rate is the 
highest among women with cervical cancer (Schiffman et al., 2007). VLP vaccines are 
not a viable form of treatment for women who are already exposed to and infected with 
HPV (Duncan, Eckert and Clawson, 2009). Moreover, these vaccines are still not 
available or affordable in less developed countries where this vaccine is most needed 
(Duncan, Eckert and Clawson, 2009). Another problem with screening for HPV-16 and 
HPV-18 lies with the fact that these two accounts for only 70% of cervical cancer cases 
and at least 13 other high risk HPV types exist (Duncan, Eckert and Clawson, 2009). 
Therefore, despite the progress made in the field, persistent HPV infections still pose a 
serious health problem stipulating the importance of research in finding alternative 
treatment/ preventative options (Duncan, Eckert and Clawson, 2009).   
 
There are other points of concern for the available screening programs. Since the site of 
pre-cancer might not necessarily be the exact site of subsequent cancer development, 
the commonly performed biopsies of colposcopically derived tissues might inaccurately 
give negative histopathological results rejecting the presence of a possible pre-cancer 
(Schiffman et al., 2007). Moreover, unlike HPV-16, HPV-18 mostly doesn’t produce 
the high-grade squamous intraepithelial lesions which might be a reason of poor 
screening performance for endocervical and glandular lesions with an increased 
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incidence of HPV-18 related adenocarcinomas as a consequence (Schiffman et al., 
2007).  
 
With the treatment strategies available as well, the most prevalent treatment of surgery 
and chemoradiotherapy results in serious side effects, including bone marrow 
depression and haematological toxicity along with development of tumour resistance to 
the drug. Moreover, radiation therapy has its own limiting drawbacks and when the 
cancer develops to an advanced stage and metastasizes, the mortality rate becomes 
insurmountably high. For these reasons, there is a necessity of exploring the efficacy of 
other established drugs against cervical cancer and a means of increasing their 
therapeutic index in vivo by delivering the drug specifically to the target cells sparing 
normal cells. ATO is one such drug that has established itself as a broad spectrum anti-
cancer drug and has also shown efficacy against cervical cancer cell lines by 
downregulating HPV E6 oncogenes and reducing the survival of cancer cells. 
Equipping it with nanotechnology based drug carriers presents us with an attractive 
approach in our quest for finding a novel, non-invasive, affordable and fertility sparing 
treatment option for cervical cancer. 
 
 
1.2.2 Arsenic Trioxide 
 
 
Arsenic is a naturally occurring metalloid found as a trace element in the earth’s crust 
(Shen et al., 2013). Instead of being present in its elemental state; it exists as highly 
toxic arsenates of metals like calcium, sodium and potassium or as oxides and 
sulphides. Among its three inorganic forms of red, yellow and white arsenic, the latter is 
ATO which is industrially produced as a by-product while roasting arsenic containing 
ores and purifying the smoke (Fig 1.2.6) (Miller et al., 2002).
 
The rise of ATO from its 
reputation of “king of poisons” to a “broad spectrum anti-cancer drug” is among the 






Fig 1.2.6: structure of ATO (Platanias, 2009) 
 
Despite being the mainstay of materia medica for over 2400 years, arsenic faced a 
decline in its use as a therapeutic agent in the twentieth century due to an increasing 
awareness of its toxicity (Evens, Tallman and Gartenhaus, 2004). The resurgence of 
ATO transpired when a group of Chinese physicians realised its presence in ancient 
Chinese medicine as the main anti-leukemic agent and decided to evaluate its potency 
on patients with APL, a subtype of acute myeloid leukemia. The following clinical trials 
of ATO on APL patients as a single agent or in combination with conventional 
chemotherapy yielded highly encouraging results. ATO was consequently approved by 
FDA as a frontline therapy for APL in 2000 (Antman, 2001).
 
The same kind of clinical 
success was translated for other haematological malignancies as well although not for 
the solid tumours. Rapid clearance of arsenic and its products from the blood by 
reticuloendothelial system limits the therapeutic dose reaching the tumour site. 
Escalating arsenic dosage could not be an alternative as it led to systemic toxicities such 
as long term memory damage, liver failure, cardiac failure and peripheral neuropathy 
(Swindell et al., 2013).  
The enigma of arsenic with its carcinogenic and anti-carcinogenic effects may very well 
be related to the length (chronic vs acute), level (high dose vs low dose) and type 
(arsenite/ arsenate/ methylated species) of arsenic exposure. Several attempts have been 
carried out to utilise arsenic’s significant anti-cancer properties for treating solid 
tumours by reducing its administered dosage while increasing its bioavailability and 
specificity. This includes employing ATO with other conventional chemotherapeutic 
agents to explore their synergistic actions, sensitising the cells prior to ATO treatment 
or employing nanotechnology to increase bioavailability of arsenic while reducing its 
systemic toxicity (Akhtar et al., 2017).  
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1.2.2.1 Arsenic history: renown, decline and resurgence 
 
Arsenic presents a rich history in medicine with its therapeutic applications dating back 
to more than 2400 years (Waxman and Anderson, 2001). Nicknamed as the “therapeutic 
mule” for its widespread use in a variety of ailments, the tenacity of it being used 
despite the inconsistent toxicity associated with this compound, arsenic remains one of 
the most popular drugs of the material medica (Miller et al., 2002).  
For thousands of years, arsenic has been used in traditional Chinese medicine to treat 
syphilis, psoriasis, rheumatism and to devitalise inflamed pulp tissue of the diseased 
teeth prior to dental work (Waxman and Anderson, 2001). Hippocrates used arsenic 
sulphides, orpiment (As2S3) and realgar (As4S4), as escharotics to treat ulcers and skin 
and breast cancers while Dioscorides administered orpiment as a depilatory (Waxman 
and Anderson, 2001). Centuries later, Angelus Salva administered arsenic against 
plague, Jean de Gorris used it as a sudorific and Lentilius recommended it as a cure for 
malaria (Miller et al., 2002).
 
Arsenides and salts, observed to be more therapeutic than 
the pure, metallic arsenic, found diverse uses as anti-spasmodics, anti-pyretics, anti- 
periodics, caustics, sedatives, hematinics and tonics (Haller, 1981). Among the 60 
different therapeutic preparations of arsenic in the course of its illustrious history, 
twenty were still prevalent at the turn of 19
th
 century including Andrew’s tonic, 
Arsenauro, Aiken’s Tonic Pills and Gross’s neuralgia pills (Haller, 1981).  
Until the 17
th
 century, the application of arsenic salts and sulphides was generally 
external. However, physicians soon found that boiling arsenous acid with an alkali gave 
water soluble solution could be administered internally. In 1780’s, Thomas Fowler 
became intrigued with the “Tasteless Ague Drops” which was a popular anti-periodic 
remedy of the time and decided to imitate the preparation (Haller, 1981). The resulting 
solution of ATO in potassium bicarbonate (1%w/v), named Fowler’s solution, quickly 
earned great fame for its efficacy in treating  rheumatism, Hodgkins disease, pernicious 
anaemia, psoriasis, epilepsy, eczema, paralysis, heart palpitations, convulsions, syphilis, 
ulcers and cancer (Miller et al., 2002; Waxman and Anderson, 2001).  Paul Ehlrich, 
founder of chemotherapy, further experimented with properties of arsenic and in 1910, 




known as Salvarsan or compound 606, it remained the mainstay treatment for syphilis 
for 40 years before being replaced by penicillin (Miller et al., 2002). It was also used to 
treat African trypanosomiasis, the sleeping sickness (Aronson, 1994). 
Although arsenic and its anti-cancer properties were known way back in the empirical 
era of therapeutics, its anti-leukemic activity was first reported in 1878. ATO in the 
form of Fowler’s solution caused a drastic decline in white blood counts in a patient 
with “leucocythemia” and also in two normal individuals (Kwong and Todd, 1997). The 
discontinuation of the therapy resulted in a progressive increase in the white blood 
count in the patient until the therapy had to be re-instated. Its efficacy against chronic 
myelogenous leukemia (CML) and other forms of cancer resulted in arsenic being the 
dominant anti-leukemic treatment until it was superseded by radiation therapy (Kwong 
and Todd, 1997).  
Arsenic was not always explored for its medicinal purposes only. The women peasants 
of Syria and Austria habitually consumed arsenic to attain a healthy pallor with blushed 
cheeks and a plumper appearance, a habit which was later adopted by Victorian women. 
The men peasants consumed it as it gave them a better digestion, appetite, muscular and 
nervous functions (Haller, 1981).
 
Moreover, when ATO was dissolved in an aqueous 
solution, the colourless and odourless arsenous acid formed was termed as the “king of 
poisons”, because it was virtually undetectable with its symptoms being easily mistaken 
for natural disorders like haemorrhagic gastroenteritis, psychiatric disorders or cardiac 
arrhythmias (Antman, 2001).
 
Gradually, as the awareness of the toxicity of arsenic spread, its medicinal use declined 
until by the turn of twentieth century, arsenic acquired the reputation of a toxic 
compound and a carcinogen (Antman, 2001).
 
In one study, all of the patients developed 
palmar and plantar keratosis after long-term ingestion of Fowler’s solution, though the 
minimum onset of the disease was 15 years from the beginning of the treatment 
(Jackson and Grainge, 1975). A majority of the patients procured basal cell carcinoma 
around the same time. Some other manifestations were squamous cell carcinoma, colon 
carcinoma and breast adenocarcinoma which developed around 28-63 years after 
arsenic exposure (Jackson and Grainge, 1975). Acute arsenic poisoning caused 
gastrointestinal distress, headaches, and cardiac arrhythmias along with liver and renal 
failure (Swindell et al., 2013). 
24 
Chronic exposure to environmental arsenic also became a serious cause of concern in 
some parts of the world.  In Bangladesh, contamination of arsenic in ground water 
caused severe health problems for millions of people (Antman, 2001). The most 
common side effects included hyperpigmentation of the skin, in some severe cases, 
bladder, lung, kidney and prostate cancers along with neuropathy, encephalopathy, 
leucopenia and diabetes were also reported (Swindell et al., 2013). Arsenic induces cell 
transformation and promotes tumour formation in vitro according to some experimental 
studies depending on the dose administered (Meng and Meng, 2000). In one study, rat 
epithelial cell line (TRL 1215) was exposed to 0.5µM arsenite for a period of 18 weeks. 
This chronic exposure induced malignant transformation of the cell lines and produced 
tumours which metastasized on being injected to the nude mice (Morikawa, 2000).
 
Therefore, despite its reported anti-leukemic and medicinal properties and lack of direct 
experimental proof of its carcinogenicity in humans, the International Agency for 
Research on Cancer (IARC) declared arsenic to be in the category one of carcinogens in 
1979 (Waxman and Anderson, 2001). 
The resurgence of arsenic in recent times owes the credit to its long history of use in 
Chinese medicine as mentioned preciously (Shen et al., 1997). In 1990s, after an initial 
study at Harbin Medical University of the anti-leukemic properties of arsenic in 
traditional Chinese medicine, a group of physicians at Shanghai Second Medical 
University tried its efficacy on leukemic patients. In a careful clinical trial, they 
administered very low doses of intravenous ATO and observed remarkable results in 
patients with relapsed and refractory APL (Zhang, 1996). It was a finding of major 
importance because 20-30% of patients with APL relapsed after treatment with all-trans 
retinoic acid (ATRA) and anthracycline based chemotherapy and died (Waxman and 
Anderson, 2001). The major course of therapy then used to be bone marrow 
transplantation (Waxman and Anderson, 2001).  
Further reports from China suggested that ATO alone induced and maintained complete 
remission in 9 out of 10 patients with relapsed APL without any myeloid suppression 
and lesser toxic side effects (Shen et al., 1997). At low doses, Chen et al. observed that 
ATO caused differentiation in APL cells, while at higher doses; it induced apoptosis 
(Chen et al., 1997). The findings, which were later successfully replicated in United 
States, proved to be a major breakthrough and led to the approval of ATO (Trisenox
TM
) 
by FDA as a frontline drug for relapsed and refractory APL in Sept, 2000 (Antman, 
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2001). The intravenous administration of ATO doses, while being very effective and 
well tolerated, do show some side effects of cardiotoxicity with a prolonged QTc as 
measured on an electrocardiogram (Swindell et al., 2013).  
Till recently, the maximum success of ATO therapy has been observed in 
haematological cancers, where the therapeutic dosage administered is low, hence the 
commonly reported side effects are low grade and reversible after ceasing the ATO 
therapy (Swindell et al., 2013).
 
However, the same kind of clinical success has not been 
translated for solid cancers in humans despite positive results in experimental animal 
models. This is primarily due to the rapid clearance of arsenic and its metabolites from 
the blood by reticuloendothelial system (RES). This limits the therapeutic dose of 
arsenic reaching the tumour site and hence a requirement arises for escalating arsenic 
dosage which might, in turn, lead to systemic toxicities associated with high arsenic 
concentration in blood, such as peripheral neuropathy, cardiac and liver failure 
(Swindell et al., 2013). Arsenic toxicity also leads to long-term memory damage and 
hormonal imbalance (Platanias, 2009). 
 
1.2.2.2 Mechanism of action for solid tumours 
 
Following the huge clinical success of ATO therapy on APL and later in other 
haematological malignancies such as multiple myeloma and myeloma dysplastic 
syndrome, the mechanism of its action on blood cancers has been carefully elucidated 
and reviewed (Evens, Tallman and Gartenhaus, 2004).
 
Although promising results are 
shown on the experimental models, therapy by ATO on solid tumours remains limited 
as mentioned earlier. There have been several ongoing clinical trials to investigate its 
efficacy on a variety of solid tumours such as lung cancer, hepatocellular carcinoma, 
malignant glioma, endometrial cancer, basal skin cancer, liver cancer, germ cell 
tumours, colorectal cancer, pancreatic cancer, breast cancer, kidney, ovarian and 
cervical cancers, albeit without appreciable clinical success in human patients (Murgo, 
2001). (http://www.clinicaltrials.gov ) This brings to our attention the crucial need for 
understanding the chemistry of arsenic and identification of its potential molecular 
targets in different solid tumours leading to a successful treatment along with analysing 
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other possible ways of increasing the bioavailability of arsenic without raising its 
dosage.  
Oxidation state of arsenic ranges from -3 in AsH3 to +5 in arsenic acid (Chen et al., 
2015). Most of the common arsenicals found in nature are either pentavalent or 
trivalent, out of which trivalent arsenicals are more relevant to our study as they have a 
high binding affinity for thiols (sulfhydryl groups) (Evens, Tallman and Gartenhaus, 
2004). The interaction is rapid, energetically favoured and reversible (Swindell et al., 
2013). Since in a protein, cysteine is the only naturally occurring amino acid which can 
be the source of accessible thiol group attachments, it is a major target for arsenic 
binding (Lu et al., 2008). One arsenic molecule is known to form different trigonal 
pyramidal complexes with three cysteine molecules in proteins (Fig 1.2.7). This 
interaction results in conformational changes and the consequent loss of function of the 
enzyme. It might also affect its interaction with other functional proteins. It has also 
been recently reported that arsenic has the capability to distort a polypeptide to 
reorganise its structure where maximum number of thiols are exposed to arsenic for 
coordination (Shen et al., 2013). For instance, in APL, arsenic directly binds to the 
cysteine residues in the zinc fingers of promyelocytic leukemia fusion protein (PML-
RARα). This initiates a cascade of events like its oligomerisation, attachment to small 
ubiquitin like modifier protein and finally degradation by ubiquitination (Evens, 







Fig 1.2.7: Trivalent arsenic binds to the residues Cys172, Cys 422 and Cys 113 of a polypeptide (Evens, 
Tallman and Gartenhaus, 2004).  
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Besides sulfhydryl groups, hydroxyl groups have also been reported to be another target 
for arsenic binding, making serine to be the other target for arsenic ligation (Shen et al., 
2013). Hence, identifying oncoproteins for various solid tumours might be a fruitful 
approach in developing arsenic compounds and delivery systems for effective therapy. 
Some enzymes are commonly known to be inhibited by arsenic include glutathione 
peroxidase, glutathione reductase, glutathione S-transferase, protein tyrosine 
phosphatase, DNA ligase and JNK phosphatase (Shen et al., 2013). Mechanisms of its 
anti-cancer actions are proposed as following. 
 
1.2.2.2.1 Induction of apoptosis 
Inarguably, the most plausible mode of action of ATO is its ability to induce apoptosis 
in the cancer cells. Apoptosis or the programmed cell death however, might result from 
a multitude of factors such as mitochondrial damage and oxidative stress to the cell 
(Emadi and Gore, 2010). The key molecular enzymes in initiating apoptosis are 
caspases which are intracellular cysteine proteases. They cleave crucial cellular proteins 
which bring about the morphological features characteristic of apoptosis, i.e. nuclear 
condensation and fragmentation. Pro-apoptotic stimuli or mitochondrial membrane 
damage leads to the release of cytochrome c from the intra-membrane space of 
mitochondria into the cytosol where it binds to apoptosis protease activating factor 
(Apaf-1). This binding activates pro-caspase-9 to caspase-9 which cleaves pro-caspase 
3, leading to its activation of Caspase 3. Caspase-3 eventually initiates other sub cellular 
events culminating in apoptosis of the cell (Emadi and Gore, 2010). 
 
1.2.2.2.2 Mitochondrial toxicity 
ATO is believed to bind to the thiol groups in the permeability transition pore complex 
(PTPC) in mitochondrial membrane, permeabilising it and decreasing membrane 
potential ∆ψm as a consequence (Larochette et al., 1999). The subsequent release of 
soluble intermembrane proteins (SIMPS) is responsible for the biochemical and 
morphological manifestations of apoptosis (Kroemer and de The, 1999). For instance, 
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cytochrome c, as mentioned earlier, activates pro-caspase-9; apoptosis inducing factor 
(AIF) causes wide spread DNA fragmentation after relocating to nucleus and activation 
of other pro-caspases ultimately results in proteolytic degradation of major cellular 
proteins (Kroemer and de The, 1999).
 
 
1.2.2.2.3 Generation and accumulation of ROS 
Reactive oxygen species (ROS), including free radicals such as superoxide (O2.͞ ) and 
hydroxyl (OH·) and molecules such as hydrogen peroxide (H2O2) are damaging to the 
cell’s molecular machinery (Emadi and Gore, 2010). ROS are generated due to the 
accumulation of electrons, which in turn might happen when there is a mutation in the 
genes encoding for the mitochondrial electron transport chain. Arsenic interferes with 
the activity of redox sensitive signalling molecules, for instance, AP-1, p53, p21 and s-
nitrothiols which changes the signalling pathways and consequently alters the gene 
function. The hydrogen peroxide or other ROS generated effectuate apoptosis though 
multiple pathways, one of which includes aggregation of mitochondria (Miller et al., 
2002). 
Redox capacity of many proteins depends on the sulfhydryl groups on cysteine, which 
detoxify the cells by binding to ROS generated by normal mitochondrial metabolism. 
When arsenic binds to these thiol groups instead, the capacity of these proteins to bind 
to ROS is compromised, leading to oxidative stress.  
Intracellular redox reactions which protect the cells from oxidative stress damage are 
regulated by thioredoxin system of the cell which includes enzymes like NADPH, 
thioredoxin and thioredoxin reductase (Platanias, 2009). Other anti-oxidant enzymes 
involved in protecting the cell against ROS are glutathione, glutathione peroxidase, 
superoxide dismutase and catalase. Many of them possess vicinal thiols, and so are 
susceptible to arsenic action (Emadi and Gore, 2010). Arsenic blocks or intervenes in 




Along with direct binding of arsenic with PTPC in the mitochondrial membrane, 
accumulation of H2O2 due to generation of ROS from arsenic action, is hypothesised to 
be another factor responsible for lowering of mitochondrial membrane potential and 
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consequent release of cytochrome c in the cytosol, leading to apoptosis (Fig 1.2.8) 





Fig 1.2.8: Pathways of apoptosis induction by ATO treatment via mitochondrial membrane destabilisation 
owing to increased accumulation of ROS (Platanias, 2009). 
 
ATO enters the mammalian cells in the form of arsenous acid either via diffusion or by 
neutral solute transporter proteins of aquaporin family (Yang et al., 2012). Once inside, 
it binds to numerous available thiol residues of proteins and effectuate its anti-cancer 
response. Besides the abovementioned modes of arsenic action, it also interferes in 
other cellular events, for instance, tubulin polymerisation, DNA repair or cell cycle 
progression (Kroemer and de The, 1999). It inhibits the transcription of the telomerase 
transcriptase subunit of human telomerase hTERT gene, which leads to genomic 
instability and cancer cell death, as telomerase is essential for maintaining chromosomal 
ends’ length which shorten after every cell division and is responsible for senescence 
after the chromosomal ends are reduced below a certain threshold (Chou et al., 2001). 
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ATO also inhibits proliferation of carcinogenic cells and is also observed to inhibit 
tumour angiogenesis by either down-regulating vascular endothelial growth factor 




1.2.2.2.4 Mode of action of ATO for cervical cancer treatment  
There have been few studies investigating ATO’s mode of action, specifically for 
cervical cancer treatment. A study demonstrated that ATO causes G2/M phase arrest, 
caspase-9 activity and mitochondrial destabilisation on a range of cervical cancer cell 
lines including HeLa, C33a, SiHa and Caski cells (Yu et al., 2007). For mitochondrial 
destabilisation, ATO induced homodimerisation of voltage dependent anion channel 
(VDAC) proteins, an abundant protein in the outer mitochondrial membrane, leading to 
the formation of a channel through which cytochrome c migrates from the mitochondria 
to the cytosol, causing apoptosis (Yu et al., 2007). In a separate study, ATO was shown 
to cause the translocation of Apaf-1, a mitochondrial intermembrane flavoprotein, to the 
nucleus which resulted in DNA fragmentation and chromatin condensation (Kang et al., 
2004).  
Cervical cancer cell lines were also tested for their attachment and migration ability 
after the treatment with ATO as tumour cell migration and metastasis are highly 
interlinked processes (Yu et al., 2007). The crucial proteins here are E-cadherin which 
enhances intercellular adhesion and inhibits tumourigenecity and invasiveness of 
epithelial tumour cells (Vleminckx et al., 1991); β-catenin which links E-cadherin to 
actin cytoskeleton (Rimm et al., 1995); and Caveolin-1 which targets or anchors 
proteins to their specific site of action (Yu et al., 2007). ATO treatment was observed to 
upregulate caveolin-1 and E-cadherin and downregulate β-catenin which enhanced the 
cell-cell contact and invasion suppression of tumour cells (Yu et al., 2007). 
Cervical cancer cells potentially offer a unique environment as unlike other carcinomas, 
they have HPV as the major etiologic agent for carcinogenesis and the critical 
molecules responsible for HPV oncogenesis are viral E6 and E7 oncoproteins (Yu et al., 
2007). Hence, downregulating their expression might provide an effective form of anti-
cancer therapy. ATO downregulated viral E7 gene expression which is closely 
associated with the apoptosis induction in HPV-16 DNA immortalised HCE-16/3 cells 
31 
(Zheng et al., 1999). The results were consistent with another set of findings by Um et 
al. (2002) where they observed a downregulation of HPV E6 and E7 oncogene 
expression in ATO-treated HeLa cells. This downregulation was hypothesised to be due 
to the repressing of the activity of AP-1 transcriptional factor in HPV-18 URR (Um et 
al., 2002). This led to the inhibition of growth, induction of apoptosis and increased 
levels of p53 in human cervical cancer cells (Um et al., 2002). 
As evidenced above, ATO demonstrates significant efficacy against cervical cancer cell 
lines. However, chemotherapy is always riddled with serious side effects due to the 
toxicity to the surrounding normal tissue. A truly desirable treatment would be one 
where the therapeutic index of the drug is made considerably higher to selectively target 
cancer cells. This would overcome the side effects arising from systemic toxicities 
which are common with chemotherapeutic treatments. The advent of nanotechnology in 
the field of drug delivery has given us the possibility to realise such an ideal treatment 
for a variety of problematic cancers including cervical cancer.  
 
 
1.2.3 Nanotechnology in drug delivery 
 
 
Utilising traditional chemotherapeutic drugs including ATO to treat cervical cancer is 
riddled with challenges currently. One of the major issues in cancer therapeutics is 
tissue selectivity (Danhier, Feron and Preat, 2010). Limited dose reaching the solid 
tumour causes problems of suboptimal treatment and excessive toxicities, which further 
result in poor quality of life of the patient and low overall survival (Danhier, Feron and 
Preat, 2010). The same issue has plagued the utilisation of ATO for treatment of solid 
cancers, like cervical cancer. The typical limitations of commercial drugs are their poor 
solubility, low bioavailability, high toxicity, non-specific delivery, short circulation 
times and in vivo degradation (Orive et al., 2003). In general, therapeutic potential of 
any anti-cancer drug can be improved if its toxic side effects to the healthy surrounding 
tissue could be reduced and it could be delivered specifically to the cancer cells.  In 
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essence, in the current scenario, the field of drug delivery presents itself as a major 
impediment to pharmaceutical and biotechnology industries requiring to be mastered in 
order to fully utilise the plethora of new and old therapeutics that are hampered by their 
poor delivery and toxicity issues (Sahoo, Misra and Parveen, 2017). 
One of the most effective steps in the direction of addressing this issue is the 
implementation of nanotechnology in the field of drug delivery. As per the National 
Nanotechnology Initiative (http://www.nano.gov), nanotechnology is defined as the 
controlled development and utilisation of structures, devices and systems at atomic, 
molecular and or macromolecular scale approximately in the 1-100nm size range in at 
least one dimension (Zamboni et al., 2012; Farokhzad and Langer, 2009). This 
technology is increasingly being applied to healthcare and drug delivery is one of its 
most rapidly developing fields of research which attempts to deliver a bioactive agent to 
its therapeutic site of action at a predetermined rate (Sahoo, Misra and Parveen, 2017).  
 
The advent of nanotechnology has already changed the landscape of drug delivery.  It 
focusses on formulating therapeutic agents by encapsulating drugs in biocompatible 
nanocarriers such as nanoparticles, dendrimers, micelles or nanocapsules (Sahoo, Misra 
and Parveen, 2017). Encapsulating chemotherapeutic drugs in nanocarriers promises 
considerable benefits including: protecting the drug from chemical and biological 
degradation in the blood stream, improving bioavailability and stability of the drug, 
eliminating the toxic side effects of the free form, providing the possibility for 
encapsulating both hydrophilic and hydrophobic drugs and the option of targeted drug 
delivery (Sahoo, Misra and Parveen, 2017), (Bulbake et al., 2017). Nanocarriers also are 
known to increase drug specificity, improve absorption rates, and overcome multi-drug 
resistance phenomenon and penetrate cellular barriers like blood brain barrier among 
others (Zamboni et al., 2012; Bulbake et al., 2017). They can provide sustained release 
of the drug at a predetermined rate for specified time (Bulbake et al., 2017). They can 
reduce the need for repeated drug administration, which could lead to increased 
patient’s compliance and reduced healthcare costs (Sahoo, Misra and Parveen, 2017). 
The biggest advantage, however, in employing nanotechnology is the possibility of 
achieving targeted drug delivery either through passive targeting or active targeting 







1.2.3.1 Types of targeting 
 
 
1.2.3.1.1 Passive targeting 
 
When solid tumours are smaller than 2mm
3
, they are dependent on their 
microenvironment for oxygen and nutrients, which easily diffuses to the core of the 
tumour (Malam, Loizidou and Seifalian, 2009). However, when tumour reaches the size 
of 2mm
3
 and beyond, the cells at the centre get hypoxic initiating angiogenesis (Malam, 
Loizidou and Seifalian, 2009). Hypoxia instigates a cascade of events which lead to the 
upregulation of pro-angiogenic proteins such as VEGF, platelet derived growth factor 
(PDGF) or tumour necrosis factor α (TNF-α) (Malam, Loizidou and Seifalian, 2009). 
Consequently, new blood vessels are formed but the immature vasculature undergoes 
rigorous remodelling aided by pericytes and smooth muscles cells (Danhier, Feron and 
Preat, 2010). This process remains incomplete leading to the formation of dilated and 
irregular shaped tumour vessels lacking in integrity (Danhier, Feron and Preat, 2010).  
 
The creation of long circulating “stealth nanoparticles” which could evade immune 
response by having a polyethylene glycol (PEG) layer grafted on their surface allow an 
opportune exploitation of the above mentioned structural changes in vascular 
pathophysiology (Danhier, Feron and Preat, 2010). The tumour blood vessels are 
abnormal with decreased number of pericytes lining the rapidly multiplying endothelial 
cells and an aberrant basement membrane formation with pores in the range of 10nm-
1000nm (Torchilin, 2000; Haley and Frenkel, 2008). This is in stark contrast with the 
tight endothelial junctions of normal blood vessels (Haley and Frenkel, 2008). Hence, 
nanoparticles in the size range of 20-200 nm can extravasate from this “leaky 
vasculature” into the interstitial spaces of tumour tissue but not through a healthy blood 
vessel of a surrounding normal tissue (Fig 1.2.9) (Danhier, Feron and Preat, 2010). 
Moreover, lymphatic vessels in tumour tissue are either absent or non-functional 
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leading to a poor lymphatic drainage (Danhier, Feron and Preat, 2010). The 
nanoparticles leaking through the pores are hence not removed leading to their 
accumulation within the interstitial space of the tumour (Danhier, Feron and Preat, 
2010). This phenomenon was discovered by Matsumura and Maeda in 1986 and they 










Fig 1.2.9: Differences between the tumour and normal blood vessels which explain the passive 
accumulation of nanoparticles via EPR effect.  (Park and Na, 2015) 
 
 
The inefficient lymphatic drainage has another beneficial effect from using 
nanoparticles carrying chemotherapeutic drug over their free molecular counterpart. It 
causes a high osmotic pressure in tumours, which is highest at its centre while fading 
away at the periphery (Jain, 1987). This results in a mass flow of fluid away from the 
centre so the drug molecules are unable to penetrate the inside of tumour resulting in an 
inefficient treatment (Danhier, Feron and Preat, 2010). For this reason, conventional 
drugs have a poor pharmacokinetic profile with an implication that they are distributed 
non-specifically in the body leading to debilitating and systemic toxicities (Danhier, 
Feron and Preat, 2010). However, the larger sized nanoparticles are less resisted by this 
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high tumour interstitial fluid pressure, resulting in their overcoming of these barriers 
and successful accumulation within the tumour (Danhier, Feron and Preat, 2010). 
Another relevant characteristic of tumour environment that facilitates the release of 
active drug molecule from nanocarrier once it has accumulated within the tumour is the 
presence of lower pH in tumours than normal tissues (Van Sluis et al., 1999). The 
extracellular pH of normal tissues is 7.4, whereas the average extracellular tumour pH is 
between 6 and 7 (Van Sluis et al., 1999). The lower pH destabilises the nanocarrier 
which might release the drug in the vicinity of the cancer cells expediting their uptake 
(Danhier, Feron and Preat, 2010). 
 
EPR effect is a technique that has been greatly exploited to deliver the therapeutics to 
their site of action. Also, the transport of nanocarriers through the leaky vasculature into 
the tumour interstitium via EPR effect is popularly termed as passive targeting 
(Danhier, Feron and Preat, 2010). This targeting is only conceivable when the 
nanocarriers carrying the drug payload can escape the immune surveillance and 
circulate for a longer period of time (Danhier, Feron and Preat, 2010). To this end, 
nanoparticle’s surface is grafted with polyethylene glycol PEG layer, as mentioned 
above, which acts as a brush and prevents opsonisation and immune clearance by 
reticuloendothelial system (RES) (Danhier, Feron and Preat, 2010). 
 
One of the first sterically stabilised PEGylated liposome (lipid nanoparticles) 
encapsulating a chemotherapeutic drug, doxorubicin, approved by FDA was Doxil 
(Gullotti and Yeo, 2009). Doxil displayed a good retention time in its liposomal 
formulation, a better circulation time in vivo and was almost 6 times as effective as the 
parent drug (Gullotti and Yeo, 2009). Relying on EPR mechanism, it proved a success 
in shrinking tumour size both in animal models and patients (Maeda, Bharate and 
Daruwalla, 2009). Consequently, it was approved for the treatment of chemotherapy 
refractory AIDS related Kaposi’s sarcoma, advanced ovarian cancer and metastatic 
breast cancer (Gullotti and Yeo, 2009). Currently, there are apparently fifteen approved 
liposomal formulations including liposomal cytarabine (DepoCyt), paclitaxel albumin 
bound nanoparticles (Abraxane) and liposomal daunorubicin (DaunoXome) (Fig 1.2.10) 







Fig 1.2.10: FDA approved liposomal formulations and their therapeutic areas (Bulbake et al., 2017). 
 
 
1.2.3.1.2 Active targeting  
 
Passive targeting has limitations owing to differential susceptibility of different tumour 
tissues to the EPR effect (Federman and Denny, 2010). Consequently, passive targeting 
may bring the nanoparticle in close proximity to the tumour tissue but not guarantee its 
entry within the tumour cells (Federman and Denny, 2010). To achieve the latter, the 
approach of active targeting is employed (Federman and Denny, 2010). Active targeting 
is accomplished when a receptor specific ligand is conjugated to the nanocarrier 
encapsulating therapeutic drug to stimulate site specific targeting (Sahoo, Misra and 
Parveen, 2017). This receptor mediated binding of nanoparticles to the surface receptors 
expressed on tumour cells leads to a preferential accumulation of drug at the diseased 
site (Sahoo, Misra and Parveen, 2017), (Zamboni et al., 2012). These ligand-liposomal 
complexes are then internalised by tumour cells via receptor mediated endocytosis (Fig 
1.2.11) (Kirpotin, 2006). The success of active targeting relies on few factors: 1, the 
targeting ligand should have a high affinity and high specificity for the surface 
receptors, 2 be amenable to surface modifications to permit conjugation, 3 surface 
37 
receptor and ligand should be abundant to increase the chances of conjugation between 







Fig 1.2.11: Passive targeting vs active targeting (Farokhzad and Langer, 2009) 
 
 
The optimum size of nanoparticles and the ability to conjugate ligands complementary 
to diseased cell’s receptors facilitates overcoming of the physiological barriers followed 
by efficient uptake and cellular internalisation (Sahoo, Misra and Parveen, 2017). 
Hence, drug encapsulated in nanocarriers have a greater opportunity to accumulate in 
cancerous tissue than its free form (Sahoo, Misra and Parveen, 2017). Targeting ligand 
acts as a “homing device” for nanocarriers and increases their specificity to target 
specific tissues and cells (Danhier, Feron and Preat, 2010). Despite proving their 
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efficacy in preclinical models, only three actively targeted nanocarriers have reached 
clinical trials till now: transferrin conjugated liposome containing oxaliplatin, 
galactosamine targeted PHPMA doxorubicin and GAH conjugated liposome containing 





Many types of nanoparticles have been employed for the purpose of drug delivery in 
medicine including dendrimers, micelles, nanospheres, nanocapsules, fullerenes, 
nanotubes, polymer nanoparticles and liposomes (Fig 1.2.12) (Haley and Frenkel, 
2008). Our main interest however is in liposomes which were first described in 1960 by 
Alec Bangham and colleagues (Bangham, Standish and Watkins, 1965). In 1971, 
Gregory Gregoriadis established the utility of liposomes in encapsulating drugs 
(Gregoriadis and Ryman, 1971). Since then, liposomes have been the object of immense 
research and directed effort to improve their efficacy as drug delivery vehicles. A 
myriad of drugs have been incorporated in liposomes, including anti-cancer or anti-
microbial drugs, proteins, peptides, hormones, genetic material, chelating agents and 
vaccines, to achieve selective delivery to target cells for therapeutic applications (Chang 
and Yeh, 2012). Liposomes have gained increased interest among other nanoparticles 
due to their good biocompatibility, easy control over their compositions and properties 








Fig 1.2.12: Different types of nanoparticles commonly employed in biomedical applications of drug 
delivery (Mc Carthy et al., 2015) 
 
 
Liposomes are spherical vesicles composed of phospholipid bilayers surrounding an 
aqueous core (Malam, Loizidou and Seifalian, 2009). The aqueous core can be utilised 
to encapsulate hydrophilic drug molecules whereas the lipid bilayer can entrap lipid 
soluble drugs (Haley and Frenkel, 2008). The “first generation” liposomes suffered 
from a major drawback of rapidly getting opsonised soon after an intravenous injection 
and consequent clearance by RES (Haley and Frenkel, 2008). They were taken up the 
cells of mononuclear phagocytic system (MPS), particularly spleen and liver leading to 
their inactivation along with causing toxicity to the MPS organs involved (Allen and 
Cullis, 2013). Liposomes were further rendered vulnerable from electrostatic, van der 
Waal’s and hydrophobic forces which could lead to their disintegration (Haley and 
Frenkel, 2008). This warranted a need for steric stabilisation of liposomes which could 
be attained by coating their surface with an inert polymer (Lasic, 1996). PEG surface 
coating could provide this steric stabilisation and render the particle invisible to the 
opsonins, subsequently preventing their clearance by immune system (Haley and 
Frenkel, 2008). This “stealth” technology utilising “second generation” liposomes, first 
described in 1987, had much longer circulation times, better bio-distribution and dose 
dependent pharmacokinetics as they had a higher opportunity to accumulate within 
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tumour tissue via EPR effect (Allen and Chonn, 1987; Allen and Cullis, 2013; Haley 
and Frenkel, 2008).  
 
When a targeting ligand is attached to the PEG layer of liposomal surface, the resulting 
nanoparticle is classified as a “third generation” liposome (Farokhzad and Langer, 
2009). In 1987, Heath et al. showed that targeting the liposome with an antibody 
complimentary to receptors on cancer cell surface could indeed enhance the selectivity 
of the liposomal anti-cancer drug in cultures (Heath et al., 1983). Both the targeted and 
non-targeted liposomes have similar distribution in the cancerous tissue via EPR effect, 
however in the vicinity of the target cells; conjugated liposomes might exhibit an 
increased uptake due to receptor mediated endocytosis (Allen and Cullis, 2013). 
However both the targeted liposomes and passively targeted liposomes should have an 
appreciable content retention and an appropriate release rate to increase their therapeutic 
index (Allen and Cullis, 2013).  
 
 
1.2.3.2.1 Considerations of liposomal design 
 
Despite the fact that liposomes are biocompatible and biodegradable systems, on 
entering the blood stream, they are susceptible to destabilisation after opsonisation and 
consequent immune response in the form of MPS or the complement system 
(Vonarbourg et al., 2006). The phospholipid component of the liposomal composition is 
a strong activator of the complement system (Vonarbourg et al., 2006). Hence, a careful 
consideration is required to design the liposomal surface in a way that its circulation 
time is increased to allow the EPR effect to take place, to make active targeting possible 
by conjugating ligands specific to the target cancer cells’ receptors, to have a scope of 
sustained release of drug when in the vicinity of the tumour or inside cancer cells and 
also have a good drug encapsulation efficiency with a high, specific uptake by target 
cells (fig 1.2.13).  To that effect, soy lecithin (phosphatidyl choline PC or phosphatidyl 
ethanolamine PE) is added to the liposomal composition as their choline and phosphate 
groups impart hydrophilic properties to the surface and henceforth, inhibit complement 
activation (Mosqueira et al., 2001). A few other factors which have an inhibitory effect 
on the complement activation are the presence of a low surface charge, smaller size, 
rigid membrane and cholesterol (Vonarbourg et al., 2006). Cholesterol has been 
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reported to increase the mechanical strength, membrane elasticity, reduce the membrane 
surface defects and hence remove the potential adsorption sites for blood proteins which 







Fig 1.2.13: Liposomal design for drug delivery (Torchilin, 2006) 
 
 
The introduction of hydrophilic polymer chain such as PEG at the nanoparticle surface 
is a very effective way to make the surface hydrophilic and reduce hydrophobic 
interactions (Van Oss, 1975). These PEG chains, with a high affinity for water 
molecules, create a ‘water cloud’ around the nanoparticle, leading to repulsion from the 
environmental proteins (Coleman, Gregonis and Andrade, 1982). PEG is uncharged and 
non-immunogenic in nature and can be easily grafted or incorporated on the 
nanoparticle surface, increasing the latter’s biocompatibility (Vonarbourg et al., 2006). 
Moreover, the presence of two terminal hydroxyl groups allows functionalisation and 
covalent coupling to ligands to achieve active targeting (Vonarbourg et al., 2006). 
However, the PEG’s capacity to prevent opsonisation depends largely on the 
optimisation of various parameters including its molecular weight, flexibility, density 
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and conformation of the chains (Gref, 1995). It has been reported that the efficient 
molecular weight is around 1500-3000 Da and the presence of PEG chains of mixed 
lengths can have an advantage of long chains providing accessibility for ligands for 
endocytosis and smaller lengths providing the coating necessary for longer circulation 
(Pavey and Olliff, 1999). In addition, the more flexible and dense the chain is, the more 
efficient it is in improving circulation profile (Vonarbourg et al., 2006).   
 
1.2.3.2.2 Liposomes and cervical cancer 
With its growing prowess, researchers have started using liposomal technology to 
specifically treat cervical cancer (Casagrande et al., 2013; Saengkrit et al., 2014; Saini 
et al., 2014). The conventional drug for treating cervical cancer, cisplatin, was 
encapsulated in liposomes and the resultant formulation was termed lipoplatin 
(Casagrande et al., 2013). Lipoplatin showed similar efficacy as the parent drug with 
associated reduced toxicities on metastatic breast cancer, head and neck and pancreatic 
cancers (Casagrande et al., 2013). It was recently tested for cervical cancer and 
lipoplatin displayed appreciable anti-tumour activity on cisplatin resistant cervical 
cancer cell lines and was able to induce apoptosis and inhibit migration and invasion 
(Casagrande et al., 2013). Other drugs that have been encapsulated in liposomes for 
treating cervical cancer are bleomycin sulphate and curcumin (Saengkrit et al., 2014; 
Saini et al., 2014). Similarly, ATO along with few other organic arsenicals has also 
been encapsulated in nanoparticles and their efficacy investigated and verified, although 
not for cervical cancer.  
 
Owing to the immense potential of liposomes in the field of clinical medicine and 
research, there is no doubt that they can be fittingly envisioned as the future of drug 
delivery technology along with other nanoparticles (Sahoo, Misra and Parveen, 2017). 
Nanomedicines are the answer to an increasingly efficient cancer therapy and an 
improved patient’s quality of life, holding the potential to radically change the way in 
which we diagnose, image and treat cancer. However, massive challenge still remains to 
specifically tailor the nanocarrier and optimise its design to treat a specific tumour. 
Liposomal size, charge, cholesterol content, PEG density to be used and loading 
techniques of the drug are only few of the parameters among many that need an arduous 
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and careful optimisation before they can be employed as carriers of ATO for effective 
treatment of cervical cancer. The specific aims for the undertaken research are 
enumerated in the following section to optimise the liposomal ATO carrier to display a 























The overall aims of this project were to selectively deliver ATO to HPV positive cervical 
cancer cells in vitro via an optimized liposomal carrier. The effectiveness of delivered 
ATO via the formulated drug delivery system by targeting identified surface markers on 
target cancer cells was evaluated. The molecular mechanisms of ATO action delivered 
through this route including changes in cancer cell apoptosis and the expression of HPV 
oncogenes along with tumour suppressor proteins were then examined and compared with 
free ATO, which was tested on HPV positive cervical cancer cell lines along with control 
cell lines.  
 
The aims were achieved from the following steps: 
1.3.1 Optimising physical parameters (mainly, size and charge) of drug encapsulating 
liposomes to increase their efficacy as nano-carriers of ATO to HPV positive cervical 
cancer cells. 
Specific objectives were: 
i. To synthesise ATO encapsulating liposomes and to optimise their physico-
chemical and biological properties (loading efficiency, stability and inherent 
cytotoxicity) in terms of best size and charge, specifically for HPV positive 
cervical cancer cells; 
ii. To compare any differences seen in liposomal uptake, cellular toxicity and 
apoptosis induction in the cancer lines towards the optimised liposomal 
treatment based on the presence or absence of HPV oncogenes. 
iii. To investigate their toxicity towards non-cancerous normal cells.  
 
1.3.2 Selecting the best ligand for liposomal conjugation to actively target HPV positive 
cervical cancer cells. 
Specific objectives were: 
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i. To screen for surface markers (EGFR, folate receptor and transferrin) on 
cervical cancer cells (both HPV positive and HPV negative)  
ii. To identify a surface marker which is abundantly expressed on HPV positive 
cervical cancer cells (HeLa cells) and negligibly expressed in HPV negative 
cervical cancer cells (HT-3 cells), in order to find the best targeting ligand 
for liposomes targeting specifically the HPV positive cervical cancer cells. 
  
1.3.3 Designing targeted ATO liposomes and optimising their physical parameters 
(mainly, ligand-PEG spacer length and ligand density) to attain highly specific cellular 
uptake in HPV positive cells. 
Specific objectives were: 
 
i. To design targeted, PEGylated liposomes conjugated with the chosen 
ligand; 
ii. To optimise their parameters including PEG spacer length of conjugated 
ligand for better selectivity and uptake to receptor positive cell lines 
(preferably HPV positive cells) and evaluate their physico-chemical 
properties and biological responses (including cellular uptake and in vitro 
cytotoxicity). 
 
1.3.4 Selecting the best delivery method for ATO to HPV positive cervical cancer cells 
by investigating and comparing the molecular mechanism of ATO delivered free or 
encapsulated in (both targeted and non-targeted) liposomes.  
Specific objectives were: 
 
(i) To investigate the mechanism of ATO action delivered via the three routes: 
free form and liposomally (both non-targeted and targeted approach) by 
examining the induction of apoptosis, downregulation of oncogenes E6 and 
E7 and upregulation of tumour suppressor proteins p53/ pRb. 
(ii) To investigate which delivery method is the most selective and effective for 








2.1.1 Major Equipment 
 
PLATE READER FLUOStar Omega BMG Plate Reader, 
BMG LABTECH Ltd., 
Bucks, UK 
 
FLOW CYTOMETER BD FACSCalibur, 
BD BioSciences,  
Oxford, UK 
 
FLOW CYTOMETER  
SOFTWARE  
Cell Quest Pro software, 
BD BioSciences,  
Oxford, UK 
 
WESTERN BLOT  
IMAGING SYSTEM 







WESTERN BLOT  
IMAGING SOFTWARE 
Image Studio Lite ver. 4.0,  
LICOR BioSciences,  
Cambridge, UK 
 
WESTERN BLOT  
TRANSFER EQUIPMENT 
Trans-Blot® Turbo™ Transfer System, 
Bio-Rad Laboratories Ltd.,  
Hertfordshire, UK 
 
GEL ELECTROPHORESIS TANK Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell,  
Bio-Rad Laboratories Ltd.,  
Hertfordshire, UK 
 
GEL ELECTROPHORESIS  
TANK POWER SUPPLY 
Mini Trans-Blot® Module and 
PowerPac™ HC Power Supply, 
Bio-Rad Laboratories Ltd.,  
Hertfordshire, UK 
 
EPPENDORF THERMOSTAT  
HEATING BLOCK 
Eppendorf ThermoStat plus, 
Fisher Scientific,  
Leicestershire, UK 
 
DYNAMIC LIGHT SCATTERING  
(DLS) INSTRUMENT  
Zetasizer Nano ZS, 
Malvern Instruments Ltd,  
Malvern, UK 
 
INDUCTIVELY COUPLED  
PLASMA-MASS SPECTROMETER  
(ICP-MS) 




INDUCTIVELY COUPLED  
PLASMA-OPTICAL  
EMISSION SPECTROMETER  




CONFOCAL MICROSCOPE Leica Mircosystems, 
Milton Keynes, UK 
 
0.4µm, 0.2µm and 0.1µm  
SYRINGE FILTERS  
Whatman Anotop Filters, 
Sigma-Aldrich Company Ltd.,  
Dorset, UK 
 
DIALYSIS TUBING  Dialysis tubing (MW 20kDa), 
Sigma-Aldrich Company Ltd.,  
Dorset, UK 
 
MINI DIALYSIS DEVICES 
 
Slide-A-Lyzer™ MINI Dialysis Device, 
20K MWCO 
Fisher Scientific,  
Leicestershire, UK 
 
CELL CULTURE HOODS Mars Class 2 Cabinets 
Labogene, Thistle Scientific Ltd., 
UK 
 
CO2 INCUBATOR  Binder CO2 incubator, Series C, 
BINDER GmbH – Headquarters, 
Germany 
 
WATER BATH Grant SUB Aqua 5 digital water bath, 
Laboratory Analysis Ltd., 
Exeter, UK 
 
DIONISED WATER PURIFIER Purite Select Fusion Water  
Purification System, 




ICE MACHINE Scotsman AF200 Ice flaker, 
Hubbard Systems,  
Suffolk, UK 
 
pH METER Jenway 3505 pH meter, 






















VORTEX Vortex Genie-2T, 
Scientific Industries, 





ROTATOR Rotator Variable Speed Stuart SB3, 
Camlab Limited   
Cambridge, UK 
 
ROLLER MIXERS (1) Thermo Denley Spiramix 5, 
Thermo Scientific, 
Paisley PA4 9RF, UK 
 




ROCKER Rocker 35 EZ Large Capacity Lab Rocker 
Labnet International Inc., 
Edison, NJ 
 

















2.1.2 Minor equipment 
 
PIPETTES, PIPETTE TIPS,  Gilson Pipettes 
Starlab UK Ltd., 








GAS 95% O2; 5% CO2; NITROGEN 
 
BOC Group Plc., 
Surrey, UK 
 
PIPETTE TIPS, 5000ML, 2000ML AND 
1000ML GRADUATED BEAKERS, 
GRADUATED PIPETTES, EPPENDORF 
TUBES, CORNING™ FALCON™ 
ROUND-BOTTOM POLYSTYRENE 
TUBES, GLASSWARE, STARSTEDT 
96, 24, 12 AND 6 WELL PLATES,  
GLOVES, 1.5 ML, 4ML AND 7ML 
GLASS VIALS, BD PLASTIPAK 
SYRINGES, WYPALL ABSORBENT 













Superfrost Microscopic Slides 





2.1.3.1 Cell culture 
 
Cell Lines: Two human cervical cancer cell lines, HeLa (HPV positive) and HT-3 
(HPV negative) along with two normal cell lines, human epidermal keratinocytes HK 
and human colon epithelial cells CRL-1790, were used in the first part of the study. For 
the liposomal conjugation studies, nasopharyngeal cell line KB and lung cancer cell line 
A549 were also included as controls along with the cervical cancer cell lines. All the 
cancer cell lines were used till passage number 40 or below, while the normal cell lines 
were used between passage numbers 3 and 12. 
 HeLa (ATCC® CCL-2™, UK) is a human cervical epithelial cancer cell line of 
adenocarcinoma. HeLa cells have been reported to contain HPV-18 sequences. 
 HT-3 (ATCC® HTB-32™, UK) is also a human cervical cancer cell line of 
epithelial origin which is negative for HPV DNA or RNA.  
 HK (Fisher Scientific, UK) cells are primary human epidermal keratinocytes 
which are isolated from neonatal foreskin. 
 CRL-1790 (ATCC, UK) cells are normal human colon epithelial cells.  
 KB (ATCC® CCL-17™, UK) cell line was originally derived from an 
epidermal carcinoma of the mouth but was later contaminated with HeLa cell 
line. Hence, it has been reported to contain HPV-18 DNA sequences. It is highly 
positive for folate receptor expression.  
 A549 (ATCC® CCL-185™, UK) cells are human lung epithelial cancer cells. 
They have been reported to be negative for folate receptor expression.  
 
Culture media:  
 RPMI media-1640 (Gibco, Thermo Fisher Scientific, UK)  
 DMEM Media - GlutaMAX™ (Thermo Fisher, UK)  
 Folate free RPMI-1640 media (Fisher Scientific, UK)  
53 
 Gibco McCoy’s 5A (Modified) medium (Fisher Scientific, UK) 
 Ham’s F-10 Nutrient Mix (Thermo Fisher Scientific, UK).  
 Fetal Bovine Serum (Invitrogen Life Technologies, Fisher Scientific, UK) 
 Penicillin-Streptomycin (5000U/ml) (Invitrogen Life Technologies, Fisher 
Scientific, UK) 
 EpiLife® Medium, with 60 µM calcium (Fisher Scientific, UK) 
 Human Keratinocyte Growth Supplement (Fisher Scientific, UK) 
 Trypsin-EDTA (Fisher Scientific, UK) 
 DMSO (Sigma, UK)  
 Trypan Blue (Fisher Scientific, UK) 
 
Toxicity and apoptosis studies:  
 Thiazolyl blue tetrazolium bromide powder (Sigma, UK), which is dissolved in 
serum free media at a concentration of 2.5mg/ml immediately before use. 
 Isopropanol (Fisher Scientific, UK) 
 Sheath Fluid, BDTM FACSClean, BDTM FACS Rinse (BD Biosciences, UK).  
 Annexin V FITC apoptosis detection kit (Abcam, UK) has 500µl Annexin V-
FITC, 500µl Propidium iodide and 50ml binding buffer.  
 
 
2.1.3.2 Liposome studies  
 
Synthesis: The lipids were purchased from Avanti Polar Lipids (AL, USA) unless 
mentioned specifically, 
 Soy phosphatidylcholine (PC) 
 Methoxypolyethyleneglycol-distearoyl- phosphatidylethanolamine (DSPE-
PEG2000; with mPEG MW2000Da) 
 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-folate(polyethylene 
glycol)-2000 (DSPE-PEG2000- Folate; with mPEG MW2000Da)  
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 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-folate(polyethylene 
glycol)-5000 (DSPE-PEG5000- Folate; with mPEG MW5000Da)  
 1,2-distearoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (sodium salt) (DSPG)  
 Cholesterol (Chol)  
 Didodecyldimethylammonium bromide (DDAB) (Sigma, UK) 
 Nickel acetate (Sigma, UK) 
 ATO (Sigma, UK) 
 Methanol (Fisher Scientific, UK) 
 Dichloromethane (Fisher Scientific, UK) 
 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindocarbocyanine-5,5'-Disulfonic Acid 
(DiIC18(3)-DS) ( Invitrogen, ThermoFisher Scientific, UK).  
 Sodium dihydrogen phosphate, NaH2PO4 (Fisher Scientific, UK) 
 Disodium Hydrogen Phosphate, Na2HPO4 (Fisher Scientific, UK) 
 Dialysis buffer (0.01M NaH2PO4/Na2HPO4 pH 7): Dissolve 1.2gm NaH2PO4 
and 4.26gm Na2HPO4 in 4 lit dH2O. 
 
Characterisation: All the chemicals were purchased from Fisher Scientific (UK), 
 Nitric acid  
 Hydrogen chloride 
 Sodium hydroxide 
 Calibration standards for arsenic, nickel and phosphorus 
 Oxoid Phosphate Buffered Saline Tablets 
 
 
2.1.3.3 Protein expression studies 
 
Antibodies: All the antibodies were supplied by Abcam (UK) unless stated otherwise, 
 β-actin antibody (ab119716, rabbit polyclonal to beta actin); 
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 transferrin antibody (ab84036, rabbit pAb to transferrin receptor); 
 EGFR antibody (ab137660, rabbit pAb to EGFR N-terminal);  
 Active caspase-3 antibody: (ab32042, rabbit mAb to active caspase-3) and 
(ab2302, rabbit pAb to active caspase-3); 
 Rb antibody: (ab24, mouse mAb to Rb) and (ab181616, rabbit mAb to Rb); 
 HPV18 E7 antibody: (ab100953, mouse mAb to HPV-18 E7); 
 p53 antibody: (ab28, mouse mAb to p53), (ab26, mouse mAb to p53) and 
(ab131442, rabbit pAb to p53); 
 E6 antibody: (ab70, mouse mAb to HPV-16+Anti-HPV18 E6); 
 Caspase 3 antibody: (ab32351, rabbit mAb to caspase-3) and (ab13847, rabbit 
pAb to caspase-3); 
 Rabbit FOLR1 Polyclonal Antibody (Fisher Scientific UK);  
 Goat Anti-rabbit IgG FITC Conjugate (Fisher Scientific UK); 
 Mouse mAb to HPV18 E6 (Santa Cruz Biotechnology, UK). 
 
Immunocytochemistry/ Immunofluorescence cytochemistry:  
 Haematoxylin (Sigma, UK) 
 Paraformaldehyde (Fisher Scientific, UK)  
 Triton X-100 (Sigma, UK) 
 Immunomount (Fisher Scientific, UK) 
 Hydrogen peroxide 30% (v/v) (Thermo Fisher Scientific, UK)  
 VECTASHIELD Hard Set Mounting Media with DAPI (Vector Labs, UK)  
 Pierce™ DAB Substrate Kit (Thermo Fisher Scientific, UK) has 25ml of 10X 
DAB solution and 250ml of stable Peroxide Substrate Buffer. The working 
solution must be prepared immediately before use by combining 2.5mL of DAB 
with 22.5mL of the Stable Peroxide Substrate Buffer and mixing thoroughly. 
 TSA™ Cyanine 5 System, for 50-150 Slides (Perkin Elmer, USA) has 15 ml of 
1X Plus Amplification Diluent and Cyanine 5 Plus Amplification Reagent (2 
tubes, to which 150 µL DMSO has to be added). To prepare working solution 
for this stock, before each procedure, TSA Plus Stock Solution is diluted in the 
ratio of 1:50 in 1X Amplification Diluent. 
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 TSA™ Fluorescein System (Perkin Elmer, USA) has similar 15ml of 1X Plus 
Amplification Diluent and Fluorescein Plus Amplification Reagent (2 tubes 
where 150µl of DMSO has to be added in each tube). Working solution is 
prepared in the same way as TSA™ Cyanine 5 System. 
 VECTASTAIN Elite ABC HRP Kit (Vector Labs, UK) contains 3 ml Blocking 
Serum (Normal Serum), 1 ml biotinylated, affinity-purified anti-
Immunoglobulin, 2 ml Reagent A (Avidin DH) and 2ml and Reagent B 
(Biotinylated Horseradish Peroxidase H). Biotinylated Antibody is prepared by 
added 150µl of normal blocking serum stock to 10ml of PBS along with 50 µl of 
biotinylated antibody stock. For VectaStain ABC reagent, 100 µl Reagent A and 
Reagent B are added to 5ml of PBS and allowed to stand for 30 min before use.  
 
Western blot:  
 Halt Protease Inhibitor Cocktail (100X) (Fisher Scientific, UK) 
 Halt Phosphatase Inhibitor Cocktail (100X) (Fisher Scientific, UK).  
 Pierce RIPA buffer (ThermoScientific, UK).  
 Bradford Reagent (Sigma-Aldrich, UK) 
 2x Laemmli Sample Buffer (Biorad, UK) 
 PageRuler Prestained Protein Ladder 10-180kDa (ThermoFisher, UK) 
 Trizma Base (Sigma-Aldrich, UK) 
 Ethylenediaminetetraacetic acid EDTA (Sigma-Aldrich, UK) 
 Glycine (Fisher Scientific, UK) 
 Mini-PROTEAN® TGX™ Precast Gels (Biorad, UK) 
 Trans-Blot® Turbo™ Mini Nitrocellulose Transfer Packs (Biorad, UK)  
 REVERT Total Protein Stain (Licor, UK).  
 Tween-20 (Fisher Scientific, UK) 
 Skimmed Milk Powder (Sigma-Aldrich, UK) 
 Restore Western Blot Stripping buffer (Fisher Scientific, UK) 
 Running buffer: 10X running buffer is prepared by dissolving 30.0 g of Tris 
base, 144.0 g of glycine, and 10.0 g of SDS in 1000 ml of H2O. The pH of 
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the buffer should be 8.3 and no pH adjustment is required. The running buffer is 
stored at room temperature and diluted to 1X before use. 
 Washing buffer: 0.3% Tween 20 in PBS, pH 7.2-7.4 
 Blocking buffer: 5% skimmed milk in PBS- 0.1%Tween 20 
 Antibody solution: Antibody is dissolved in appropriate dilution in blocking 
buffer. 
 Pierce ECL Western Blotting Substrate (Fisher Scientific, UK) has substrate A 
and substrate B which are mixed in equal proportion just before the development 
















2.2.1 Cell culture 
 
2.2.1.1 Growing conditions 
 
All cells were grown at 37°C in a humidified atmosphere of 5% CO2, usually in T-75 
flasks with a volume of 12 ml of media. Media was renewed two to three times per 
week. HeLa was grown in RPMI media-1640, HT-3 in McCoy’s 5A (modified) media, 
HK in EpiLife® Medium and CRL-1790 in DMEM Media - GlutaMAX™. For folate 
conjugation studies, HeLa and KB cell lines were grown in folate free RPMI-1640 
media for a minimum of three weeks before experiments’ commencement and A549 
cell lines in Ham’s F-10 Nutrient Mix. All these media (except for HK’s EpiLife® 
media, which was supplemented with Human Keratinocyte Growth Supplement) had 
10% Fetal Bovine Serum –FBS and 1% Penicillin-Streptomycin (5000U/ml) added to 
them. Freezing media for each cell line was additionally supplemented with 10% 
DMSO. Cells were detached from their surface using Trypsin-EDTA and counted 
employing Trypan Blue on haemocytometer to distinguish between viable and non-
viable cell population. 
 
2.2.1.2 Storage of cells 
 
For long term storage, cells were harvested from the confluent flask using dissociating 
agent Trypsin-EDTA and centrifuged at 1500 g-force for 3 min. The pellet was re-
suspended in freezing medium such that there were 2 million cells/ ml and transferred to 
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cryogenic vials (Nunc). The vials were stored at -80°C overnight and then transferred to 
liquid nitrogen tanks.  
 
2.2.1.3 Passaging of cells  
 
The cells were allowed to reach 80% confluence before splitting them in 1:3 ratios. 
After passage, the cells were transferred to new culture flasks with fresh media.  
 
2.2.1.4 Cell counting 
 
For counting, each flask was firstly washed with 1 ml PBS, followed by adding 2 ml of 
0.25% Trypsin – 0.53mM EDTA and incubating at 37 ºC for 2-5 minutes. To stop 
trypsin action, media supplemented with FCS (volume 3ml) were added to flasks. The 
trypsin with media was then aspirated into 15ml Falcon tubes and centrifuged for 3 
minutes at 1500 rpm. To count the cells, 2 ml of medium was added to the cell pellet 
and resuspended thoroughly. 20μl of cell suspension was then mixed with 20μl of 0.4% 
Trypan blue with the help of a vortex in a 1ml centrifuge tube and 20μl of the obtained 







2.2.2 Liposome synthesis and conjugation 
 
Liposomes were composed of soy PC, cholesterol, and methoxypolyethyleneglycol-di-
stearoyl-phosphatidylethanolamine at a molar ratio of 53:45:2 mol %. Liposomes were 
prepared as described elsewhere with slight modifications (Chen et al., 2006). Briefly, 
the lipids were dissolved in methanol: dichloromethane 1:2 (v/v) at room temperature. 
The lipid mixtures were deposited on the side wall of the rotary glass vial by removing 
the solvent with nitrogen. The dried lipid films were hydrated in 730 mM nickel acetate 
(Ni(OAc)2) aqueous solutions for 1 h with gentle rotation. This process led to the 
spontaneous formation of multilamellar PEGylated liposomes. The liposome suspension 
was subsequently subjected to 10 freeze-and-thaw cycles (freezing in liquid nitrogen for 
3 min and thawing in 37 °C water bath for 3 min). For different sizes, the liposomes 
were downsized by passing through 0.1, 0.2 and 0.4-μm Anotop filters (Whatman, UK). 
Extruded liposomes were dialysed overnight against 10 mM sodium phosphate buffer at 
pH 7 to get rid of unencapsulated Ni(OAc)2. The nickel acetate encapsulated liposomes 
were then incubated with 20mM ATO solution at room temperature with gentle rolling 
for 5 h. The unencapsulated ATO was further removed by dialysis overnight.  
Liposomes of different charges were prepared as described above with the exception of 
positive liposome composition to be PC/Chol/DSPE-PEG2000/DDAB at a molar ratio of 
50/33/1/16 and negative liposome composition to be PC/Chol/DSPE-PEG2000/DSPG at 
molar ratio of 50/33/1/16. The positive and negative liposomes were extruded with 
0.1µm Anotop filters. Similarly for conjugated liposomes with PEG-ligand spacer 
length of 2000MW and 5000MW, PC/Chol/mPEG-DSPE /DSPE-PEG2000-FA and 
PC/Chol/mPEG-DSPE /DSPE-PEG5000-FA were taken respectively at a ratio of 
53/45/1.9/0.1mol% and passed through 0.1µm Anotop filters. Rest of the procedure was 





2.2.3 Liposome characterisation 
 
The mean sizes and zeta potential of synthesised liposomes were obtained through 
dynamic light scattering on a Zetasizer-Nano ZS. The concentrations of phospholipids 
(P), encapsulated arsenic (As) and nickel (Ni) in the liposomes were determined by 
ICP-OES.  
 
2.2.3.1 Size and zeta potential measurement by Zetasizer  
 
Principle  
Size: Zetasizer makes use of DLS technique to determine the size distribution profile of 
nanoparticles in liquid (Fig 2.2.1) (Pecora, 2000). Also referred to as photon correlation 
spectroscopy (PCS), it is based on the fact that when light hits small particles, with the 
particles’ sizes comparable to the wavelength of the incident light, it scatters in all 
directions (Reyleigh scattering). Since small particles in suspension undergo random 
thermal motion referred to as Brownian motion, the light scattered from a dispersion of 
such particles interferes (constructively or destructively) on the surface of a square-law 
detector (Goldburg, 1999). This interference defines the scattering angle and intensity of 
the scattered beam. The positions of the particles in the medium relative to the incoming 
and scattering beams determine the phases obtained at the detector. Since, the position 
constantly changes as a result of Brownian motion, the scattered light also fluctuates 
(Goldburg, 1999). These intensity fluctuations are used to calculate time correlation 
function and from that, translational self-diffusion coefficient D of the nanoparticle is 






Fig 2.2.1: Hypothetical fluctuations of scattered light from larger and smaller particles; with larger 
particles generating higher intensity than smaller particles (Kim et al., 2014). 
 
For spherical particles in a dilute dispersion, the obtained translational self-diffusion 
coefficient D can be used to calculate particle radius R using Stoke-Einstein equation, 
which is,  
 
 
where, k is the Boltzmann’s constant, T absolute temperature and η is the dynamic 
viscosity of the dispersing medium (Schmitz and Phillies, 1991). When nanoparticles 
are polydisperse, as is usually the case, then particles have different self-diffusion 
translation coefficients. In those instances, a cumulant method is used to calculate the 
sum of exponentials, which provides a size distribution range of the particles (Goldburg, 
1999). 
Zeta Potential: Apart from the hydrodynamic size, Zetasizer can also calculate zeta 
potential of the particles in suspension. Zeta potential is the net electric charge of a 
particle in dispersion within a region bound by the slipping plane (Fig 2.2.2) 
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(Bhattacharjee, 2016). Briefly, a charged particle in a suspension attracts oppositely 
charged ions, the closer ones are tightly bound by the particle, while the farther ones are 
loosely bound, forming a Diffuse Layer. Theoretically, any ions within this boundary 
are liable to move with the particle while the ions outside will stay where they are. This 
notional boundary is called Slipping Plane (Bhattacharjee, 2016). The potential at the 
Slipping Plane is called the zeta potential, which is indicative of the charge of the 
particle. Zeta Potential is determined using a combination of two techniques: Laser 
Doppler Velocimetry and Electrophoresis which measures velocity of a particle in a 





Fig 2.2.2: Illustration of potential difference and ionic concentration as a function of distance from the 
charged surface of the particle dispersed in a medium (Contributors, 2018). 
 
Zeta potential is a key indicator of stability of colloidal dispersions (Bhattacharjee, 
2016). High zeta potential (positive or negative) values are indicative of high 
electrostatic repulsion between adjacent, similarly charged particles in dispersion. If the 
zeta potential values are low, the repulsive forces may be weak and easily overcome by 
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the attractive forces, leading to the coagulation of the particles in the colloid 
(Bhattacharjee, 2016).  
Instrumentation 
A typical Zetasizer installation has the following components as depicted in Fig 2.2.3 
(a). The optical set up for DLS is shown in Fig 2.2.3 (b). After the light illuminates the 
sample from a laser source, it gets scattered which is collected, either at a 90 degree 
(right angle) or 173 degree (back angle) scattering angle.  Only liquid refractive index 






Fig 2.2.3: (a) Representation of a typical DLS instrument, (b) Optical setup for DLS nanoparticle size and 
zeta potential analyser (Bose, 2016). 
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Protocol 
The process of taking a measurement from Zetasizer is very straightforward. The 
sample is introduced in the optical unit in a clear cuvette and then the Zetasizer software 
can be used to either run a manual or standard operating procedure (SOP) measurement. 
However, care should be taken for sample preparation. The particle concentration 
should not be too low in case that scattered light will not be picked up by the detector. 
The concentration should also not be high to avoid multiple scattering (Bhattacharjee, 
2016). For size measurements, the liposomes diluted in PBS with 1:100 ratio gives the 
appropriate reading with 500µl total volume. The PBS needs to be filtered to remove 
dust particles which might give additional peaks and interfere with the results. For zeta 
potential, liposomes need to be diluted in the same ratio in deionised water to get the 
readings in 1ml final volume.  
 
2.2.3.2 Loading efficiency of arsenic and time/ pH stability studies of 
liposomes by ICP-OES 
 
Principle 
ICP-OES is a versatile analytical technique for the detection of trace metals. It is a type 
of emission spectroscopy that utilises inductively coupled plasma to generate excited 
atoms or ions which emit electromagnetic radiation at wavelength characteristic to the 
particular element (Principle of ICP Optical Emission Spectrometry (ICP-OES), 2018). 
The excitation temperatures are generated using inert gas Argon using flame technique 
which generates a temperature of 5000K to 7000K, capable of exciting many elements.  
This optical emission spectroscopy is based on the principle that when a sample is 
imparted plasma energy, its individual components (atoms) are excited and while 
returning to their low energy state, they emit radiations of wavelength specific to the 
element, which is measured and analysed. The radiation’s intensity corresponds to the 








Fig 2.2.4: Diagram representing the various components of ICP-OES including torch generating plasma, 
nebuliser, peristaltic pump and spray chamber (Haung and Hieftje, 1989) 
 
According to its name, ICP-OES has two principle components, ICP torch and optical 
spectrometer. The ICP torch consists of three concentric quartz glass tubes, around 
which the work coil of radiofrequency (RF) generator is wound (Rezaaiyaan et al., 
1982). When the torch is turned on, high frequency electric current flows through the 
work coil at the tip of the torch tube which generates electromagnetic field (Principle of 
ICP Optical Emission Spectrometry (ICP-OES), 2018). To this torch coil, argon gas is 
applied which get ionised, generating plasma of high electron density and temperature 
of the magnitude of 10000K as a consequence of inelastic collisions between charged 
ions and neutral argon atoms (Haung and Hieftje, 1989).  This energy is used in the 
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excitation-emission of the sample. A peristaltic pump introduces the solution samples 
into a spray chamber through an analytical nebuliser where the sample is turned into 
mist and fed to the plasma torch (Haung and Hieftje, 1989). The high temperatures 
cause the individual molecules to be broken down to their respective atoms and lose 
electrons and when they recombine, they give off radiation in the wavelength 
characteristic of the element (Fig 2.2.4) (Haung and Hieftje, 1989). The emitted light is 
focussed on a diffraction grating, where it is separated into its individual component 
wavelengths in the optical spectrometer. The separated wavelengths fall upon an array 
of semiconductor photodetectors such as charged coupled devices (CCD) which are 
capable of measuring the intensities of all the wavelengths simultaneously, allowing the 
samples to be analysed very quickly. The intensities are then compared to the intensities 
of known concentration of the elements and the unknown concentrations are then 
calculated based on the extrapolation along calibration graph (Charles and Freeden, 
1997).   
 
Protocol 
Liposome samples were acidified in 2% nitric acid and delivered in 15 ml falcon tubes 
to the ICP-OES instrument. The concentrations of phospholipids (P), encapsulated 
arsenic (As) and nickel (Ni) in the liposomes were determined. The molar ratios of As/ 
P were calculated and used to determine loading efficiency. Liposomal stability over 
time was determined by checking the As/ P ratio over a period of 4 weeks when 
liposomes were stored at 4°C in buffers of pH 7.4.  Drug leakage at different pH was 
studied by dialysing liposomes in buffers of pH 4, pH 7 and pH 10 and assessing their 
loading efficiency at a period of 1, 2, 4, 6 and 24 h by measuring the As/P ratio of the 






2.2.4 MTT toxicity analysis 
 
Principle 
Cytotoxicity of various liposomal formulations of ATO was determined by an MTT 
Assay as described previously (Lee and Low, 1995). This in vitro assay is based on the 
principle that tetrazolium salts can be reduced to a different coloured formazan in living 
cells. Metabolically active cells reduce the yellow tetrazolium salt MTT by the action of 
dehydrogenase enzymes to generate reducing equivalents such as NADH and NADPH. 
The resulting intracellular purple formazan is solubilized and quantified by 
spectrophotometric means. Through this assay, a linear relationship between cell 
number and optical density signal produced is established, which allows an accurate 
quantification of changes in the rate of cell proliferation. 
 
Protocol 
Briefly, the experiments were set up in 96 well plates, where the toxicity of control 
empty and ATO encapsulating liposomes of varying sizes, charges and compositions 
were investigated. Around 30,000 cells were seeded per well in 100µl media and 
allowed to attach overnight. Next day, the cells were treated with liposomes in varying 
dilutions for different time periods and at the end of the treatment, the spent media was 
removed carefully and 50µl of MTT solution was added per well. Cells were further 
incubated for 30 minutes at 37°C with 95% O2 and 5% CO2. MTT solution was then 
removed and 100μl propanol was added per well for at least 30 minutes incubation at 
37°C to dissolve crystals. The absorbance of this coloured solution was quantified by 





2.2.5 Flow Cytometry studies for apoptosis, cellular protein 
expression and liposomal uptake 
 
Principle 
Flow cytometry is a popular biophysical technique that employs laser technology to 
count, sort and profile cells in a heterogeneous fluid mixture. In a flow cytometer, the 
cells in a liquid stream pass in a single file through a laser light beam and their 
interaction with the light is detected by a detector either as light scatter or fluorescence 
intensity (Vladimir et al., 2007). It is also a quantitative technique as when a fluorescent 
label is bound to a cellular component, the fluorescent intensity detected, represents the 
concentration of that particular component.  
Flow cytometry is a powerful tool because it allows simultaneous multiparametric 
analysis of the physical and chemical characteristics of up to thousands of particles per 
second. This makes it a rapid and quantitative method for the analysis of cells in 
suspension. In a conventional flow cytometry, forward-scatter, side-scatter, and 
fluorescent signal are detected from different filters and electronical data are collected. 
The diagram below illustrates the general procedure of a typical flow cytometry set up 




Fig 2.2.5: Illustration of a flow cytometry experimental set up (Flow cytometry, no date.) 
 
This technique is especially useful when specific biomarkers presented on the cellular 
surface, the expression of proteins and apoptosis induced in the cells after a certain 
treatment need to be determined. 
  
Apoptosis analysis   
Apoptosis is genetically programmed cell death in eukaryotes which is crucial during 
embryogenesis, in immune response development, maintenance of homeostasis and 
tumour regression (Wyllie, 1997). During the early stages of apoptosis, certain signals 
activate a family of proteins known as caspases in the cells.  These enzymes cleave key 
cellular substrates necessary for cellular functions such as nuclear proteins and 
structural proteins in cytoskeleton (Riccardi and Nicoletti, 2006). This brings about a 
number of morphological and distinct biophysical changes in the cells such as plasma 
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membrane blebbing or its loss of plasma membrane symmetry, nuclear condensation 
and internucleosomal DNA cleavage (Arends, Morris and Wyllie, 1990). In essence, the 
loss of plasma membrane symmetry is one of the earliest hallmarks of apoptosis. During 
the induction of apoptosis, the membrane phospholipid phosphatidylserine (PS) which 
is usually present in the inner leaflet of the plasma membrane translocates to the outer 
side, exposing itself to the external cellular environment (van Heerde et al., 2007).  
Annexin V is a 35-36 kDa phospholipid-binding protein which has a high affinity for 
PS. Hence, Annexin V binds to the exposed apoptotic cell surface PS (Vermes et al., 
1995). Annexin V is usually conjugated with fluorochromes (for instance, FITC) and 
hence, it can serve as a sensitive probe for flow cytometric analysis of early apoptotic 
cells (van Heerde et al., 2007).  
PS translocation is usually followed by a loss of membrane integrity either from 
apoptotic or necrotic processes. Hence, another dye such as propidium iodide (PI) is 
used in conjunction with Annexin V to distinguish between cellular populations 
undergoing early or late apoptosis. Viable cells undergoing early apoptosis have intact 
membranes, so they bind to Annexin V but exclude PI, whereas the membranes of 
damaged cells are permeable to PI. Therefore, viable cells are both Annexin V and PI 
negative, early apoptotic cells are Annexin V positive but PI negative and late apoptotic 
or necrotic cells are both Annexin V and PI positive (van Heerde et al., 2007). This 













Fig 2.2.6: Illustration showing healthy and apoptotic cells with markers for detection of apoptosis and 
flow cytometric analysis of such cell populations before and after the apoptosis inducing treatment 
(Apoptosis, no date). 
 
Protein analysis 
It works on the principle that when antibodies are conjugated to fluorescent dyes, they 
can bind to specific proteins either on the cell surface or intracellularly. When such 
fluorescently labelled cells pass through the laser, the fluorescent molecules are excited 
to higher energy state, which emit radiations upon returning to their ground state, 





Cellular uptake studies of fluorescent liposomes 
Labelling liposomes by coupling a fluorescent dye with their membrane component or 
encapsulating a fluorescent compound within their lumen can allow us to analyse the 
amount of fluorescent liposomes taken up by the cells through flow cytometry (Ducat et 
al., 2007). Following laser excitation, each cell emits fluorescence characteristic of the 




A flow cytometer has three main components: fluidics, optics and electronics (Ãlvarez-
Barrientos, 2000). The first component has a flow cell where the sample fluid is 
injected. The sheath fluid carries and aligns the cells in a single file through a narrow 
channel where it can be intercepted with the laser beam. The optics component has a 
laser light source and various filters and light detectors.  Lasers are available at different 
wavelengths ranging from ultraviolet to far red and have a variable range of power 
levels. The interaction with the laser light causes a compatible fluorophore to excite and 
then fluoresce at a certain wavelength. The detector in the front measures forward 
scatter (FSC) while the detectors to the side measure side scatter signals (SSC). 
Fluorescence detectors measure the fluorescence intensity from the positively stained 
cells. These light signals are converted to data by the electronics system that can be 
visualized and interpreted by software (Adanet al., 2017). The diagram below illustrates 











Cells from different cell lines were seeded at 5 × 10
5
/ml in six-well culture plates and 
grown overnight for the cell attachment. Desired treatments were applied to the cells. 
After appropriate time interval, the cells were washed twice with PBS, trypsinized, 
washed again by PBS twice and then collected into 15-ml centrifuge tubes for further 
staining. The cells were re-suspended in 500µl Annexin-V binding buffer before 
incubating them with 5µl FITC- conjugated Annexin-V and 5µl PI according to the 
protocol described for the product. All samples were analysed within 1 h of PI staining 
using FACSCalibur. Excitation was done at 488 nm and the emission filters used were 
350nm FL1 detector (Annexin V-FITC) and FL3 detector for PI. A minimum of 10000 
cells per sample were analysed. Electronic compensation was used to eliminate bleed 
through of fluorescence. Data analysis was performed with the standard CellQuest Pro 
software where percentages of events in each quadrant were calculated from the 
scatterplot to analyse the cellular population undergoing early or late apoptosis. 
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Protein expression analysis 
Cells were grown in T-75 flasks till they attained confluency. After being treated for the 
intended duration of time, they were harvested with trypsin followed by centrifugation 
to collect them. The obtained cell pellet was resuspended in media and counted to 
collect around two million cells in separate Eppendorf tubes. The tubes were again 
centrifuged at 1500rpm for 3 min and resuspended in 4% formaldehyde at 37°C for 10 
min to fix the cells. The tubes with the cell pellets were chilled on ice for 1 minute. The 
cells were pelleted by centrifugation, the fixative removed and resuspended in 90% 
methanol for 30 min on ice to permeabilise the cells. The cells are centrifuged and 
washed once with incubation buffer containing 0.5% BSA in PBS. The cells are blocked 
in the same incubation buffer for 10 minutes at room temperature. Primary antibody is 
added to each assay tube at an appropriate dilution and incubated for 1 hour at room 
temperature. After washing the cells in the incubation buffer once, the cells are 
incubated with fluorochrome- conjugated secondary antibody diluted in incubation 
buffer, for 30 minutes at room temperature. The cells are washed once with incubation 
buffer, resuspended in 0.5 ml PBS and analysed on flow cytometer. The fluorescence 
intensity observed by flow cytometry corresponds to the amount of proteins present in 
the sample. A histogram of the fluorescence intensity was plotted and the percentage 
total of cells staining for the protein for each cell type was compared. 
 
Cellular uptake of fluorescent liposomes analysis 
Briefly, the experiments were set up in 6 well plates, where the cellular uptake of non-
targeted and targeted liposomes of varying ligand PEG spacers were investigated. 
Around 1 million cells were seeded per well in 1 ml media and allowed to attach 
overnight. The cells were drugged with 9μM liposomes for 2 h, 6 h and 24 h and were 
washed twice with PBS. The cells were trypsinised and the cell pellet obtained was 
washed again. The cells were centrifuged to obtain a pellet which was resuspended in 
500µl ice cold PBS and analysed. The fluorescence intensity of the samples were 
analysed and the histograms obtained of targeted liposomes were compared with that of 
non-targeted liposomes to draw a comparative study of any enhancement in cellular 
uptake resulting from liposomal targeting.  
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2.2.6 ICP-MS uptake studies 
 
Principle 
Inductively Coupled Plasma-Mass Spectrometry is perhaps the fastest growing 
analytical technique for trace elements determination. It is capable of carrying out rapid 
multi-element determinations at the ultra-trace levels (Thomas, 2013). ICP-MS has a 
clear advantage over ICP-OES with its superior detection limits and isotopic 
capabilities.  An ICP-MS combines a high temperature ICP (Inductively Coupled 
Plasma) source with a mass spectrometer. The ICP source converts the atoms of the 
elements in the sample to ions. These ions are then separated and detected by the mass 
spectrometer (Thomas, 2013).  
 
Instrumentation 
The main components of ICP-MS are nebuliser, spray chamber, plasma torch and 
detector (Fig 2.2.8). The sample, usually in the liquid form, is pumped into the nebuliser 
with a peristaltic pump, where it is converted into a fine aerosol with argon gas. The 
spray chamber separates the fine droplets of the aerosol containing 1-2% of the sample 
from the larger droplets. The fine aerosol emerging from the spray chamber is 






Fig 2.2.8: Schematic representation of ICP-MS instrument (ICP-MS, no date) 
 
The plasma is formed in exactly the same way as ICP-OES, by the interaction of argon 
gas with an intense magnetic field produced by RF passing through a copper coil 
through ICP torch. However, this is where the similarity ends. In ICP-OES, whereas the 
plasma is used to generate photons of light, in ICP-MS, it is used to generate positively 
charged ions and not photons. In fact, every attempt is made to stop the photons from 
reaching the detector because they have the potential to increase signal noise. It is the 
production and the detection of large quantities of these ions that give ICP-MS its 
characteristic low parts per trillion (ppt) detection capability—about three to four orders 
of magnitude better than ICP-OES (Thomas, 2013). 
Once the ions are produced in the plasma, they are directed into the mass spectrometer 
via the interface region, which consists of two metallic cones, called the sampler and a 
skimmer cone, each with a small orifice (0.6–1.2 mm) to allow the ions to pass through 
to the ion optics. The ion optics serves the purpose of electrostatically focusing the ion 
beam towards the mass separation device while stopping photons and neutral species 
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from reaching the detector. The most commonly used mass separation devices are 
quadrupole, magnetic sector, time of flight, and collision/reaction cell technology, 
which serve the common purpose of allowing analyte of a particular mass to charge 
ratio through to the detector while stopping the interfering ions. The final process is to 
convert the ions into an electrical signal with an ion detector (Thomas, 2013). The basic 




Fig 2.2.9: A Thermo Scientific X-Series 2 ICP-MS instrument. 
 
Protocol 
For the analysis of cellular uptake of liposomal arsenic via ICP-MS, cells from different 
cell lines were seeded into 75-cm
2
 flasks at a density of 1 × 10
6
 cells/flask, with two 
flasks for each treatment as a doublet. Following a 24-h cell attachment, cells were 
treated with appropriate liposomal formulation or free arsenic. After incubation for the 
desired time interval, cells were washed by PBS, trypsinized and counted before they 
were collected into Falcon tubes for further analysis. Cells were extracted by adding 1 
ml of nitric acid while vortexing and heated at 90°C for ten minutes to further complete 
the digestion. The cellular extract was topped up with deionised water in the ratio 
similar to ICP-MS matrix and arsenic concentration analysed using ICP-MS. The 






Immunocytochemistry (ICC) is a common laboratory technique that is used to visualise 
the location of specific proteins in cells by exploiting the specific epitope-antibody 
interactions. Briefly, the cells are attached to a solid support such as a coverslip and 
then fixed with either 4% paraformaldehyde or ice-cold methanol to preserve tissue 
morphology and retain the antigenicity of the target epitope. After fixation, the cells 
have to be blocked with a blocking reagent such as goat serum or bovine serum albumin 
to prevent non-specific interactions, i.e. binding of the primary antibody to amino acids 
other than those within the desired epitope of the antigen. These steps are performed 
prior to incubation of the sample with the primary antibody. Following incubation with 
the primary antibody, antibody binding is visualized using an appropriate detection 
system. The method of detection can be direct or indirect, and may generate a 
fluorescent or chromogenic signal depending on the substrates and conjugated signal 
tag. Direct detection involves the use of primary antibodies that are directly conjugated 
to a label. Indirect detection methods utilise a labelled secondary antibody raised against 
the primary antibody host species (Fig 2.2.10) (Paul, 2003). Indirect methods can also 
include amplification steps to increase signal intensity. The most common amplification 
method used in ICC is Avidin-Biotin complex (ABC) method.  
 
 
Fig 2.2.10: Indirect and direct detection in ICC (Direct vs indirect immunofluorescence, no date) 
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ABC method takes advantage of the fact that Avidin, a 68 kDa glycoprotein in egg 
white, has a strong affinity for Biotin. Biotin is a low molecular weight vitamin that can 
be conjugated to a variety of biological molecules such as antibodies (Hsu, Raine and 
Fanger, 1981). Avidin is labelled with peroxidase or fluorescein. If a biotinylated 
secondary antibody is employed, the signal can be significantly amplified by subsequent 
incubation with an Avidin-Biotin complex. 
For the visualization of epitope-antibody interactions, commonly used labels include 
fluorophores and enzymes that convert soluble substrates into insoluble, chromogenic 
end products.  
 
Fluorescent staining 
Fluorescence staining is based on the principle that a fluorochrome, conjugated to the 
primary or secondary antibody, emits light when excited by light of shorter wavelength. 
Immunofluorescence cytochemical staining is a powerful technique for the 
simultaneous visualisation of multiple cellular targets. For that purpose, fluorochromes 
should be chosen that emit light of different wavelength and the primary antibodies 
should be derived from different species to avoid cross-reactivity. The excitation and 
emission wavelengths for fluorescent markers used in this study are presented in Table 
2.2.1. 
 
Table 2.2.1: The excitation and emission wavelengths of fluorophores used in the study. 
 







490nm 520nm Green 
4',6-diamidino-2-
phenylindole (DAPI) 
372 456 Blue 
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The slides are then visualised with confocal microscopy. For amplification of 
fluorescent signals, Tyramide Signal Amplification (TSA) detection method might also 
be used that utilises the catalytic activity of horseradish peroxidases (HRP) to activate 
multiple copies of dye labelled tyramide. (Fig 2.2.11) This signal amplification caused 
due to multiple tyramide substrate activation per peroxidase label results in 
ultrasensitive detection of low-abundance targets and the use of smaller amounts of 




             (a)                                          (b)                                         (c)                                         (d) 
 
Fig 2.2.11: TSA signal amplification method (McCloughlin, 2016). (a) Incubation with primary antibody 
(b) secondary antibody incubation with HRP (c) Incubation with TSA reagent where HRP catalyses 
formation of TSA free radicals and (d) TSA free radicals form covalent bonds with tyrosine residues 
proximal to HRP causing signal amplification. 
 
Chromogenic staining  
For chromogenic staining, an enzyme is conjugated to either primary or secondary 
antibody.  When a suitable soluble organic substrate is added, the enzyme which is 
conjugated with the bound antibodies will react with the substrate and generate an 
insoluble, coloured product. This coloured product is localised to the sites of relevant 
protein expression. One of the most commonly used enzymes is Horseradish Peroxidase 
(HRP) which catalyses the oxidation of 3, 3′-diaminobenzidine (DAB) reagent into a 
dark brown precipitate (Fig 2.2.12). A counterstain is employed along with DAB such 
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as haematoxylin to stain cellular nucleus. Chromogenic staining is more sensitive than 
immunofluorescence albeit less convenient due to the necessity of more incubation 
steps and blocking. Additionally, DAB precipitate is not sensitive to light and can be 
stored for many years. It also requires only a common light microscope rather than a 
fluorescent microscope for fluorescent staining (Immunohistochemical Staining 










The cells were counted and seeded at a density of 5 × 10
4
/ml on sterile cover slips 
placed in six-well plates. The cells were grown for overnight attachment followed by 
washing and fixation with 4 % paraformaldehyde in PBS for 8 mins. 0.1% Triton in 
PBS was then applied for 7 mins to permeabilise cellular membranes in instances where 
detection of intracellular proteins was desired, but this permeabilisation step was 
skipped if surface antigens had to be probed. Unspecific antigenic binding were blocked 
with 50% horse serum for 8 min before the primary antibody was applied for 90 min at 
room temperature,  which was  followed by 30 and 20 min of secondary and tertiary 
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antibodies respectively, using an ABC universal kit. Visualisation of the desired antigen 
was made using a Tyramide Signal Amplification (TSA) Cyanine 5 or Fluorescein 
System. Cover slips were then washed in PBS and mounted on slides using anti-fade 
mounting media with DAPI and kept for 15 min in dark before examination. The 
fluorescence emitted from each slide was observed via a confocal microscope and 
images were recorded accordingly. 
 
Chromogenic staining  
For chromogenic staining, a similar protocol was followed as in fluorescent staining till 
the tertiary antibody incubation from the ABC universal kit. Following that, DAB 
reagent was applied for 1-2 minutes and washed with PBS as soon as the dark brown 
precipitate formation was observed. Slides were then counterstained with haematoxylin 
for 5 mins, followed by a quick rinse in acid alcohol to differentiate and then left in 
running tap water for 5 mins. The slides were mounted using immunomount and 











2.2.8 Western blot 
 
Principle 
Western blotting, also referred to as immunoblotting, is a widely accepted technique to 
detect specific proteins in a given sample. It employs sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) to separate various proteins in a given 
sample based on the length of their polypeptide following their denaturation. The 
separated proteins are transferred onto a matrix (usually nitrocellulose or PVDF) and 
probed with antibodies specific to the target protein. A secondary antibody raised 
against the primary antibody host species and conjugated to HRP is used which gives a 
signal in the form of a “band”, capable of being analysed. By analysing location and 
intensity of the band, expression of the target protein in the given cell samples can be 
determined (Hall, 2004).   




SDS-PAGE entails the electrophoresis technique based on the principle that under the 
influence of an electric field, charged particles move towards the opposite electrodes. 
This results in separation of proteins as their electrophoretic mobility depends on 
charge, molecular size and structure. Polyacrylamide gel (PAG) is a three dimensional 
polymer network prepared by free radical polymerisation of acrylamide and a cross 
linker bisacrylamide, initiated by ammonium persulfate and under the catalytic effect of 
tetramethylenediamine (TEMED). PAG is a versatile supporting matrix and has 
multiple electrophoretically desirable features including its being synthetic, transparent, 
strong, chemically inert and thermo-stable (Kinoshita, Kinoshita-Kikuta and Koike, 
2009). It is also amenable towards being prepared with a wide range of pore sizes 
(Kinoshita, Kinoshita-Kikuta and Koike, 2009).  
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In the presence of SDS, which is an anionic detergent, electrophoretic mobility is based 
on molecular weight instead of charge and size of the protein. This is owing to the fact 
that SDS denatures the proteins and breaks their secondary and tertiary structures by 
breaking hydrogen bonds between and within the molecules. Stronger reducing agent 
such as mercaptoethanol further disrupts the disulphide linkages between cysteine 
residues. These reducing agents linearize the proteins and impart a negative charge to 
them. This negative charge imparted to the protein molecule due to the binding of SDS 
causes proteins to unfold into a rod-like shape, with the length proportional to the 
molecular weight of the protein. The samples are further heated at 90°C which further 
promote SDS binding and rod-shape formation of the proteins. Bromophenol blue dye is 
added to the sample to track the movement of protein solution through the gel during 
the electrophoretic run. As the voltage is applied, the negatively charged proteins-SDS 
molecules migrate towards the positive electrode in the lower chamber, with proteins of 
small molecular weight migrating faster than the heavier protein molecules (Fig 2.2.13) 





Fig 2.2.13: Illustration of the principles of SDS-PAGE (Molecular Weight Determination of Protein 
Extracts – Background, no date) 
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Protein Blotting 
Proteins are blotted from the gel onto a membrane, usually made of nitrocellulose (NC) 
or polyvinylidene difluoride (PVDF) (Fig 2.2.14). NC membranes of 0.45 µm pore size 
are usually chosen for proteins with molecular weight over 20kDa. Transfer methods 
are mostly of two types: semi-dry transfer and wet transfer. In the semi-dry transfer, 
Filter-Gel-Membrane-Filter sandwich is loaded with transfer buffer and the transfer 
process occurs by current conduction produced by transfer buffer.  
 
 




There are four principle steps in the protein probing on nitrocellulose membrane: 
blocking, primary and secondary antibody incubation, protein detection and analysis. To 
probe for a specific protein, it is crucial to first block the unreacted sites on the 
membrane to reduce the amount of non-specific binding during subsequent steps of 
antibody incubations. Blocking buffers should block all the non-specific sites, must not 
bind to the epitope of the target protein or cross-react with the antibodies or detection 
reagents. Typically 5% non-fat dry milk in PBT-T or TBS-T (Tween-20) is the most 
economic choice. Following the blocking step, the membrane is incubated with a 
primary antibody specific to the target protein. Membrane is washed to remove the 
unbound primary antibodies and further incubated with a secondary antibody 
conjugated to an enzyme, usually HRP. Following the washing steps to again remove 
unbound secondary antibodies, a substrate specific to the enzyme conjugated to 
secondary antibody is applied to the membrane. The enzyme converts the substrate to a 
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coloured product which shows as a visible protein band on the membrane (Fig 2.2.15) 




Fig 2.2.15: The probing of membrane for the protein of interest via primary and secondary antibody 





Cells were seeded and grown overnight in 25cm
2
 flasks and incubated with desired 
treatments for pre-determined length of time. Following the treatment step, cells were 
washed twice with ice cold PBS and lysed with RIPA buffer and protease inhibitor 
cocktail at a concentration of 1 ml: 10µl per 1-10×106 cells for 30 min at 4°C. Cell 
lysate was collected with a cell scraper and cleared of cell debris by centrifugation at 
10000g for 10 min at 4°C. The cell lysates were either stored at -80°C or quantified for 




Protein concentration was determined by Bradford Assay. Briefly, protein standards 
were prepared with 2mg/ml BSA stock solution at a range of 0.1-1.4 mg/ml and 5µl of 
the standards were added to the wells of 96 well plate. 5µl of lysates of cell samples 
were also added as the unknown samples along with dionised water as control buffer. 
250µl of Bradford reagent was added to all the wells, mixed on a shaker for 30 sec and 
incubated further for 2 min. The absorbance was read at 595nm on FluoStar Omega 
BMG Plate Reader and the concentration of unknown samples was calculated with the 
curve obtained after plotting the net absorbance vs protein concentration of the 
standards. 
 
Protein probing via Western Blotting technique 
After calculating the concentrations, samples containing 30µg of protein for each lysate 
was mixed with reducing loading buffer, separated on an SDS-12% polyacrylamide gel 
and transferred to nitrocellulose membrane. Total protein quantification for 
normalisation was done using REVERT total protein staining technique by incubating 
the membrane with the stain for 5 min, imaging it at 700nm channel on Licor Odyssey 
Imaging system. Nitrocellulose membranes were then blocked with 5% non-fat dry milk 
in PBS containing 0.3% Tween 20 for 1 h. It was incubated overnight with primary 
antibody and anti-β-actin as a loading control (in instances where REVERT total protein 
stain quantification was not performed) at 4°C. After intensive washings with PBS 
containing 0.1% Tween, membrane was incubated with HRP conjugated secondary 
antibody for 1 h at room temperature. After repeated washings, detection was performed 






2.2.9 Statistical analysis 
Statistical analysis described in experimental sections was done with Minitab17. 
Statistical significance was determined by 2-sample t-test. P< 0.05 was considered as 
statistically significant difference. For flow cytometry, statistical analysis was carried 
out automatically through BD Calibur software provided. Mean and coefficient of 
variation (CV) were calculated accordingly. For results from Western blotting studies, 
the signals were normalised using Image J software and mean and SD calculated. For 
immunostaining results, an average number from positively stained cells in a total of six 





















3.1 OPTIMISING LIPOSOMES FOR EFFECTIVE 
DELIVERY OF ARSENIC TRIOXIDE TO HPV 
POSITIVE CERVICAL CANCER CELLS: SIZE 







Cervical cancer is linked to high-risk HPV infections, especially the subtypes HPV-16 
and HPV-18 (Appleby et al., 2007; Doorbar et al., 2012; Lorusso et al., 2014). Since, 
the combination treatment of surgery and/or chemoradiotherapy has severe side effects, 
alternative treatment options are sought that provide better efficacy and specificity with 
fewer side effects on the surrounding healthy tissues and cells (Ordikhani et al., 2016; 
Schiffman et al., 2011). Ideally, an anti-HPV agent that can be taken up more 
specifically by HPV-infected cells is needed because of the crucial role of high-risk 
HPV infections in the pathogenesis of cervical cancer. In addition, if a drug carrier can 
deliver the drug to the cancer cells and release it slowly, a consistent flow of 
medication, which may enhance the therapeutic effect of the delivered drug, could be 
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maintained. Moreover, the toxic effects on non-HPV-infected surrounding cells and 
tissues would be reduced.  
 
Our research team along with others have shown that ATO, as a therapeutic drug, has an 
inhibitory effect on HPV infected cervical cancer cells HeLa and it downregulates 
HPV’s cancer causing genes (Um et al., 2002; Wen et al., 2012). However, 
conventional chemotherapeutics, including ATO, face severe limitations in clinical 
utility to treat solid tumours, either due to their inability to reach target tissue in 
therapeutic drug concentrations or causing systemic toxicities to surrounding healthy 
organs and tissues (Chang and Yeh, 2012). Nanotechnology-based drug delivery 
systems can specifically target cancer cells, avoid their healthy neighbours and also 
prevent its rapid clearance from the body, thereby resulting in an increase of the drug’s 
therapeutic index (Ordikhani et al., 2016; Shi et al., 2010).  
 
Among the many nanocarriers that have been discovered to date, the oldest and most 
commonly employed nanoparticles are liposomes (Allen and Cullis, 2013; Farokhzad 
and Langer, 2009; Sercombe et al., 2015). Liposomes are nano-scaled, spherical 
compartments which surround an aqueous core capable of encapsulating water soluble 
drug within a phospholipid bilayer. Aided by PEG layer to evade immune response, 
these long circulating liposomes show improved pharmacokinetics and bio-distribution 
in clinical trials minimising toxicity to surrounding organs by accumulating within the 
target tissue (Chang and Yeh, 2012). 
 
One of the initial attempts to form ATO encapsulated liposomes was by hydrating lipids 
in a concentrated solution of ATO followed by freeze drying (Kallinteri et al., 2004). 
Zhao et al. (2008) prepared liposomes encapsulating ATO and intravenously injected 
them to investigate their therapeutic effect on C6 gliomas established in rat brains. 
Liposomal preparation led to a five-fold increase in arsenic concentration in rat brains 
as compared to ATO solutions, along with fewer side effects. It was observed to induce 
apoptosis and inhibit tumour angiogenesis by interfering in the expression of VEGF. 
However, the liposomes formulated suffered acute limitations of stability and were 
stable only for a maximum of three days, which severely hampered their further 
therapeutic use. 
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This lack of stability was to be expected as in physiological solutions, ATO is present as 
neutral arsenous acid, which rapidly diffuses across the lipid membranes (Kallinteri et 
al., 2004). The formulated liposomes hence were highly unstable with a stability life 
span of around 3 days. The issue of such “leaky liposomes” was solved when Chen et 
al. (2006) utilised the “remote loading phenomenon” to stably encapsulate ATO in 







form a precipitate. Utilising this property, liposomes formed were first loaded with 
acetate solution of a transition metal ion, Ni found to be the most efficient, and then 
ATO was added to the liposomes formulated (Chen et al., 2006). Efflux of protonated 
acetic acid drove ATO to get loaded within the liposomes where it was stably 
encapsulated with the transition metal ion in the form of a solid, crystalline precipitate 





Fig 3.1.1: Schematics of arsenic loading mechanism within a liposome. The external, neutral As (OH)3 
diffuses across the membrane and forms insoluble nickel arsenite complex within the liposomes. The 
protons released associate with basic acetate ions. The weak acetic acid diffuses out of the liposomes in 
exchange for more As (OH)3 leading to arsenic loading (Chen et al., 2006). 
 
Although drug encapsulating liposomes are an exciting and promising prospect, 
optimisation is required in order to use them as a desirable drug delivery vehicle. There 
are many physicochemical characteristics that need to be considered, including size, 
surface charge, zeta potential, shape, membrane lipid packing, steric stabilization, and 
PEG fluidity. These features influence the pharmacokinetic properties of liposomes by 
controlling their clearance process, surface toxicity, MPS recognition, and EPR effect 
(Chang and Yeh, 2012; Zamboni et al., 2012). Among these factors, size and surface 
93 
charge are the two key characteristics of nanoparticles that affect their EPR, immune 
clearance, and cellular adhesion and uptake (Yu Nie et al., 2012). 
 
While a few studies have investigated the effects of both the surface charge and size of 
liposomes on cellular uptake, the results have been inconsistent (Dan, 2002; Gabizon et 
al., 1999; Kijanka et al., 2015; Miller et al., 1998; Yu Nie et al., 2012). Regarding 
surface charge, Yu Nie et al. (2012) reported that positively-charged cationic liposomes 
were more readily taken up by cells, both in vitro and in vivo, because of the interaction 
with the negatively-charged cell membrane. In contrast, Miller et al. (1998) found that a 
negative surface charge on liposomes increased endocytosis by some cell types. An 
earlier study reported that liposome–cellular interaction depends not only on the 
liposomal charge, but also on the lipid composition and, more importantly, the cell type 
(Dan, 2002). Therefore, it is crucial to optimise the liposomal construct in order to 
identify the best charge for the target cancer cell line under investigation.  
 
An optimum size for nanoparticles is also important, as the kidneys rapidly clear any 
nanoparticle with a size below 10 nm, while those above 150 nm in size would face the 
risk of recognition and clearance by the body’s immune system (Kijanka et al., 2015). 
However, larger nanoparticles have been reported to benefit from having higher 
encapsulation efficiencies, which increases drug delivery to the target tissue (Gabizon et 
al., 1999). Based on the inconsistency of previous findings, this study attempted to 
identify the most suitable liposomal formulation, with respect to size and charge, for 
delivering ATO into cervical cancer cells, and thereby enhance the therapeutic potential 
of the delivered drug.  
 
 
3.1.1.2 Aims:  
 
The aim of this chapter was to optimise the ATO encapsulating liposomes in terms of 
best size and charge to increase their efficacy as nano-carriers of ATO to HPV positive 




3.1.1.3 Objectives:  
 
i. To synthesise and characterise ATO encapsulating liposomes of different sizes 
(100nm, 200nm and 400nm) and charges (neutral, positive and negative);  
ii. To select the most optimal formulation based on its physicochemical and 
biological properties (loading efficiency, stability and inherent cytotoxicity);  
iii. To investigate the in vitro anti-tumoral efficacy and uptake of the most optimal 
formulation on both HPV positive and negative cell lines, HeLa and HT-3, along 
with any difference in its anti-cancer response towards them; and  
iv. To investigate its toxicity towards normal cells. For that purpose, two normal 















3.1.2 Materials and Methods 
 
3.1.2.1 Liposome Preparation and Characterisation 
 
Liposomes of different sizes and charges were synthesised as detailed in Chapter 2. 
Their loading efficiency (As/P ratio) was determined by ICP-OES and mean liposomal 
size along with zeta potential was calculated via dynamic light scattering on a Zetasizer-
Nano ZS. Liposomal stability over a period of a month was assessed by analysing their 
loading efficiency every week while liposomes were stored at 4°C in buffers of pH 7.4. 
Drug release as a function of pH was assessed by checking their As/ P ratio when 
liposomes were dialysed in buffers of pH 4, pH 7 and pH 10 for a period of 1, 2, 4, 6 
and 24 h.  
 
3.1.2.2 Cell lines 
 
Two cervical cancer cell lines, HeLa and HT-3 along with two control cell lines, human 
epidermal keratinocytes HK and human colon epithelial cells CRL-1790 were employed 
for this study. The following experiments were set up for further investigations 
following liposomal ATO exposure for different time intervals: cellular toxicity via 
MTT Assay, flow cytometry analysis for cell apoptosis and quantification of cellular 
arsenic uptake. 
 
3.1.2.3 Cellular toxicity via MTT Assay 
 
Cytotoxicity of various liposomal formulations of ATO was determined by an MTT 
Assay as described in Chapter 2. Briefly, the experiment was set up in a 96 well plate, 
where the toxicity of control empty liposomes was investigated by taking an initial 
starting amount containing 0.5mM of phospholipid concentration and diluting it in 1:10 
ratio to further 6 wells. The ATO encapsulating liposomes contained 30µM of ATO 
concentration in the initial sample, which was further diluted in the 1:6 ratio down to 6 
wells. The wells were seeded with HeLa, HT-3, CRL 1790 and HK at a density of 0.6 
million cells per ml and incubated at 37°C in the humidified incubation chamber for 24 
96 
h, 48 h and 72 h. After the intended incubation, MTT Assay was performed as per the 
described protocol and absorbance of the final coloured solution read and quantified via 
BMG LabTech FLUOstar Omega Plate Reader at a wavelength of 570 nm. 
 
 
3.1.2.4 Analysis of Cell Apoptosis by Flow Cytometry
 
 
Cells from the four different cell lines were seeded at 5 × 10
5
/ml in six-well culture 
plates and grown overnight for cell attachment. 100nm, neutral liposomes were 
employed for this experiment. After 24 h of treatment (media only, liposomal ATO at a 
dilution having 5µM ATO encapsulated, empty liposomes at the same dilution as 
liposomal ATO, 5µM free ATO), the cells were analysed for apoptosis induction via 
flow cytometry according to the protocol described for Annexin V FITC apoptosis 
detection kit (Abcam, UK) used for this study (more details in Chapter 2).  
 
3.1.2.5 Quantitative Analysis of Cellular Uptake of Arsenic by ICP-MS 
 
Cellular uptake was analysed for different treatments at a time period of 6, 24 and 48 h 
by ICP-MS as described in Chapter 2. For each analysis, cells from the four different 
cell lines were seeded into sixteen 75-cm
2
 flasks at a density of 1 × 10
6
 cells/flask, with 
two flasks for each treatment as a doublet. Following a 24-h cell attachment, cells were 
treated as described below: control (cells in untreated media), ATO lipo (5µM ATO 
encapsulating liposomes), empty lipo (control liposomes at the same dilution as ATO 
lipo), and ATO (5µM free ATO) and their arsenic concentration determined after the 
desired time interval.  
 
3.1.2.6 Statistical Analysis 
 
Statistical analysis described in experimental sections was done using Minitab17. 
Statistical significance was determined by 2-sample t-test. P< 0.05 was considered 
significant. For flow cytometry, statistical analysis was carried out automatically 






3.1.3.1 Liposome Preparation and Characterization 
 
The mean sizes and zeta potential of control liposomes were determined by dynamic 
light scattering on a Zetasizer-Nano ZS (Malvern Instruments) as represented in Fig 
3.1.2. The DLS measurements of the hydrodynamic sizes of the 100nm, 200nm and 
400nm liposomes were 138.5 ± 1.22nm, 187 ± 2.96nm and 243 ± 2.68nm respectively 
(Fig 3.1.2a). All of the charged liposomes were extruded through a 100 nm filter. 
Positively-charged and neutral PC liposomes had a similar hydrodynamic size of 138.5 
± 1.22 nm and 143.9 ± 3.19 nm, respectively. However, the incorporation of a 
negatively-charged lipid DSPG slightly increased the particle size to 165.2 ± 3.26 nm 
(Fig 3.1.2b). No significant differences were observed between these three sizes. The 
polydispersity index of the investigated vesicles had values from 0.12 to 0.175 
indicating homogenous population of liposomes. Regarding the zeta potential, the group 
of liposomes that exhibited a small negative surface charge, (-) 24.4 ± 0.46 mV were 
considered neutral. Cationic liposomes possessed a positive charge, (+) 23.2 ± 0.44 mV, 



































Fig 3.1.2: Diameter and zeta potential of liposomes of (a) different sizes and (b) different charges as 
measured from Zetasizer with a polydispersity index of around 0.1. All of the different-sized 
liposomes (100 nm, 200 nm, and 400 nm) have a neutral charge, whereas all of the different-charged 
liposomes (neutral, positive, and negative) are 100 nm in size. Data are means ± standard deviations of 
three replicate measurements of at least three independent experiments. * p≤0.05. 
 
 
The liposomes were efficiently loaded with arsenic co-encapsulated with transition 
metal ion Ni. The phospholipids, encapsulated arsenic and nickel in the liposomes were 
quantified by ICP-OES. The loading efficiencies (encapsulated arsenic/phospholipids) 
of liposomes of different sizes and charges are depicted in Fig 3.1.3. The loading 
efficiency was the highest for 100nm neutral liposomes at 24.2 % As/ P ± 0.848. The 
liposome suspension was stored at 4°C for a month and its stability was deduced by 
analysing its loading efficiency every week (Fig 3.1.4). Less than 10% arsenic leaked 
from the liposomes in a time period of 1 month. All the liposomal formulations 












































































Fig 3.1.3: Loading efficiency of synthesised liposomes of (a) different sizes and (b) different charges. 
Data are means ± standard deviations of three replicate measurements of at least three independent 
experiments. An unpaired t test (p > 0.05) was used to test for any significant difference in the loading 
efficiency of liposomes of three sizes (ranging from 100 to 400 nm), and three charges (neutral, negative, 
and positive). No significant difference was observed between the liposomes of different sizes, although 







Fig 3.1.4: ATO encapsulated over a period of 4 weeks of storage at 4°C. Data shown is means ± standard 




In order to assess the effect of pH on the liposomal formulation (and hence determine 
the drug leakage pattern that is initiated when encountering different pH), liposomes 
were dialysed in buffers of pH 4, pH 7 and pH 10. The amounts of the drug that were 








































































































3.1.5). At pH 4, approximately 40% of the drug was lost within the first four hours. 
Among the different sizes, the smallest (100nm) liposomes were found to be the most 
stable at all pH values. With respect to charge, the negatively-charged liposomes 
displayed a significant loss of stability among the charged vesicles when they were 
exposed to a higher pH in comparison with those with a neutral or positive charge.  
 
 

















Fig 3.1.5: Stability studies of different liposomal formulations under various pH conditions. ATO was 
encapsulated in liposomes of (a) different sizes and (b) different charges after dialysing in buffers at pH 
4, pH 7, and pH 10. Data are shown as mean ± SD of three independent experiments. * p < 0.05,  
















































































































































3.1.3.2 Analysing cytotoxicity of control empty liposomes with differing 
sizes and charges 
 
The success of nanoparticles as drug carrier relies on their inherent non-toxic properties. 
Control empty liposomes of various formulations were synthesised and their 
cytotoxicity analysed via MTT assay on HeLa cell line at 24, 48 and 72 h as depicted in 
Fig 3.1.6. The phospholipid concentrations of the liposomes were diluted at the same 
dilution factor that was used for liposomal ATO (encapsulating 5 µM ATO). No 
significant difference in the cytotoxicity from different-sized liposomes was observed at 
the relevant concentrations of liposomes. However, when the surface charges were 
taken into consideration, the empty positively-charged liposomes displayed significant 
toxicity over an incubation period of 48 h. The 100nm, neutral empty liposomes were 






































         represents the concentrations of phospholipid at dilutions used for treatment of liposomal ATO. 
 
Fig 3.1.6: The MTT assay used to test the cytotoxicity of various control liposomal formulations on 
cervical cancer cells. The cellular toxicity that is induced by control (empty) liposomes of different (a) 
sizes and (b) charges is represented following an incubation period of 24, 48 and 72 h with HeLa cells. 
The positively-charged liposomes displayed noticeable toxicity at 48 h exposure and at the same 
dilution factor that was used for diluting liposomal encapsulated ATO. Neutral liposomes were found to 
show the least toxicity. Data are presented as mean± SD of three replicate experiments; ** p < 0.01. 
 




         represents the concentrations of phospholipid at dilutions used for treatment of liposomal ATO. 
 
Fig: 3.1.7: The phospholipid concentrations at dilutions used for the treatment of 100nm, neutral 



















































































































































3.1.3.3 Cytotoxicity and Apoptosis induction of ATO-Encapsulated 
Liposomes in HPV-Positive and HPV-Negative Cervical Cancer Cell Lines 
 
After establishing that neutral liposomes of 100 nm in size were the most stable 
formulation, possessed the highest encapsulation efficiency, and displayed the least 
intrinsic toxicity, this form of liposome was chosen as the drug carrier for the remainder 
of the experiments. The response of cervical cancer cell lines of differing HPV statuses 
(HPV-positive HeLa and HPV-negative HT-3) to the treatment with ATO, delivered 
either in the free form or encapsulated in the chosen liposomes, was investigated with 
regards to cytotoxicity (MTT assay), cellular uptake (ICP-MS), and induction of 
apoptotic response (flow cytometry). 
 
The dose response curve obtained from MTT assay for free drug and liposomal drug 
reveals that liposomal encapsulation mitigates toxicity which is in accordance with 
findings from other cell lines (Chen et al., 2006; 2009; Ahn et al., 2010) (Fig 3.1.8). 
This trend became more noticeable as the drug exposure time increased. The differences 





































      points to 5µM ATO concentrations which is typically used for treatment. 
 
Fig 3.1.8: Liposomal encapsulation attenuates drug toxicity to the cells in vitro. HPV positive and 
negative cervical cancer cells were treated with free ATO and liposomal ATO for a duration of 24 h, 48 




We next analysed the cytotoxic mechanism of free ATO and liposomal ATO in vitro by 
using quantitative flow cytometric analysis of apoptosis after a 24 h and 48 h treatment. 
The cells were labelled by FITC conjugated Annexin-V and PI for the detection of early 
apoptotic and late apoptotic cells. The fluorescence was detected on FL1 and FL3 
channels, respectively, by flow cytometer. The percentage of cell population distributed 
in different quadrants represents live cells (lower left quadrant, Annexin− PI−), early 
apoptotic cells (lower right quadrant, Annexin+ PI−), late apoptotic cells (upper right 
quadrant, Annexin- PI+) and necrotic cells (Annexin+ PI+). The fold increase of 




























































































different treatments (free ATO and liposomal ATO) is summarized in Fig 3.1.9. More 
than 90 % of the cells were alive when treated with cell media or control liposomes. For 
HeLa and HT-3 cells, more apoptotic cells were observed when treated with free ATO, 
which is consistent with MTT assay findings that liposomal ATO is less potent in 
inducing cell death. 
 
 






Fig 3.1.9: Flow cytometry analysis of apoptotic cells in HeLa and HT-3 after treatment with only media, 
empty liposomes, ATO encapsulating liposomes and free ATO of 5µM concentration after (a) 24 h and 
(b) 48 h treatment. Free ATO is more apoptotic than liposomal ATO. Data displayed is mean ± SD from 




















































































































































3.1.3.4 Time course study of cellular uptake of liposomal arsenic 
 
For the cellular uptake studies, the cervical cancer cell lines, HeLa and HT-3, were 
incubated with media only, empty liposomes, liposomal and free drug with 5µM ATO 
concentration for a time period of 6 h, 24 h and 48 h. The cellular concentration of 
arsenic was determined by ICP-MS (Fig 3.1.10). Results showed that no arsenic was 
detected in all the cell lines when treated with cell media or control liposomes. The 
uptake of free ATO was higher than liposomal ATO, around 2.5 times higher for HeLa 
and 6.3 times higher for HT-3 cell line after 6 h incubation. With HT-3, the ratio 
steadily declined with time from 6.3 to 4.9 and finally to 1.9 after 48 h treatment. It 
stayed almost similar though for HeLa at 6 h and 24 h treatment, however slightly 
increased to 4 after 48 h treatment. In both the cell lines, there was a steady increase in 
arsenic concentration with time, except for free ATO treatment on HT-3, where arsenic 
concentration for the free drug was observed to go down by a factor of 0.76 from 24 h 
to 48 h treatment. It was apparent that the uptake for both the treatments is most rapid in 






Fig 3.1.10: Arsenic concentration per cell in HeLa and HT-3 as determined by ICP-MS after 6 h, 24 h and 
48 h treatment with (a) only media, (b) empty liposomes (c) ATO encapsulating liposomes and (d) free 
ATO of 5µM concentration. Free ATO is taken up more than liposomal ATO. Data displayed is mean ± 























































3.1.3.5 Comparisons of the cytotoxicity and uptake of ATO encapsulating 
liposomes between HPV positive and negative cell lines  
 
A comparative study was drawn relating the responses of HPV positive HeLa and HPV 
negative HT-3 cell lines towards liposomal and free ATO in terms of cellular toxicity, 
apoptotic response and cellular uptake of liposomes and free arsenic (Fig 3.1.11 and 
12). The MTT results demonstrated that the cell survival rates after treatment in both 
cervical cancer cell lines were similar for up to 72 h (Fig 3.1.11a). Moreover, using flow 
cytometry to measure apoptosis (Figure 3.1.11b), no statistically significant difference 
was found between the apoptotic populations in HT-3 and HeLa cell lines after 
incubation with either free or encapsulated ATO for up to 48 h treatment. However, a 
clear trend of increased cell death induced by directly exposing both of the cell lines to 
free ATO was observed. The IC50 results that were obtained from the cytotoxicity 
assays are presented in Figure 3.1.11c. The results display similar values for both of the 






































   
(b) 24 h 48 h 
  
 










24h 48h 72h 24h 48h 72h 
HeLa 29.7±2.6 24.8±0.5 17.1±0.3 21.0±0.5 14.7±0.0 14.2±0.2 
HT-3 35.8±1.1 24.3±0.1 14.6±0.9 17.4±1.2 14.4±1.4 12.2±0.6 
 
        
           points to 5µM ATO concentrations which is used for treatment. 
 
Fig 3.1.11: The MTT assay and flow cytometry analysis to compare cellular toxicity and apoptosis 
induction of varying treatments on HeLa and HT-3 cells. (a) Cell viability of HeLa and HT-3 cell lines 
following incubation with liposomal encapsulated ATO (ATO lipo) and free ATO for 24, 48 and 72 h; 
(b) Flow cytometry analysis of apoptotic populations that were treated with complete media as control, 
empty liposomes, liposomal 5 µM ATO, or 5 µM free ATO on HeLa and HT-3 cell lines following 
treatment for 24 and 48 h; (c) Calculated IC50 values for ATO lipo and free ATO treated HeLa and HT-










































































































































































(a) 6 h 24 h 48 h 
 
   





Fig 3.1.12 A comparative study of the arsenic uptake and toxic response of different drug formulations 
on HeLa and HT-3 cells. (a) Comparison of the arsenic uptake by HeLa and HT-3 after 6, 24, and 48 h 
of treatment, as determined by ICP-MS. Free ATO was taken up more than ATO lipo in both cell lines. 
However, the uptake was higher in HT-3 for all treatments, except for the free ATO uptake after 48 h. 
(b) Ratios of toxicity vs. uptake of liposomal and free ATO for the two cervical cancer cell lines after 
24 h treatment. Data are displayed as mean ± SD from at least three independent experiments;  
* p < 0.05, ** p < 0.01, and *** p < 0.001. 
 
Despite a similar response to treatment with free and encapsulated ATO from both of 
the cell lines with respect to toxicity and induction of apoptosis, the uptake of both free 
and liposomal arsenic by the cell lines varied at different time points (as can be 
observed in Figure 3.1.12a). The uptake by HT-3 cells was found to be higher than the 
uptake by HeLa cells at 6 and 24 h. This trend reversed for the free drug uptake at 48 h 
treatment, when HeLa cells were observed to have taken up significantly more ATO. In 
Figure 3.1.12b, toxicity–uptake ratios for HeLa and HT-3 are shown to indicate the 
level of toxicity that was induced in the cell lines per unit of arsenic taken up by the 
cells. Liposomal ATO was observed to be more effective than the free drug in inducing 
toxicity per unit of arsenic uptake in both cell lines. However, liposomal ATO treatment 
















































































































3.1.3.6 Selectivity of Liposomal Encapsulated ATO in Killing Cervical 
Cancer Cells 
 
One of the most crucial aspects of an effective drug formulation is its demonstrable 
selectivity in its anti-cancer response by sparing normal healthy cells. Hence, after 
establishing the efficacy of liposomal ATO in inducing cell death per unit of arsenic 
uptake in HPV-positive HeLa cells, we further investigated the effect of liposomal ATO 
on non-cancerous cells by choosing two cell lines as controls, namely human 
keratinocytes (HK) and human colon cells (CRL-1790) (Figure 3.1.13a,b). Among the 
three cell lines investigated, the uptake of liposomal arsenic was highest in HK cells, 
with a lower uptake by HeLa and CRL-1790 cells. In contrast, the highest uptake of free 
ATO was by HeLa cells (Figure 3.1.13a). However, when cytotoxicity was investigated, 
cell survival was insignificantly affected in CRL-1790 and HK cell lines (Figure 
3.1.13b). The ratio of cell death to the amount of arsenic taken up by the cells after 
incubation with liposomal encapsulated ATO and free ATO for 24 h is presented in 
Figure 3.1.13c. Liposomal ATO resulted in a higher cell death rate per unit uptake of 
arsenic than free ATO for HeLa cells, while a minimal toxic effect was observed in the 
control cells. The IC50 values for the liposomal ATO treatment were calculated, and 






















Fig 3.1.13: Arsenic uptake and toxic response in the control cells and HeLa cells. (a) A comparative 
study of arsenic concentration per cell in CRL-1790, HK and HeLa—as determined via ICP-MS after 
24 h of treatment with media, control liposomes, ATO lipo, and free ATO; (b) Cell survival following 
the exposure of cervical cancer and control cell lines to ATO lipo for 24 h—assessed using the MTT 
assay; (c) Cell death–uptake ratio of ATO lipo and free ATO in HeLa cells compared to control cell 
lines, after treatment for 24 h. ATO lipo is effective in generating toxicity in HeLa cells, while having a 
non-toxic effect on the normal cells; (d) The IC50 values for three cell lines following 24 h of ATO 


















































































3.1.4 Discussion  
 
Since the recognition of the potential of ATO as a broad spectrum anti-cancer drug, it is 
being increasingly explored for the treatment of various cancer types (Swindell et al., 
2013). However, the systemic toxicities associated with this drug while treating solid 
cancers impedes its therapeutic use in clinical applications. We have previously shown 
that a low concentration of ATO (≤2µM) is capable of selectively inducing cellular 
apoptosis and increasing p53 expression in HPV-positive cervical cancer cells in vitro 
(Wen et al., 2012). However, increasing the ATO dosage to 5µM resulted in most of the 
cells being killed because of drug-induced toxicity, irrespective of their HPV status. In 
order to reduce ATO’s toxicity and raise its therapeutic index, liposomal encapsulated 
ATO at 5µM concentration was used to treat cervical cancer cells (Wang et al., 2016). 
The results from our previous study indicated that, although liposomal ATO was less 
readily taken up by cells than free ATO (Chen et al., 2009), the delivered ATO was able 
to reduce the oncogene E6 expression while exhibiting reduced toxicity (Wang et al., 
2016). Since the size and surface charge of liposomes play important roles in drug 
stability and sustained release, an optimised liposome formulation with appropriate 
physical features would be essential for further improving the drug loading efficiency 
and boosting the killing effects for cancer cells. Therefore, the aim of this work was to 
optimise the liposomal design, with respect to size and charge, for use as drug delivery 
vehicles to specifically target HPV-positive cervical cancer cells in vitro. Liposomes of 
different sizes (100 nm, 200 nm, and 400 nm) and different charges (neutral, positive, 
and negative) were synthesised, with ATO co-encapsulated with a transition metal ion 
(Ni
2+
) in a stable, precipitate form. 
 
For the preparation of liposomes, soy PC was chosen as along with conferring high 
stability to the vesicles, it has a lower phase transition temperature eliminating the 
requirement of high temperatures during liposome synthesis/ drug incubation and 
specialised heating blocks as is the case with DSPG (Wang et al., 2016). Cholesterol 
plays a vital role in the stability of the liposomes by imparting rigidity to the lipid layer 
with some studies indicating an inverse relationship between the leakage of drug from 
liposomes in the bloodstream and its cholesterol content (de Meyer and Smit, 2009). 
However, by imparting rigidity, it also affects the loading efficiency of the drug within 
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the liposomes (Magarkar et al., 2014). Hence, to strike a balance between good stability 
and maximum encapsulation efficiency, a molar ratio of 45% of cholesterol for neutral 
liposomes and 33% cholesterol for charged liposomes was selected. DSPG and DDAB 
were chosen to impart negative and positive charge to the liposomes respectively 
(Gabizon et al., 1982; Filion and Phillips, 1997).  
 
The size measurement analysis indicated a disparity between the actual and expected 
sizes of the formed liposomes. The 200 nm liposomes were closest to the expected size, 
with the 100 nm liposomes being slightly larger and the 400 nm liposomes being 
smaller. This could be caused by the choice of filter extruders (discontinuous syringe 
filtration vs. continuous high-pressure devices), the inaccuracy of the actual pore 
diameter of the commercial filter, or the particle size analysis technique that was 
employed (Berger et al., 2001). However, as these liposomes still displayed an expected 
incremental size range, it was decided to proceed with the planned analysis. 
 
Circulating liposomes with stability in the retention of drugs is a desirable feature in 
order to ensure that a sufficient amount of the drug reaches the target tissue. Our 
stability tests showed that all the liposomes, irrespective of sizes and charges, displayed 
high stability with a loss of less than 10% of arsenic over four weeks storage at 4°C. 
The pH stability studies were carried out under three pH conditions (pH 4, pH 7 and pH 
10). The liposomes displayed highest stability at pH 7 which is the physiological pH. At 
the acidic pH 4, to be encountered in the acidic tumour milieu or endocytic pathways of 
cancer cells, liposomes underwent a rapid release of arsenic with a loss of more than 
50% of the drug within the first four hours, after which the release tapered off. In 
alkaline conditions, the arsenic release was gradual with time reaching up to 50% in 24 
hours. Among the studied sizes, 100 nm liposomes were the most stable at all three pH 
values. Negative liposomes displayed instability at higher pH, most likely owing to the 
changes in lipid orientation in the alkaline conditions leading to liposome disintegration 
(Dimitriu, 2001). 
 
The results from the drug loading efficiency studies among different formulations 
indicated that 100 nm neutral liposomes had the highest drug encapsulation. Since the 
success of nanoparticles as drug carriers relies on them being inherently non-toxic, we 
further tested whether these liposomes displayed any intrinsic toxicity towards the cells. 
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This was tested by incubating their empty counterparts with HeLa cells for 24, 48 and 
72 h. The dilutions of liposomes that were tested for toxicity studies were the same as 
the dilutions that were used for preparing liposomal encapsulated ATO samples 
(liposomes encapsulating 5µM ATO). Size did not have any significant effect on 
toxicity in the range that was tested (Figure 3.1.6a). However, among the charged 
liposomes, positively-charged liposomes began to display toxicity to HeLa cells after 48 
h of incubation, killing almost 20% of cells at the dilutions that were employed for the 
treatment (Figure 3.1.6b). One possible reason suggested for the high toxicity of 
cationic lipids is their translocation to the cell membrane, which eventually results in its 
destabilisation (Soenen, Brisson and De Cuyper, 2009). This finding excludes 
positively-charged liposomes from being employed as drug carriers for ATO delivery to 
cervical cancer cells, even though a higher uptake by cells was previously observed with 
this type of liposome (Yu Nie et al., 2012). Moreover, negatively-charged liposomes 
were demonstrated to be unstable at a higher pH. Considering the above reasons, 100 
nm, neutral liposomes were chosen as the carrier for ATO delivery and were used for 
further in vitro analysis. 
 
The cells were incubated with free and liposomal ATO of 5µM concentration for a 
period of 24 h, 48 h and 72 h and their cytotoxicity assessed by MTT assay. Liposomal 
encapsulation alleviated ATO toxicity in vitro for both the cell lines. The higher toxicity 
of free ATO than its liposomal counterpart was confirmed by the investigation of rate of 
apoptosis by flow cytometry, which clearly showed that free ATO generated higher 
apoptosis than liposomal ATO for both cell lines. The toxicity from both the treatments 
increased with drug exposure time in both of the cervical cancer cell lines that were 
tested (Fig 3.1.8).  
 
Cellular uptake studies showed that arsenic was transported more readily within the 
cells when the free form was applied with concentrations of 78.5±3.5 and 207.4±15.5 
fg/cell in HeLa and HT-3 respectively after 24 h treatment. The cellular uptake of 
liposomal ATO was 2.6 times lower for HeLa and 4.9 times lower for HT-3. In HeLa 
cells, there was a steady increase in intracellular arsenic concentration with both the 
treatments as incubation period was increased from 6 to 48 hours. This trend was also 
observed with liposomal ATO in HT-3, however not with the free form of arsenic. After 
24 h, the intracellular arsenic concentration decreased in HT-3 cell line, which might 
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refer to a possibility of activation of cellular efflux mechanisms in HT-3 cells. This 
trend was not observed in HeLa cells, with ATO concentrations continuing to increase 
at 48 h. It could be postulated that this was related to the presence of HPV within the 
cell. The mechanism behind this warrants further investigation. 
 
An interesting observation was that for both the cell lines, free ATO was taken up more 
rapidly within the first 24 hours than liposomal ATO. However, the rate of increase in 
intracellular arsenic was higher for liposomal ATO from 24 h to 48 hours. This 
confirms the hypothesis that liposomes act as a depot for the drugs and allow a slow 
release of ATO in an extended time frame, resulting in a prolonged anti-tumour activity 
even after the treatment has been stopped 16. This is contrary to the free drug which is 
taken up rapidly and non-specifically, killing the cells in the process and with a 
potential to cause “rebound” tumour growth associated with maximal tolerated dose 
(MTD) based chemotherapy (Ahn et al., 2010). Delivering ATO by liposomes may 
prevent this rebound tumour growth by gradually and steadily loading the tumour with 
the drug as opposed to peak-trough kinetics associated with chemotherapeutic drugs 
(Ahn et al., 2010).  
 
A comparative study on the toxicity, apoptosis inducing responses and arsenic cellular 
uptake was performed in HPV positive and negative cell lines and it was revealed that 
the toxicity profile for both liposomal and free drug was quite similar for HPV negative 
HT-3 and positive HeLa cell lines at 24 and 48 h. These results were confirmed by the 
flow cytometric analysis of apoptosis where statistically similar apoptosis was induced 
in both the cell lines after 24 and 48 hours treatment of liposomal and free ATO.  
 
The comparable toxicity of free and liposomal ATO towards both cell lines might 
initially be thought of as a result of similar arsenic uptake by these cells. However, the 
uptake studies gave completely contradictory findings with HT-3 taking up 
considerably more arsenic from both the treatments. It was observed that HT-3 takes up 
around 1.4 times more arsenic from liposomal ATO treatment and around 2.6 times 
more from free ATO treatment in the first 24 hours. This point towards a higher 
susceptibility of HeLa cell line towards the treatments as despite a lower uptake of 
arsenic, they display an appreciable toxicity profile. To further reinforce the argument, 
toxicity vs uptake ratio was plotted for both HeLa and HT-3 cell lines for liposomal and 
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free ATO treatment. It was found that liposomal ATO induced 71 times more toxicity 
per unit arsenic in HeLa than HT-3. In contrast, free ATO was more efficient in 
inducing toxic response per unit arsenic in HT-3 cells, which demonstrates the selective 
nature of liposomal encapsulated ATO for HPV-positive HeLa cells. This finding 
further supports the suitability of the optimised formulation of liposomes as the desired 
nanocarrier for introducing arsenic to HPV-positive cell lines.  
 
One of the main aims of employing nanotechnology in pharmaceutics is to deliver the 
drug specifically to the cancer cells while sparing the normal cells. There has been a 
lack of literature reporting on studies involving non-cancerous cell lines while 
investigating liposomal ATO efficacy in vitro. Hence, after establishing the 
effectiveness of the liposomal construct for HPV-positive cervical cancer cells, we 
decided to investigate the toxicity and uptake response profile of non-cancerous control 
cells to liposomal treatment. Two control cell lines were chosen for this study, namely 
human keratinocytes (HK) and human colon (CRL-1790) cells. The uptake of liposomal 
arsenic by HK cells was found to be higher than in the other cell lines (Figure 3.1.13a). 
The second control cell line, CRL-1790, displayed lower intracellular arsenic 
concentrations than HeLa cells after incubation with liposomal ATO (Figure 3.1.13a). 
However, after 24 h of treatment with liposomal encapsulated ATO, results showed that 
the non-cancerous cell lines were the least affected by the treatment, with cell survival 
rates close to 95% at the same length of incubation and the same dose of the treatment 
(Figure 3.1.13b). This is independent of the amount of ATO uptake by the cells. This 
finding suggests that liposomal-delivered ATO could be a promising candidate for 
targeting cervical cancer cells, because it demonstrated less toxicity to the non-
cancerous cells, even at a much higher concentration. It may be the case that when 
liposomal-encapsulated ATO reaches the cells, it results in bio-physical changes in the 
cell membrane that may in turn affect the cellular transport systems. Different types of 
cells may react to these changes in different ways. However, HeLa cells appear to be 
more vulnerable to this drug treatment, which could be relevant to HPV. 
 
The cell death–uptake ratio indicates the toxicity induced per unit of liposomal arsenic 
uptake, and is an effective means of comparing the efficacy of a treatment on different 
cell populations. For an ideal treatment, the cell death–uptake ratio would be low for 
normal cells and high for the target cancer cell population. Our results indicated that this 
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ratio was indeed lowest for the control cell populations and highest for HeLa cells, 
indicating that liposomal-encapsulated ATO is a promising treatment for HPV-positive 
cervical cancers. When IC50 (the half maximal inhibitory concentration) was calculated 
for the cell lines, it was found to be the highest for the two normal cell lines; 
corroborating the above result that larger dose of the treatment is required for generating 
the similar cell death in normal cells as cancer cells. These results emphasise the 



















Treatment of cancer patients with chemotherapeutics has always been associated with 
debilitating side effects, systemic toxicities and unfavourable bio-distribution. Advent 
of nanotechnology based drug carriers with better pharmacokinetics, distribution, ability 
to escape immune clearance while being non-toxic to healthy tissues have provided us 
with a solution to most of the cancer related problems. Approval of Doxil by FDA in 
1995 has even further strengthened the confidence in these nanotechnology based 
therapeutics. However, the road to the translation of nanomedicine into clinical practice 
requires thorough understanding of pharmacokinetics, toxicity and efficacy of the drug 
formulation. The nanocarrier has to be carefully optimised and its efficacy against the 
target cancer cells tested. Herein, we prepared six liposomal formulations with three 
sizes (100nm, 200nm and 400nm) and charges (neutral, positive and negative) and 
tested them for their loading efficiencies, stability, anti-cancer toxicity, cellular uptake 
and apoptotic response by the cancer cells. Of all the formulations, 100nm, neutral 
liposomes were chosen as the most optimal owing to best loading efficiency, high 
stability and least intrinsic toxicity. The liposomal encapsulation attenuated the toxicity 
of the drug, allowed for its sustained release while sparing the normal cells.  The next 
step was to further improve the therapeutic potential of these optimised liposomes by 
conjugating them with cancer cell specific ligand. This can be achieved by screening the 
target HeLa cells for most overexpressed surface marker and choosing a ligand to 
conjugate to the optimised formulation of liposome henceforth. The screening of surface 


















Anti-cancer drugs usually cause systemic toxicities as their principle mechanism of 
action is to target cells with high proliferation rates (Sapra and Allen, 2003). This 
marginal selectivity towards malignant cells results in high toxicities to the rapidly 
dividing normal cells including hair follicles, haematopoietic cells, mucosal lining of 
the gastrointestinal tract and germ cells leading to deleterious side effects including 
nausea and vomiting, stomatitis and mucositis among others (Sapra and Allen, 2003). 
These side effects limit the effective dose that can be administered to a patient which 
might lead to relapse of the cancer or even development of tumour resistance. This low 
selectivity of anti-cancer drugs for tumour cells is due to the fact that cancer cells share 
some common features with the host cells from which they originate, hence finding 
specific features from cancer cells in order to uniquely target those cells become 
challenging (Sapra and Allen, 2003).  
Intensive research has been ongoing to overcome these challenges and drug delivery via 
liposomes has been one such major advance in this direction. In addition to reducing 
systemic toxicities, liposomes also alter pharmacokinetics and bio-distribution of anti-
cancer drugs by allowing their “passive” accumulation within solid tumours (Jain, 
1987). Passive targeting has been reported to increase the drug concentrations within the 
tumour manifolds than that of the free form where liposomes release the drugs in a 
sustained manner either within the tumour interstitium or following uptake by the 
tumour cells (Jain, 1987).  
In order to further increase the specificity in the drug delivery by liposomes to the target 
cells, efforts have been focussed on the development of ligand conjugated liposomes 
(Allen et al., 1995). These liposomes have targeting moieties conjugated to their surface 
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which selectively delivers the drug payload to the desired site of action (Allen et al., 
1994; Kirpotin et al., 1997; Carter, 2001). The conjugated moieties facilitating this form 
of active targeting are basically any molecule which can selectively recognise and bind 
to antigens or receptors overexpressed or selectively expressed by cancer cells (Fig 
3.2.1) (Allen et al., 1995; Allen, Hansen and de Menezes 1995). These molecules can be 
antibody, antibody fragments, natural or synthetic ligands. Hence, a crucial aspect for 
utilising active targeting is to first find that receptor which is either exclusive to the 
cancer in question or is overexpressed as compared to the surrounding healthy tissue. 
Since very few antigens either exist or are known that are exclusive to a particular 
cancer, it is more common to rely on the receptors overexpressed on tumour cells 











To successfully utilise active targeting, there are a few considerations to bear in mind: 
firstly, the receptor density should be high on the target cells; secondly, the receptor 
should not be shed during the treatment and lastly, the receptor expression should not be 
too heterogeneous (Dubowchik and Walker, 1999; Kindt et al., 2007; Regimbald et al., 
1996). The heterogeneity of receptor expression in tumour cells arises due to their 
genetic instability and the ability of antigens expressed on their surface to present 
different glycosylation patterns for conjugation (Kindt et al., 2007). Under such 
circumstances, two situations can arise: the cells which lack the receptor might escape 
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cytotoxic effects of targeted liposomes leading to disease relapse, or the receptor 
negative cells might still be killed from the drug released in the vicinity by the 
liposomes, known as “bystander effect” (Kindt et al., 2007). Hence, a thorough 
investigation is required to screen for surface markers on target tumour cells to select 
the one which is most expressed with minimal heterogeneity.  The most well established 
surface receptors which are routinely employed for targeting by liposomes are folate 
receptors, transferrin receptors and epithelial receptors including epidermal growth 




Folate receptor (FR), also known as high affinity membrane folate binding protein, is a 
38-40 kDa glycosyl phosphatidylinositol anchored glycoprotein which is significantly 
upregulated in cancer cells as opposed to normal cells (Lee and Low, 1995; Pan et al., 
2002; Sudimack and Lee, 2000; Zhao and Lee, 2004; Low and Antony, 2004). In 
humans, two isotypes have been identified for FR, α and β (Sudimack and Lee, 2000). 
Among the two isotypes, FR α is the one that binds to folic acid and its various 
derivatives have been reported to be highly overexpressed in ovarian, colorectal, 
endometrial, breast, renal, head and neck, lung and brain cancer (Sapra and Allen, 2003; 
Sudimack and Lee, 2000). FR β is routinely overexpressed in cancers of non-epithelial 
origin including sarcomas and acute myeloid leukaemia, however they were reported to 
be absent in the cell lines established from them (Ross et al., 1999). Targeting FRα with  
folic acid conjugated liposomes presents itself with several advantages: a, since folic 
acid is required for the synthesis of purines and pyrimidines along with several other 
important cellular processes, the drug cargo attached to it is internalised and released in 
the cytoplasm; b, unlike normal cells which only transport reduced folate across their 
membranes but not any conjugate forms, cancer cells transport folate conjugates as well 
through folate receptors as an alternate route and lastly, c, folate receptors, while being 
overexpressed in most cancers, are generally absent in normal tissues with the exception 
of placenta, choroid plexus and weak expression in kidney, thyroid and lungs (Low and 
Antony, 2004; Sudimack and Lee, 2000). Even when expressed in normal tissue, FR 
demonstrates a highly polarised distribution on normal epithelia (Lu and Low, 2012). 
For instance, in proximal tubules, FR are only present on the urine facing surface of the 
tubule cells or in the blood brain barrier, they are only concentrated on the brain side 
122 
(Lu and Low, 2012). This polarised distribution of folate receptors is lost once the tissue 
becomes malignant and spreads throughout the entire tumour surface (Patrick et al., 
1997). Hence, targeting via folate receptors should not damage healthy tissues with FR 
expression (Lu and Low, 2012). Moreover, folic acid (Fig 3.2.2) is an ideal targeting 
ligand because it is small in size (the smaller drug ligands conjugate have a better 
pharmacokinetics and reduced possibilities of immunogenicity), it is inexpensive, non-
immunogenic and non-toxic, stable in both storage and circulation and amenable for 
conjugation with high receptor binding affinity (Low and Antony, 2004; Sudimack and 








Fig 3.2.2: The structure of folic acid with α and γ carboxyl groups depicted; conjugation of folic acid with 
the foreign molecule through its γ carboxyl group retains its high binding affinity with FR (Sudimack and 





Transferrin receptor (referred to as TfR1) is a type II receptor which resides on the cell 
surface and is a main port of entry for iron bound with transferrin (Tf), which is a serum 
non-heme glycoprotein, into the proliferating cells (Fig 3.2.3) (Singh, 1999). After 
binding with its receptor, Tf is internalised where iron dissociates in the acidic 
environment of endosomes and TfR1 is recycled back to the cell surface (Singh, 1999). 
Since, the proliferating cells including cancer cells have an increased requirement of 
iron, transferrin receptors are reported to be overexpressed in them, their expression 
correlating with cancer stage or tumour progression (Gatter et al, 1983; Daniels et al., 
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2012). Tf conjugated nanotherapeutics have already entered human clinical trials with 
cisplatin, adriamycin and diphtheria toxin (Faulk et al., 1990; Head, Wang and Elliott, 
1997; Rainov and Soling, 2005). An important consideration while using Tf ligand for 
targeting is to improve its iron-binding affinity as that, in turn, affect its binding to the 
transferrin receptors (Bellocq et al., 2003). Also, high levels of Tf circulating in the 
blood might reduce the cytotoxicity of transferrin conjugates considerably (Daniels et 
al., 2012). As Tf conjugates can interact both with TfR1 and TfR2 (a second member or 
TfR family which is mainly localised in hepatocytes), this can lead to liver toxicity 








Fig 3.2.3: Schematic representation of TfR: (a) The receptor is a heterodimer with two monomers joined 
together by disulphide bridges at cysteine 89 and 98. The extracellular domain consists of tree sub-
domains: apical A, helical H and protease like domain (P) and (b) binding of the iron conjugated 






Epidermal growth factor receptor 
 
These tyrosine kinases receptors, upon binding to the growth factor ligand, mediate cell 
signalling pathways required for growth and proliferation (Laskin and Sandler, 2004). 
EGFR binds to six known ligands including EGF, transforming growth factor-α (TGF-
α), betacellulin, amphiregulin, epiregulin and heparin binding EGF (HB-EGF) (Laskin 
and Sandler, 2004). Among these, EGF and TGF-α are the most commonly used ligands 
and upon binding to the receptor, the complex gets internalised within the cell (Byrne et 
al., 2008). EGFR is over expressed in almost one third of cancers including colorectal, 
lung, brain and breast cancers (Byrne, Betancourt and Brannon-Peppas, 2008).  
 
The present study was the next step in our original attempt to synthesise robust, targeted 
liposomal constructs of ATO for HPV positive cervical cancer cells. Previously, we 
optimised the liposomal formulation to be used for cervical cancers and demonstrated 
that 100 nm, neutral liposomes encapsulating ATO were the most optimal design. 
Results from further testing their biological properties showed that these liposomes 
attenuated drug toxicity and increased the anti-cancer activity of ATO towards HPV 
positive cell lines while sparing normal cells in vitro. ATO encapsulated in liposomes 
was selective in its action by being more effective against HPV positive cells than HPV 
negative cells. Therefore, attempts were made to further enhance the specificity of these 
liposomes towards HPV positive cervical cancer cells by finding the most suitable 
ligand for conjugation to specifically target these cells. To achieve this goal, cell lines 
were screened for the three abovementioned cell surface receptors.  
 
 
3.2.1.2 Aims:  
 
The aim of this section was to find the most appropriate ligand which could be 
conjugated to the optimised ATO encapsulated liposomes to actively target HPV 





3.2.1.3 Objectives:  
 
(i) To screen the two cervical cancer cells, HeLa and HT-3, for the surface 
markers (folate receptor, transferrin receptor and EGFR);  
(ii) To identify the surface marker which is most differentially expressed in the 
two cells lines; i.e. highly expressed in HeLa cells while being negligibly 
expressed in HT-3, in order to find the best targeting ligand for liposomes 





















3.2.2 Materials and Methods 
 
3.2.2.1 Cell culture 
 
Two cervical cancer cell lines, HeLa and HT-3, and two control cell lines for folate 
receptor expression, human lung carcinoma A549 and HeLa derivative human 
nasopharyngeal epidermal carcinoma cells KB were employed in this study. For folate 
receptor experiments, HeLa and KB cells were cultured in RPMI1640 media with no 
folic acid, HT-3 in McCoy’s (modified) 5A media and A549 in Ham’s F12 Nutrient 
Mixture, while for the other receptors’ experiments, HeLa was cultured in normal RPMI 
media. All media used contained 10 % foetal calf serum, 100 U/ml of penicillin and 100 
mg/ml streptomycin and cells were grown in 75-cm
2
 flasks. The following experiments 
were then set up for further studies including Western blot and immunocytochemical 
staining using both chromogenic and fluorescent labelling. 
 
3.2.2.2 Western blot analysis 
 
Expression of folate, transferrin and EGF receptors on HPV positive and negative 
cervical cancer cell lines were determined by Western blotting as detailed in Chapter 2. 
For folate receptor expression, two cell lines, a positive and negative control, KB and 
A549 respectively, were also included. The primary antibodies used were rabbit anti-
FOLR1 polyclonal antibody, rabbit anti-transferrin and anti-EGFR antibody (1:1000 
dilution). Protein quantification was done using REVERT total protein stain technique 
on Licor Odyssey imaging system, except in one experiment for folate receptor analysis 
where the housekeeping gene β-actin was used for normalisation. In that case, mouse 
anti-β-actin antibody was used in 1:3000 dilution.   
 
3.2.2.3 Chromogenic labelling immunocytochemical staining analysis 
 
Chromogenic labelling for folate, transferrin and EGF receptors following 
immunocytochemical staining for the above mentioned four cell lines were carried out 
as per the protocol described in Chapter 2. The primary antibodies used were the same 
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as those used in Western blotting experiments. The dilutions used however were 1 in 50 
for FOLR 1 and 1 in 100 for anti-transferrin and anti-EGFR antibody in PBS.  
 
3.2.2.4 Confocal imaging of folate receptor expression 
The cells were stained with fluorescent labelling for folate receptor and imaged via a 
confocal microscope according to the protocol described in Chapter 2.  
3.2.2.5 Statistical analysis 
 
Statistical analysis described in experimental sections was carried out with Minitab17 
using 2-sample t-test. P ≤ 0.05 was considered as statistically significant difference. For 
results from Western blotting studies, the signals were normalised using Image J 
software and mean and SD were calculated. For immunostaining results, an average 
number from positively stained cells in a total of six fields of each stained slide were 























3.2.3.1 Folate receptor is the most differentially expressed receptor in HPV 
positive HeLa and HPV negative HT-3 cell lines.  
 
Western blot analysis 
 
The expression of folate receptor α, transferrin receptor and EGFR were examined in 
HPV positive and HPV negative cervical cancer cell lines, HeLa and HT-3 respectively, 
via Western blotting. For folate receptor, results showed a distinct band at around 37 
kDa for HeLa cell line while a very faint band was observed for HT-3 cell line. The 
signal intensity for the bands obtained was normalised employing REVERT total 
protein stain (Fig 3.2.4). The relative folate expression of HT-3 was henceforth found to 
be negligible compared to HeLa.  
 
While probing for transferrin receptor expression, a band at around 98 kDa was 
observed for both the cell lines, with expression on HeLa around 1.5 times more than 
HT-3. Similarly for EGF receptor, both the cell lines displayed a band at around 134 
kDa, although HeLa expressed 1.3 times more EGF receptors than HT-3 (Fig 3.2.4). For 
all the receptors therefore, the expression on HeLa was higher than HT-3, however, 
folate receptor singularly displayed the maximum difference by being appreciably 
expressed on HeLa (around 14 times more) than HT-3. Hence, these results offer a 
possibility of selecting folic acid as the ligand of choice for conjugating to the 
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Fig 3.2.4 (a): Comparative Western blot analysis of 
folate, transferrin and EGF receptors in HeLa and 
HT-3 cell lines; (b) relative protein expression 
levels of the three receptors on the two cell lines 
after normalisation with REVERT total protein 
stain (c) as determined via Western blot.  Data 
shown were expressed as means ± standard 














































































































































Chromogenic staining  
The results obtained from Western blot were further validated by chromogenic stanining 
of the three receptors on HeLa and HT-3 cell lines (Fig 3.2.5). Chromogenic staining 
with DAB substrate was performed to evaluate the receptor expression levels on the 
cells. Consistent with the previous results, folate receptor expression displayed the 
maximum difference in the two cell lines by being expressed much more in HeLa cells 
than in HT-3 cells. The staining for EGFR and transferrin receptors on both the cell 
lines were observed to be of similar magnitude, with expressions on HeLa slightly more 
























































Fig 3.2.5: Immunocytochemical staining of folate, transferrin and EGF receptor expression in HeLa and 
HT-3 cells. DAB chromogen stained the receptor and cells were counterstained with hematoxylin to 
reveal the nuclear/ DNA location. The cells stained brown represents the presence of the receptor while 
the cells stained blue are devoid of the receptor. Cells encircled brown and blue in each image are 
representative of presence and absence of the expressed surface receptor respectively.Data  
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3.2.3.2 Folate receptor expression analysis with the controls   
 
Western blot analysis 
After establishing that the folate receptor is the most differentially expressed out of the 
three receptors investigated in the two cervical cancer cell lines; a positive control KB 
cells and a negative control A549 cells for folate receptor expression, were included to 
further validate our experiments and consolidate our previous results. Western blotting 
analysis of folate receptor expression showed a prominent band for the positive control 
and no band for negative control (Fig 3.2.6). A distinct band was observed for HeLa cell 
line, while a faint band was observed for HT-3. The relative level of folate expression of 
HeLa was half of KB expression, while the expression of HT-3 was much less than KB 
and HeLa cells. β-actin was employed as a loading control and its signal strength  was 










Fig 3.2.6 (a): Western blot analysis of folate receptor expression on KB, HeLa, HT-3 and A549 cell 
lines. (b) Relative protein expression levels of folate receptor from the four cell lines after normalisation 
with β-actin protein levels as determined via Western blot. Data shown were means ± standard deviation 



































































The four cell lines were further stained for folate receptor with DAB substrate and 
counter-stained with haematoxylin to reveal nuclear location. Similar to the results from 
Western blot, KB displayed clear surface staining with almost 90% of the cells 
positively stained. Around half of the HeLa cells were also stained positive while A549, 
the negative control, did not stain for the folate receptor. Around 10% of HT-3 cells 







































Fig 3.2.7: Immunocytochemical staining of folate receptor expression of KB, HeLa, HT-3 and A549 cell 
lines. DAB chromogen stained the folate receptor and cells were counterstained with hematoxylin to 
reveal the nuclear/ DNA location. Cells encircled brown are representative of positive receptor staining 
while cells encircled blue represents negative receptor expression. 
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Fluorescent staining 
Fluoresent labelling followed by visualisation via confocal microscopy was also 
performed to further confirm the results obtained earlier (Fig 3.2.8). KB and HeLa 
showed clear surface staining for most of the cells with higher percetage of stained cells 
in KB than HeLa which  confirmed the Western blot result. HT-3 did not show 
significant staining for folate receptor and A549 stained negative which are also 







































Fig 3.2.8: Confocal microscopic examination of folate receptor expression in KB, HeLa, HT-3 and A549 
cell lines. Red fluorescence showed the expression of folate receptor. Cells were counterstained with 






In the search for the best ligand to target HPV positive cervical cancer cell lines, we 
screened both HPV positive and negative cell lines, HeLa and HT-3, for the three most 
important, widely employed surface markers: folate receptor, transferrin receptor and 
EGFR. The first surface marker to be screened was folate receptor. Folic acid is a very 
small molecule which can be easily conjugated to a liposomal surface having H2N-
PEG-DSPE moieties via carbodiimide coupling in high densities (Gabizon et al., 1999). 
Its small size ensures the liposomal conjugate does not have complications 
extravasating from the leaky vasculature of tumour and accumulating via EPR effect 
and also not be recognised by MPS which targets larger particles for immune clearance 
(Sudimack and Lee, 2000). The second surface marker transferrin receptor, on the other 
hand, requires optimisation to increase its iron binding affinity as that directly reflects 
on its receptor binding potential (Byrne, Betancourt and Brannon-Peppas, 2008). 
Moreover, transferrin circulating in blood compromises the cytotoxic ability of the 
liposomal conjugates (Byrne, Betancourt and Brannon-Peppas, 2008). As for EGFR, 
some of the antibodies and small molecules targeting EGFR are already in clinical 
development; however they have been reported to generate immunologic response that 
may hinder repeated treatment, unlike folic acid which is non-toxic and non-
immunogenic (Low and Antony, 2004; Dancey and Schoenfeldt, 2001). 
With the primary objective of identifying a surface marker which is ideally over-
expressed by HeLa cells albeit not by HT-3 to provide targeting specific to HPV 
positive cervical cancer cells, we employed two techniques, Western blotting and 
chromogenic staining using DAB substrate, for the preliminary investigation of the 
expression of the three surface markers mentioned above on these two cell lines. While 
investigating the folate receptor expression, Western blot results gave highly 
encouraging results where the expression of the receptor on HeLa cells was appreciably 
high while it was negligible in HT-3. For the other two surface markers, both cell lines 
expressed them and HeLa was found to express both of them more than HT-3 (1.5 times 
more for transferrin and 1.3 times more for EGFR). However, the difference in their 
expression between the two cell lines was not as distinct as the folate receptor 
expression (HeLa expressed the marker around 14 times more than HT-3). To 
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corroborate the above findings, chromogenic staining of the receptors was employed on 
both cell lines for all the three receptors. Western blotting results were validated when 
around 70% of the HeLa cells stained positively for folate receptor in comparison of 
less than 10% of positive staining for HT-3 cells. Around 20-30% HeLa cells stained 
positive for both the other receptors and similar staining was observed for HT-3 cell 
lines albeit slightly lesser than HeLa cells. Based on the results, folic acid was chosen as 
the ligand to be used for liposomal conjugation targeting specifically the HPV positive 
cervical cancer cells.  
Further validation for using folate acid as the ligand of choice was also carried out by 
including two control cells lines, KB as positive control (FR+) and A549 as negative 
control (FR-) (Chen et al., 2009; Nukolova et al., 2011). Western blot results indicated 
that folate receptor expression was very high for KB cells and negligible for the 
negative control, A549, validating the accuracy of the experiments. HeLa also displayed 
a strong expression, with relative intensity after normalisation to loading control β-actin 
as around 50% to that of KB. Their expression on HT-3 cell surface, on the other hand, 
was negligible. To further validate the findings, both fluorescent staining and 
chromogenic staining were performed on HeLa and HT-3 cells along with the control 
cell lines. Chromogenic staining with DAB substrate showed a clear surface staining for 
folate receptor for KB cells and HeLa cells and negligible staining for FR- A549 cells. 
KB had a higher expression than HeLa, confirming the previous results. This staining 
pattern was replicated with confocal microscopy images of folate receptor: 90% of KB 
cells showed intense surface staining, around 60% staining for HeLa cells and 10% for 











Harnessing the power of nanotechnology in the field of drug delivery has given us 
opportunities to design passive or active targeted drug delivery system. Non-targeted 
drug carrier systems can extravasate in the tumour tissue via EPR effect and result in 
differential accumulation in tumour tissue versus healthy tissue. Moreover, if 
appropriate ligands are attached to the surface of these nano-carriers, that may act as 
“homing devices” and significantly enhance the selective delivery of drug to the target 
tissue. Herein, we investigated three most well established cell surface receptors, folate, 
transferrin and EGF receptors, against HPV positive and HPV negative cell lines to 
search for the most appropriate ligand for conjugating to ATO encapsulated liposomes 
towards a final goal of specifically targeting HPV positive cervical cancer cells. From 
the results obtained and the inherent advantages of employing folic acid as a targeting 
ligand, folic acid was selected as the suitable ligand for our future experiments. Our 
next step was to conjugate folic acid to ATO liposomes and assess their efficiency in the 
cellular uptake or inducing anti-cancer response in the FR positive HPV positive 
cervical cancer cells. We have already seen from our previous research that HeLa is 
inherently more susceptible to the liposomal treatment than HT-3. Additionally, as 
HeLa express more folate receptors than HT-3 cells, active targeting might further 
enhance the specificity of the liposomal construct, tailoring it for an effective anti-










3.3 TARGETING HPV POSITIVE CERVICAL 
CANCER CELLS WITH ARSENIC TRIOXIDE 







Since 40 years, application of nanotherapeutics has provided a distinct possibility of 
delivering therapeutic agents in a far more efficient manner than that could be achieved 
through conventional drug delivery (Strebhardt and Ullrich, 2008).  Nanoparticles have 
the potential to encapsulate poorly soluble drugs, protect the therapeutic compounds 
from degradation and modify their blood circulation and tissue distribution profiles 
(Bertrand et al., 2014).   
The tumour distribution profile of nanoparticles is primarily governed by three 
interrelated processes: their extravasation from the fenestrated blood vessels into the 
tumour interstitium; their further penetration into the tumour extravascular tissue and 
finally, their interaction with the intracellular targets within the tumour milieu (Bertrand 
et al., 2014). The first two factors, describing the passive targeting phenomenon, result 
in the transport of nanocarriers from leaky tumour fenestrations into the tumour 
interstitium where they are retained due to poor lymphatic drainage, characteristic of the 
tumour tissue (Danhier, Feron and Preat, 2010). It is dependent on the forces of 
diffusion and convection which are reliant simultaneously on both the tumour 
microenvironment and characteristics of diffusing nanoparticle such as size, surface 
properties, shape and concentration within tumour blood vessels (Bertrand et al., 2014).  
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The third parameter involving the interaction of nanoparticle with the intracellular target 
is more complex and can be greatly benefitted from the active targeting strategies of the 
drug encapsulating nanoparticles. Active targeting, also referred to as ligand-mediated 
targeting, employs the specific affinity of ligands decorated on the surface of the 
nanoparticles towards specific receptors or surface molecules overexpressed in target  
cells, tissues or organs (Cheng et al., 2012; Kamaly et al., 2012; Koshkaryev et al., 
2013; Peer et al., 2007; Shi et al., 2011). Aided by the EPR effect, which allows the 
nanoparticle carrying the drug payload to remain in the vicinity of the target cells, active 
targeting facilitates its cellular internalisation via the specific ligand-receptor interaction 
(Byrne, Betancourt and Brannon-Peppas, 2008). This is important as although the EPR 
effect does improve the target tissue distribution profile of the circulating nanoparticles, 
it alone does not guarantee that the drug would reach its pharmacological target 
(Bertrand et al., 2014). In the absence of any specific affinity between the nanoparticles 
and the target cancer cells, the chemotherapeutic payload would either have to reach its 
target on its own or endanger itself diffusing back to the vasculature (Dreher et al., 
2006).  Therefore, effects of the drug treatment will be greatly benefited from active 
targeting strategies by increasing the intra-tumoral uptake of the encapsulated drug by 
enhancing its internalisation by the target cell after extravasation and helping it reach its 
pharmacological target (Kirpotin et al., 2006; Bartlett et al., 2007; Li et al., 2008). 
Briefly, active targeting is advantageous as it increases the tumour residence time for 
nanoparticles, enhances their affinity for the target cells and helps them to reach their 
intracellular destination though receptor mediated endocytosis (Fig 3.3.1) (Bertrand et 
al., 2014).   Therefore active targeting is increasingly being recognised as an effective 




Fig 3.3.1: Receptor mediated endocytosis for folate conjugated nanocarrier in cells expressing FR (Pawar, 
Domb and Kumar, 2014). 
 
The efficiency of any actively targeting system in vitro, and most importantly in vivo, 
can be assessed by two important parameters: targeting specificity and delivery capacity 
of the drug delivery vehicle (Bertrand et al., 2014). The specificity is mainly determined 
from the choice of the ligand and how it interacts with the off-target molecules and cells 
(Bertrand et al., 2014). The delivering capacity depends on the structure and 
composition of the nanoparticle itself like its physicochemical properties such as the 
size and charge of the nanoparticle, the ligand density among others (Gu et al., 2008; 
Jiang et al., 2008; Valencia et al., 2011; Wu and Chu, 2013). Some of the other 
important factors that affect the efficacy of active targeting include the administration 
route or the non-specific binding of proteins during its passage though the bloodstream. 
Since these targeted delivery systems rely heavily on their being in the circulation for an 
extended period of time, followed by their extravasation into the tumour interstitial 
space, where they can interact with their antigenic substrate, it is imperative to surface 
functionalise these nanoparticles with the hydrophilic polymer PEG. PEG layer serves 
to delay the opsonisation of the nanoparticles and therefore evade the uptake and 
clearance by MPS (Sapra and Allen, 2003).  
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First described in 1980, this strategy of actively targeting cancer cells by conjugating 
nanoparticles with ligands rapidly became one of the most successful ways of 
improving the efficacy of nanotherapeutics, at least in animal models (Huang, Huang 
and Kennel, 1980). The ligands were selected based on the high specificity and affinity 
for the surface markers overexpressed on the target cells and the ability to trigger 
receptor mediated endocytosis following binding. Following our previous findings, we 
selected folic acid as the ligand of choice as FR was the most differentially expressed 
receptors out of the three tested tumour markers screened from HPV positive and HPV 
negative cell lines.  
Folic acid is a low molecular weight vitamin required by eukaryotic cells for de novo 
nucleotide synthesis (Stephenson, Low and Lee, 2004). Since the eukaryotes lack the 
necessary enzymes required for biosynthetic pathways for folic acid, their survival 
depends on mechanisms to capture folates to sustain life, which involves the presence of 
membrane spanning glycoproteins serving as transporting receptors for folates into the 
cells (Stephenson, Low and Lee, 2004). The FRs are overexpressed on a variety of 
cancer cells, probably owing to a greater requirement for uncontrolled growth, 
characteristic of cancer cells (Stephenson, Low and Lee, 2004).  
Folates have a very high specificity and affinity (KD=~10-9M) for its receptors 
(Bertrand et al., 2014). Tethering folic acid to the surface of nanoparticles is also 
beneficial in that, unlike high molecular weight ligands like antibodies, aptamers or 
proteins, it does not increase the hydrodynamic size of the nanoparticle appreciably and 
hence, does not interfere with the tumour accumulation due to any size restrictions 
(Danhier, Feron and Preat, 2010). Moreover, some studies showed that FR targeted 
liposomal delivery had the potential to reverse multidrug resistance or bypass it 
(Gabizon et al., 2004; Torchillin, 2010).  
Folate targeting nanoparticles have shown promising results as therapeutic and 
diagnostic agents, when evaluated in preclinical settings (Lee and Low, 1995; Ni, 
Stephenson and Lee, 2002; Pan et al., 2002; Sudimack and Lee, 2000; Werner et al., 
2011; Zhao and Lee, 2004). It has been employed as a targeting moiety for many 
nanotherapeutic platforms like quantum dots, gold nanoparticles, dendrimers, iron oxide 
and liposomes (Bazak et al., 2015). Folate conjugated liposomes have been tested with a 
wide range of drug payload including cytotoxics, genes or anti-sense oligonucleotides 
144 
(Goren et al., 2000; Lee and Low, 1994; Pan, Qualls and Thompson, 2001; Reddy et al., 
2002; Wang and Lee, 2002; Wang et al., 1995; Zhou et al., 2002). Six of the drugs 
directly conjugated to folate have entered into human clinical trials (Low and Kularatne, 
2009). In all the cases, it was observed that folate conjugates not captured by folate 
receptor in FR negative tissues were rapidly excreted from the body, limiting the off-
target toxicity (Low and Kularatne, 2009; Mathias et al., 1998; Siegel et al., 2003; 
Wang et al., 1997). Additionally, it has been reported that presence of physiological 
levels of folate in the bloodstream has minimal effect on the FR specific tumour uptake 
of the folate conjugates owing to the higher affinity of the liposomes conjugated to 
multiple ligands for the cell surface receptors (Licciardi et al., 2006). 
For the purpose of designing an actively targeting system, there are quite a few 
parameters that need careful consideration and optimisation. One of them is how the 
ligand is attached to the liposome.  If the ligand is conjugated directly to the 
phospholipid headgroup, as was done initially, the steric barrier imposed by the PEG 
layer interfered with the coupling efficiencies and binding capacity of the ligand 
conjugated nanoparticles (Klibanov et al., 1991). To circumvent this issue, ligands were 
coupled to PEG terminus which prevented their masking by the PEG layer and easier 
accessibility to their targeted antigens (Laemon and Low, 2001).  
The importance of PEG spacer in FR targeting was succinctly established by Lee and 
Low for KB cells using both targeted and non-targeted liposomes (Lee and Low, 1994). 
Liposomes with folate tethered to a long PEG spacer (250 Å) displayed a higher uptake 
than either non-targeted or targeted liposome with short spacer length (Lee and Low, 
1994). In another study by Gabizon et al., placing the ligand on a longer PEG spacer 
length of 3350 Da, as opposed to 2000 Da PEG layer used for steric stabilisation, 
increased the uptake of conjugated liposomes substantially (Gabizon et al., 1999). 
However, it has also been speculated that if ligand is conjugated to a longer PEG spacer 
than the other PEG chains involved in the PEG brush, the extra length of the long spacer 
might undergo mushroom-like folding, leading to limited exposure of ligand. Therefore, 
it might even be better to have the same length spacer as the surrounding PEG brush 
(Wang and Thanou, 2010). This ambiguity in literature therefore requires a thorough 
investigation on the appropriate spacer PEG length to be used for folate conjugation, 
targeting the specific tumour under investigation.  
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It is also imperative to optimise the ligand density on the surface of the liposomes. 
While a higher ligand density might be desirable to increase the binding avidity between 
the liposomes and the target antigen, it might also give rise to potential immunogenic 
concerns (Sapra and Allen, 2003).  A higher coverage of PEGylated liposomes with 
ligands might shield the steric stabilisation effect of PEG layer and consequently result 
in a higher recognition by plasma proteins leading to opsonisation (Wang and Thanou, 
2010). Apart from these biological effects, there is not much data on physical 
implications of high ligand density, demonstrating a need to optimise this factor to 
maximise targeting abilities of the nanocarriers (Wang and Thanou, 2010). 
As a complimentary strategy to EPR, ligand functionalised nanoparticles offer the 
potential to further augment the efficacy of nanotherapeutics in treating diseases.  
Although, there have been multiple studies reporting the enhanced uptake by FR 
positive cells following folate conjugation to liposomes carrying the therapeutic payload 
(Canal et al., 2010; Zhang et al., 2010; Zhang et al., 2010; Zhao and Lee, 2004), there 
has been few efforts, if any, to definitively determine the optimal spacer length for folic 
acid conjugation on liposomal physicochemical characteristics, inhibitory potency and 
in vitro performance on cervical cancer cells with differing HPV status.  
 
3.3.1.2 Aims:  
 
The aims of this chapter are to design folate targeted ATO encapsulating liposomes and 
assess the effect of ligand spacer length on cellular uptake and inhibitory potency 
against HPV positive cervical cancer cells in vitro.  
 
3.3.1.3 Objectives:  
 
(i) To synthesise folate conjugated, ATO encapsulating liposomes with ligand spacer 
length similar to the surrounding PEG brush and assess any enhancement in the cellular 
uptake due to ligand conjugation, compared to unconjugated liposomes in KB, HeLa, 
HT-3 and A549 cell lines with differing FR expression. 
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(ii) To examine any further improvement in cellular uptake on increasing PEG spacer 
length for folate conjugation and selecting the optimal PEG spacer length for ligand 
targeting (Fig 3.3.2). 
 
 
Fig 3.3.2: The three liposomal formulations prepared for the study: L1, unconjugated liposomes, L2, 
conjugated liposomes with FA-PEG spacer length of 2000Da and L3, conjugated liposomes with FA-
PEG spacer length of 5000Da. 
(iii) To investigate and assess the differences in cellular uptake and in vitro cytotoxicity 












3.3.2 Materials and Methods 
 
3.3.2.1 Liposome preparation and characterisation 
 
Unconjugated and folate conjugated labelled liposomes with different spacer length 
were synthesised as detailed in Chapter 2. Their loading efficiency (As/P ratio) was 
determined by ICP-OES and mean liposomal size was calculated via dynamic light 
scattering on a Zetasizer-Nano ZS. Liposomal stability over a period of a month was 
assessed by analysing their loading efficiency every week while liposomes were stored 
at 4°C in buffers of pH 7.4.  
 
3.3.2.2 Cell culture 
 
HPV positive and negative cervical cancer cell lines, HeLa and HT-3, were employed in 
this study. KB and A549 cells were taken as FR positive and negative controls 
respectively. KB and HeLa cells were grown in folate-free RPMI-1640 media (for a 
minimum of 2 months before each experiment), HT-3 cells in McCoy’s 5A (modified) 
media and A549 cells in Ham’s F12 Nutrient Mixture with 10% FBS and 1% penicillin-
streptomycin. The following experiments were set up to investigate cellular uptake 
following liposomal ATO exposure for different time intervals: confocal microscopic 
visualisation, flow cytometry, plate reader analysis and ICP-MS studies. Cellular 
toxicity was investigated via MTT Assay. 
 
3.3.2.3 Qualitative cellular uptake analysis by confocal microscopic 
visualisation of liposomal arsenic 
 
Cells were plated, 24 to 48 h before each experiment, on sterile 22-mm coverslips inside 
six-well plates at a density of 5× 104/ml. Following attachment, the cells were exposed 
to DiIC18(3)-DS labelled liposomes (L1, L2 and L3) for various time intervals at 37°C 
in the incubator. The employed liposomal dilutions had an arsenic concentration of 
18µmol/L. After the intended time period, the spent media was removed and cells were 
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washed three times with PBS and fixed with PBS-buffered 4% paraformaldehyde at 
25°C for 8 minutes. The coverslips were again washed with PBS and mounted on a 
slide using DAPI, staining nuclei in blue containing anti-fade ProLong Gold reagent 
(Life Technologies Ltd, Paisley, UK). The fluorescence emitted from each slide was 
observed via a confocal microscope (Leica Microsystems, Wetzlar, Germany). 
  
3.3.2.4 Flow cytometric analysis of liposomal arsenic uptake 
 
Cells were seeded at 5 × 10
5
/ml in six-well culture plates and grown overnight before 
exposing to the above mentioned DiIC18(3)-DS labelled liposomal formulations at a 
dilution having arsenic concentration of 18µmol/L for various time intervals at 37°C. 
After the intended time interval, the cells were trypsinized, washed twice by PBS and 
then collected into FACS tubes with 500µl PBS. All samples were analysed using 
FACSCalibur (BD, Oxford, UK). For DiIC18(3)-DS, the maximum excitation was 
obtained with He-Ne laser at 555nm and fluorescence emission intensities were 
observed at >570nm using FL-2 filter. For each sample, a minimum of 10,000 cells 
were collected. Data were analysed using CellQuest Pro software from BD Biosciences. 
The ratio of cells staining positive with labelled conjugated liposomes to cells staining 
positive for labelled unconjugated liposomes was calculated to give an estimate on the 
differences in uptake of liposomes of different formulations. All measurements were 
performed in duplicates from at least three different experiments.  
 
3.3.2.5 Plate reader analysis of liposomal uptake by cells 
 
Cells were seeded at 1 × 10
5
/ml in 96 well plates and allowed to attach overnight. Cells 
were further exposed to labelled liposomes at arsenic concentration of 18µmol/L for 
various time intervals at 37°C. Following the treatment, the cells were washed twice 
with PBS and the fluorescence measured via BMG LabTech FLUOstar Omega Plate 
Reader. As with the flow cytometric analysis, the ratio of cells staining positive with 
labelled conjugated liposomes to cells staining positive for labelled unconjugated 




3.3.2.6 Quantitative analysis of liposomal drug uptake via ICP-MS 
 
Cellular uptake was analysed for different treatments at a time period of 6 h, 24 h and 
48 h by ICP-MS as described in Chapter 2. Following a 24-h cell attachment, cells were 
treated with liposomal formulations as mentioned above and free drug with an arsenic 
concentration of 10µmol/L. Their arsenic concentration was determined and quantified 
after the desired time interval.  
 
3.3.2.7 In vitro cellular cytotoxicity assay 
 
Cytotoxicity of various liposomal formulations of ATO was determined by an MTT 
Assay as described in Chapter 2. Briefly, the experiment was set up in a 96 well plate, 
where the toxicity of control empty liposomes was investigated by taking an initial 
starting amount containing 0.5mM of phospholipid concentration and diluting it in 1:10 
ratio to further 6 wells. The ATO encapsulating liposomes contained 30µM of ATO 
concentration in the initial sample which was further diluted in 1:6 at a final working 
arsenic concentration of 5µM for treating the cells. The wells were seeded with HeLa, 
HT-3, KB and A549 at a density of 0.6 million cells per ml and incubated at 37°C in the 
humidified incubation chamber for 24 h, 48 h and 72 h. After the intended incubation, 
MTT Assay was performed as per the described protocol and absorbance of the final 
coloured solution read and quantified via BMG LabTech FLUOstar Omega Plate 
Reader at a wavelength of 570 nm. 
 
3.3.2.8 Statistical analysis 
 
Statistical analysis described in experimental sections was done using Minitab17. 
Statistical significance was determined by 2-sample t-test. P< 0.05 was considered 
significant. For flow cytometry, statistical analysis was carried out automatically though 
BD Calibur software provided. For confocal microscopy results, an average number 
from positively stained cells in a total of six fields of each sample were calculated and 





3.3.3.1 Liposome preparation and characterisation  
 
Three labelled unconjugated and conjugated liposomal formulations (L1, L2 and L3) 
were synthesised and their concentrations of P, As and Ni were determined by ICP-
OES. All the liposomal formulations were found to be efficiently loaded with arsenic, 
with loading efficiency (As/P) depicted in Fig 3.3.3 (a). The loading efficiency was 
similar for all formulations, irrespective of the presence or absence of folic acid 
conjugation. The stability of liposome suspension was analysed by storing it at 4°C for a 
month and calculating its loading efficiency every week (Fig 3.3.3 (b)). Less than 5% 
arsenic leaked from the liposomes in a time period of 1 month. All the liposomal 
formulations displayed similar storage stability. The mean sizes of control liposomes 
were determined by dynamic light scattering on a Zetasizer-Nano ZS as represented in 
Fig 3.3.3 (c). The DLS size measurement of L1, L2 and L3 were 138.5±1.2nm, 
134.4±1.7nm and 142.6±3.1nm, demonstrating that ligand conjugation had no 
considerable effect on the liposomal size. The polydispersity index for the investigated 











(a) Loading efficiency 
 
(b) Stability study (c) Size measurement 
   
 
Fig 3.3.3: Characterisation of sythesised liposomes: (a) loading efficiency (%As/P), (b) ATO 
encapsulated over four weeks of storage at 4°C, and (c) Diameter of liposomes as measured from 
Zetasizer with a polydispersity index of around 0.1. Conjugation or length of conjugating PEG spacer 
does not have any considerable effects on either loading efficiency, stability over time in storage or size 























































































3.3.3.2 Folate conjugation enhances liposomal uptake in FR positive cells   
 
Confocal microscopy analysis 
 
Any enhancement in liposomal uptake due to folate conjugation in FR positive cell lines 
was examined by confocal laser scanning microscopy (CLSM). It allowed the 
evaluation of intracellular fate of liposomes as a function of time from various cell lines. 
From previous findings on the surface receptor expression on the two cervical cancer 
cell lines investigated, HeLa cells were found to positively stain for FR while HT-3 
stained minimally for the receptor. A positive control and a negative control cell line for 
FR expression, KB and A549 respectively, were also included to validate the robustness 
of the experiments, with their receptor expression in the order of KB> HeLa>HT-
3>A549. With the initial goal of observing any improvement in liposomal uptake due to 
ligand conjugation, liposomes were first conjugated with folic acid using a PEG spacer 
having the same length as the surrounding PEG brush. Confocal microscopic 
visualisation of cellular association of DiIC18(3)-DS labelled liposomes is depicted in 
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Fig 3.3.4: Confocal micrographs showing cellular uptake of DiIC18(3)-DS-labelled L1 and L2 
liposomes (red in colour) after the treatment of (a) 2 h and (b) 24 h. Cells were counterstained with 
DAPI (blue colour) to reveal the nuclear/ DNA location. Folate targeted liposomes are selectively and 
efficiently taken up by FR positive cells KB and HeLa (according to the FR expression in the order of 
KB>HeLa). At 2 h treatment, the cell membrane association of liposomes is evident whereas at 24 h, 
the internalisation and accumulation of liposomes in the cytosol is observed.  
 
 
By keeping all the parameters for confocal microscopic visualisation the same (PMT 
and % laser), it was possible to draw a comparative study of cellular uptake of 
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liposomes, with or without ligand conjugation. Following 2 h exposure in folate free 
media, KB displayed a significant cellular binding with the conjugated liposomes 
followed by HeLa, as evidenced from the red fluorescence seen around the cell surface 
from the DiIC18(3)-DS label of the liposomes. This obvious cellular association was 
however, not visible in either HT-3 or A549 cells. Such cellular uptake was not present 
with the non-conjugated liposomes. Subsequent 24 h exposure of the liposomes to the 
cell lines indicated a widespread internalisation and accumulation of conjugated 
liposomes in the cytosol of KB cell line, which was demonstrated by red fluorescence 
around the nuclei. Similar trend was also observed in HeLa cells with increased 
amounts of red fluorescence seen intracellularly at 24 h, which was followed by HT-3. 
As for A549, no cellular uptake of the conjugated liposomes was observed, which 
demonstrates the selective nature of the conjugated ligand. After 24 h exposure, the 
unconjugated liposomes exhibited some cellular internalisation in KB cells and 
diminutive fluorescence in HT-3 cells but none for HeLa and A549.  
 
Flow cytometric analysis 
The results obtained from confocal microscopy analysis were further validated by flow 
cytometry (Fig 3.3.5). The cells from the four cell lines were exposed to fluorescently 
labelled liposomes for a period of 2 h, 6 h and 24 h. A ratio of cells staining positive for 
conjugated liposomal uptake to non-conjugated liposomal uptake was calculated for 
each cell line to estimate the efficacy of folic acid conjugation in enhancing the 
liposomal cellular internalisation. At 2 h, flow cytometry results showed that the 
cellular uptake of targeted liposomes in KB cell line was about 50 times that of non-
targeted liposomes (Fig 3.3.5 (a)). For HeLa and HT-3 cell line, the targeted liposomes 
were taken up around 2.1 and 1.6 times more than the non-targeted liposomes 
respectively. Whereas there was no significant difference in the liposomal uptake due to 





(a) (b) (c) 
   
Fig 3.3.5: Comparison of the cellular uptake of L1 and L2 by flow cytometry at the end of (a) 2 h, (b) 6 
h, and (c) 24 h treatment. Data are means ± standard deviations of duplicate measurements of at least 
three independent experiments. Unpaired t test was used to test if there is any significant difference in 
the uptake between L1 and L2 liposomes in the four cell lines. The uptake of cells due to folate 
conjugation is found to be significantly high for KB cells and HeLa cells, although it decreases with 




On increasing the liposomal incubation time from 2 h to 6 h, the trend of liposomal 
uptake remained the same for all studied cell line. For instance, KB displayed a 
significant higher liposomal intracellular uptake (30.4 times higher) with ligand 
conjugation than HeLa cells (only 2 times higher). HT-3 however, like A549, displayed 
no significant difference at this time interval. On further increasing the exposure time to 
24 h, the targeted liposomes were taken up 24 times and 2 times more than non-targeted 
liposomes in KB and HeLa respectively, whereas HT-3 and A549 displayed no 
significant difference.  
The results obtained from flow cytometry studies demonstrated a steady decrease in the 
difference between the uptakes of conjugated and non-conjugated liposomes for KB cell 
line, going from 50 times higher at 2h to 30.4 and eventually 24.1 times at 24 h. For 
HeLa, the difference (two times higher for targeted liposomes) remains almost constant 
with the time interval till 24 h. HT-3 displayed a 1.6 times higher uptake of targeted 
liposomes at 2 h; however this difference reduced with the increase in exposure time, 
with both of them displaying similar uptake at 6 h and 24 h. A549 cell line has no effect 





















































































































































































Plate reader analysis 
An additional uptake assay was performed in 96 well plates by reading the fluorescence 
of cells incubated with fluorescent targeted and non-targeted liposomes via a microplate 
reader. A comparison was drawn of the differential cellular uptake by analysing the 
ratio of fluorescence of cells incubated with targeted liposomes to non-targeted 
liposomes followed by blank correction (Fig 3.3.6).  As expected, the FR positive KB 
cells display the maximum difference among all the cell lines between fluorescence in 
cells incubated with targeted liposomes to non-targeted liposomes at all the three time 
intervals investigated; the difference being 5.15±0.18 fold at 2 h, 3.22±0.13 fold at 6 h 
and 1.9±0.12 at 24 h. In HeLa, the fluorescence of the cells incubated with liposomes, 
albeit appreciable, is lower than KB and so is the associated ratio of targeted to non-
targeted liposomes, with it being 2.81±0.18 , 2.58±0.06 and 1.82±0.04 times at 2 h, 6 
h and 24 h respectively. HT-3 cells display a higher cellular uptake of targeted 
liposomes in the first 6 h but the difference is nullified as the incubation time proceeds. 
At 24 h, there is no significant difference between cellular uptakes of targeted and non-
targeted liposomes for HT-3 cell line, as measured from the fluorescence generated by 
the cells. FR negative control cell line, A549, exhibits no significant difference in the 












(a) (b) (c) 
   
 
Fig 3.3.6: Comparison of liposomal uptake by the four cell lines with plate reader analysis at the end of 
(a) 2 h, (b) 6 h, and (c) 24 h treatment. KB and HeLa cells display a significant enhancement in 
liposomal uptake after folate conjugation, corresponding with their high FR expression on their cells’ 
surfaces. HT-3 also display a small but significant enhancement in L2 uptake till 6 h, after which the 
enhancement is nullified. Data are means ± standard deviations of duplicate measurements of at least 
three independent experiments. **p≤0.01, ***p≤0.001. 
 
 
Similar to the flow cytometry results, the difference between the liposomal uptakes was 
observed with ligand conjugation for different cell lines and the differences were 
reduced when the treatment time increased to 24 h. This reduction, while being true for 
all the cell lines investigated, is more evident from 6 to 24 h than from 2 to 6 h. Also, it 
is more obvious for KB cells than HeLa cells.  
 
Quantitative liposomal arsenic cellular uptake via ICP-MS 
Cellular liposomal arsenic was quantified with ICP-MS after performing calibrations 
using arsenic ionic standards and Ga ion as internal standard.  For every experiment 
performed, we obtained a linear correlation for arsenic with squared correlation 
coefficients R
2
>0.997. With this calibration, cellular arsenic was quantified by 
measuring the total amount of As following digestion of the cells from the four cell 
lines treated with media only, ATO encapsulating conjugated and unconjugated 
liposomes for 6h, 24 h and 48 h. A comparative study of the liposomal treatment was 





















































































































































































(a) (b) (c) 
   
 
Fig 3.3.7: Arsenic concentration per cell as determined by ICP-MS in the four cell lines after (a) 6 h, (b) 
24 h, and (c) 48 h treatment with L1and L2 liposomes. There is a significant difference in their uptake in 
FR positive KB and HeLa cells, with L2 being taken up more than L1. The arsenic concentration 
increases with time for all the cell lines. Data shown is the mean ± SD of three independent 
experiments. *p≤0.05, **p≤0.01, and ***p≤0.001. 
 
 
The results showed that as the time of incubation increased, the cellular arsenic 
increased for all the treatments for the four cell lines investigated. KB displayed the 
highest difference in the cellular uptake of liposomal arsenic after ligand conjugation by 
taking up around 3 times more at 6 h and 1.7 and 1.2 times more at 24 h and 48 h 
respectively. HeLa, at 6 h, takes up 1.6 times more targeted liposomes than non-targeted 
ones, with this difference tapering off to 1.2 times at 48 h. Corroborating the previous 
findings, the cellular uptake studies by ICP-MS are consistent with the flow cytometry 
studies and plate reader analysis in that the difference between the uptakes of targeted 
and non-targeted liposomes decreases with time. Since, KB cells have the highest folate 
expression on their cell surface; this decline is more pronounced than HeLa cells. HT-3, 
with minimal expression of cell surface FRs, displays slight difference in the first few 
hours but with time, this difference is nullified and targeted and non-targeted liposomes 
are taken up by the cells equally. A549 cells, being FR negative, display no difference 
in the cellular uptakes from ligand conjugation as expected. Regarding the total arsenic 
content in the cells from the treatment, ICP-MS studies show that HT-3 cell line takes 
up more liposomal arsenic in general than all the four cell lines regardless of the ligand 














































































3.3.3.3 Increasing folic acid conjugating PEG spacer length enhances the 
targeting by liposomes 
 
It has previously been reported in the literature that spacer length of the conjugated 
ligand impacts the efficacy of the cellular uptake of the nano-vehicle (Peng et al., 2013). 
To assess this aspect, a third formulation of liposomes was prepared where folic acid 
was conjugated to a PEG spacer having longer length (5000Da) than the surrounding 
PEG brush (2000Da). The above mentioned techniques including confocal microscopy, 
flow cytometry, plate reader analysis and ICP-MS arsenic quantification were once 
again employed to assess any enhancement in cellular targeting by liposomes from 
increasing the spacer length of PEG conjugating folic acid.    
 
Confocal microscopy analysis 
Keeping the parameters for confocal microscopic visualisation the same, a comparative 
study was drawn for the cellular uptakes of the three liposomal (L1, L2 and L3) 
formulations. The control cell lines, FR+ KB and FR- A549, were included along with 
the cervical cancer cell lines, HPV+ HeLa and HPV- HT-3.  The cells were treated for 2 
h, 4 h, 6 h and 24 h, fixed in 4% paraformaldehyde and stained with DAPI for nuclear 
imaging.  
Liposomes without surface functionalisation showed neither membrane accumulation 
nor cellular internalisation in any of the cell lines till 24 h as evidenced by the lack of 
liposomal fluorescence (Fig 3.3.8). In contrast, ligand conjugation, specifically with 
5000Da PEG spacer length, mediated an efficient fluorescence uptake in FR positive 
cell lines. After 2 h incubation, L3 was found to exhibit high cellular binding, for 
around 90% of KB cells, 25% of HeLa and 5% for HT-3, as shown by the red 
fluorescence around the cell surface. L2 liposomes exhibited minor cellular uptake by 
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Fig 3.3.8: Confocal micrographs showing cellular uptake of DiIC18(3)-DS-labelled L1, L2 and L3 after 
treatment of (a) 2 h, (b) 4 h, (c) 6 h and (d) 24 h. Cells were counterstained with DAPI to reveal the 
nuclear/ DNA location. Among targeted liposomes, L3 were much more efficient than L2 in being taken 
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up by cells according to their FR expression, therefore the uptake in KB was highest followed by HeLa. 





With time, KB cells demonstrated increasing large scale cellular internalisation and 
accumulation of L3 in their cytosol, as seen by the red fluorescence surrounding the 
DAPI-stained nuclei. L2 was also seen to enter most of the KB cells by 24 h, but to a 
much lesser extent than L3, displaying the latter’s higher efficiency in being taken up by 
the FR positive cells. For HeLa and HT-3 as well, L3 was more efficient in being taken 
up by the cells than L2, with L3 entering almost all the HeLa cells by the end of 24 h. 
The cellular uptake of conjugated liposomes (L2 or L3) in HeLa was always higher than 
HT-3. 
 
Flow cytometric analysis 
The cellular uptake of the three liposomal formulations were quantitatively analysed by 
flow cytometry, validating the previous confocal microscopy results (Fig 3.3.9). The 
four cell lines were treated with the three different formulations for a time period of 2 h, 
6 h and 24 h. To compare the differences in cellular uptake of the different liposomal 
formulations, a ratio was obtained for the cells staining positive to conjugated liposomes 
(L2 or L3) to the cells staining positive to the unconjugated liposomes (L1) (Fig 3.3.10). 
The results indicated that folate conjugation to the liposomes resulted in a dramatic 
increase in the cellular uptake by KB cell line. This was true, irrespective of the length 
of the treatment or the ligand conjugating PEG spacer length, although, the uptake did 
increase by increasing the PEG spacer length by around 1.2 times at the end of 24 h. For 
HeLa, L3 uptake was around twice the L2 uptake for the time intervals investigated.  
HT-3 also showed a higher uptake of L3 than L2 (around 1.3 times) by the end of 24 h. 
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Fig 3.3.9: Flow cytometry analysis of cellular uptake of DiI-labelled conjugated liposomes (L2 or L3) 
as compared to unconjugated liposomes L1 after treatment of (a) 2 h, (b) 6 h and (d) 24 h. Among 
targeted liposomes, L3 liposomes are much more efficient than L2 in being taken up by FR+ cells. The 
enhancement in the uptake is according to FR expression, therefore the uptake in KB is highest 
followed by HeLa. HT-3 and A549 cells display no enhancemet in uptake from liposomal conjugation. 
The difference between the uptakes in KB and HeLa also decreases with time. 
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(a) (b) (c) 
   
 
Fig 3.3.10: Comparison of the cellular uptake of non-targeted (L1) and targeted liposomes (L2 and L3) 
by flow cytometry at the end of (a) 2 h, (b) 6 h, and (c) 24 h treatment. Unpaired t test is used to assess 
any significant difference in the uptakes between the conjugated liposomes, L2 and L3. L3 uptake is 
significantly higher in both KB and HeLa cells. The difference between targeted and non-targeted 
liposomes decrease with time. HT-3 also displays a significantly higher uptake of L3 in the first 2 hours 
of treatment. Data are means ± standard deviations of three replicate measurements of at least three 
independent experiments. *p≤0.05, **p≤0.01, and ***p≤0.001. 
 
 
As with the trend seen in L2 uptake before (Fig 3.3.5), the difference between the 
conjugated (in this case L3) and non-conjugated liposomes (L1) steadily decreased with 
the time interval. This decrease resulted in HT-3 taking up all the liposomal 
formulations equally by 24 h despite showing some higher uptake of L3 in the initial 
few h. In KB, this effect was much more profound, more for L3 than L2. In contrast, 
HeLa displayed a steady difference between conjugated (L2 and L3) and non-
conjugated liposomes (L1) in the time period tested (24 h).  
 
Plate Reader Analysis 
The additional uptake assay to gauge any enhancement in cellular uptake after ligand 
conjugation to the liposomes was by reading the fluorescence of the cells via microplate 
reader and comparing L2/L3 treated to L1 treated cells. Results corroborated the 
findings from confocal and flow cytometry studies as depicted in Fig 3.3.11. 
Conjugated liposomes (both L2 and L3) were taken up in much higher proportions than 
non-conjugated L1 in KB and HeLa cells, whereas A549 and HT-3 displayed no 




















































































































































































(a) (b) (c) 
   
 
Fig 3.3.11: Comparison of cellular uptake of the three liposomal formulations L1, L2 and L3 by the 
four cell lines with plate reader analysis at the end of (a) 2 h, (b) 6 h, and (c) 24 h treatment. L3 uptake 
is significantly higher than L2 in KB and HeLa. The difference between targeted and non-targeted 
liposomes decrease with time. Data are means ± standard deviations of three replicate measurements of 
at least three independent experiments. **p≤0.01, and ***p≤0.001. 
 
 
L3 liposomal formulation had a significantly higher uptake than L2 for FR positive 
cells. They were taken up around 6.7 times more by KB cells and 4 times more by HeLa 
cells at the end of 24 h. HT-3 and A549 cells remained unaffected in their liposomal 
uptake from ligand conjugation. In fact, conjugated liposomes were taken up slightly 
less than the non-conjugated liposomes in A549 cells by a factor of 0.9.  
 
ICP-MS quantitative arsenic cellular uptake 
Quantifying arsenic by ICP-MS in cells treated with L1, L2 and L3 revealed that 
conjugating liposomes with folic acid tethered to a longer PEG spacer length resulted in 
a significant increase in the liposomal uptake by FR positive cells (Fig 3.3.12). The four 
cell lines were treated for 6 h, 24 h and 48 h. At the end of 6 h, L3 liposomes were taken 
up 2.1, 2.5, 1.3 and 0.8 times more for KB, HeLa, HT-3 and A549 respectively. As is 














































































































































































conjugating spacer length. This observation was also valid for the 24 h and 48 h 
treatment. HT-3, despite showing a slight increase in L3 uptake compared to L2 uptake 
during the first six hours, reached a similar level with further prolonged treatments. KB 
cells took up 2 times more arsenic with L3 treatment at the end of 48 h treatment while 
HeLa cells, despite starting out with 2.5 times more L3 uptake than L2 at 6 h, eventually 
tapers off to a factor of 1.2 at the end of 48 h liposomal incubation.  
 
 
(a) (b) (c) 
   
 
Fig 3.3.12: Arsenic concentration per cell as determined by ICP-MS in the four cell lines after (a) 6 h, 
(b) 24 h, and (c) 48 h treatment with the unconjugated (L1) and conjugated (L2 and L3) liposomes. L3 
is taken up more than L2 in FR positive KB and HeLa cells. HT-3 has a higher uptake of liposomes in 
general, regardless of ligand conjugation. The arsenic concentration increases with time for all the cell 




As noted previously, HT-3 inherently takes up more liposomal arsenic than the 
remaining cell lines, which is not dependent on the folate conjugation or its conjugating 
spacer length. With a 6 h treatment, KB, HeLa and A549 cells have approximately the 
same cellular arsenic when treated with unconjugated liposomes. However, when the 
liposomes are conjugated, specifically with 5000Da PEG spacer length, KB cells were 
shown to take up around 6 times more arsenic and HeLa cells took up around 4 times 
more arsenic than with L1. A549 did not show a significant increase in liposomal 



















































































unresponsiveness towards the treatment. At 48 h, although there is no statistically 
significant difference in the arsenic cellular concentration from L1 and L2 treatment, L3 
treated KB and HeLa cell lines demonstrated a significantly higher cellular arsenic 
concentration which indicates that L3 is superior to L2 in increasing arsenic cellular 



















3.3.3.4 Analysing cytotoxicity of control empty liposomes with differing 
spacer lengths of conjugated ligand  
 
The results above clearly indicated the advantages of using a long PEG spacer to tether 
folic acid to the liposomes for enhancing their uptake in FR positive cells. However, in 
order to employ them successfully as arsenic nanocarriers to manage cervical cancer, it 
becomes imperative to investigate any inherent cytotoxicity that they might possess due 
to the presence of long PEG spacers. Since our focus is on cervical cancers and presence 
or absence of HPV gene sequences, further experiments were carried out on HeLa, HT-
3 and KB cells only. KB cell line was included as despite being derived from epidermal 
mouth carcinoma, it had been contaminated with HeLa cells at some point. Therefore, it 
is positive for HPV-18 DNA sequences. Empty, unloaded liposomes of various 
formulations were synthesised and their cytotoxicity analysed on these cell lines via 
MTT assay at 48 h as depicted in Fig 3.3.13. The dilutions employed for the empty 
liposomal treatment had their phospholipid concentrations corresponding to ATO 
liposomes with 5µM encapsulated ATO concentration. At the dilutions used for 
treatment and the time period involved, none of the liposomes were toxic for any cell 
line. With these results in consideration, L3 liposomes, out of the three, proved to be the 















KB HeLa HT-3 
   
         represents the concentrations of phospholipid at dilutions used for treatment of liposomal ATO. 
 
Fig 3.3.13: Toxicity studies by MTT Assay of the control empty liposomes (L1, L2 and L3) on KB, 
HeLa and HT-3 cell lines after 48 h treatment. Increasing the spacer length for ligand conjugation does 
not result in increase of cytotoxicity as the phospholipid concentrations at dilutions used for the 
treatment of liposomes (L1, L2 or L3) are non-toxic to all the cell lines tested at 48 h, demonstrating the 









































































3.3.3.5 Quantitative analysis of cellular uptake of arsenic  
 
After establishing that L3 liposomes were more efficient than L2 in being taken up by 
the FR positive cells while not possessing any inherent toxicity of their own, further 
experiments were carried out with “L3” as the targeted liposomes, “L1” as their 
unconjugated counterparts, “ATO” as the drug in free form and media only as “con”. 
The cells were treated for 6 h, 24 h and 48 h, digested and their arsenic intake was 
quantified by ICP-MS (Fig 3.3.14).  
 
(a) (b) (c) 
   
 
Fig 3.3.14: Arsenic concentrations per cell in KB, HeLa and HT-3 as determined by ICP-MS after (a) 6 
h, (b) 24 h and (c) 48 h treatment with only media, unconjugated ATO liposomes L1, FA conjugated 
ATO liposomes L3 and free ATO of 5µM concentration. Data displayed is mean ± SD from five 
independent experiments. Unpaired t test is used to calculate any significant difference in the arsenic 
intake from L3 and ATO treatments, **p≤0.01. L3 is taken up more than free ATO in KB at 6 h, after 
which their uptakes are equalised when the time of treatment is increased to 24 h and 48 h. The cellular 
arsenic intake from free ATO gets higher than L3 in HeLa at 48 h, whereas for HT-3 it gets higher from 
24 h.  
 
 
Results showed that after 6 h of treatment, targeted liposomes L3 were taken up more 
than free ATO in both KB and HeLa, with cellular arsenic concentration in the order of 
con<L1<ATO<L3.  Arsenic concentration due to L3 uptake was 2.1 and 1.3 times than 
from ATO in KB and HeLa cells respectively. Prolonging the incubation period to 24 h 
and further to 48h resulted in equalising of cellular arsenic concentration from both the 




















































































free ATO was taken up more than L3 in HeLa cells, 1.3 and 2.8 times more at 24 h and 
48 h respectively. In HT-3 cells, free ATO was always taken up more than the 
liposomal counterparts, both conjugated and non-conjugated, in the time periods tested. 
The results showed a consistent increase in the cellular arsenic concentration as the 
incubation time period increased for all the cell lines and the treatments, except the 
control. There was one anomaly seen in HT-3 cellular arsenic concentration however. 
From 24 h to 48 h, the arsenic concentration per HT-3 cell, instead of increasing, saw a 























3.3.3.6 Toxicity studies of liposomal arsenic using optimised formulation 
 
With differing cellular uptake of liposomal and free ATO, the cervical cancer cell lines, 
HPV positive HeLa and HPV negative HT-3, along with KB, were next evaluated for 
cytotoxicity induction from these treatments. The dose response curve obtained from 
MTT assay for free drug and liposomal drug revealed that liposomal encapsulation 
mitigated toxicity except in the case of KB, where the targeted liposomes L3 induced 
more toxicity than free ATO in the first 48 h (Fig 3.3.15). At 72 h, L3 and ATO had 
almost the same dose response curve. For HeLa and HT-3 cells, however, free drug 
always induced more toxicity than L3. At the dilutions used for treatment, i.e. at 5 µM 
ATO concentration, free drug caused toxicity to around 23% more cells than L3 in 



































              points to 5µM ATO concentrations which is typically used for treatment. 
 
Fig 3.3.15: MTT test analysis to compare cellular toxicity of non-targeted and targeted liposomal 
formulations of ATO along with the free drug on HeLa, KB and HT-3 cells at 24 h, 48 h and 72 h. Points 
refer to the means and bars refer to ±SD, where n=3. Unpaired t test (p > 0.05) was used to test if there is 
any significant difference in the cytotoxicity between L3 and ATO at 5µM ATO concentration. 
Liposomal encapsulation attenuates drug toxicity to the cells in vitro, except for KB cell line where L3 
liposomes were more toxic than free ATO till 48 h, after which their cytotoxicity equalised. For HeLa and 
HT-3, free ATO induced more toxicity than either liposomal constructs at all time intervals investigated.  



































































































































In Figure 3.3.16, cell death–uptake ratios for KB, HeLa and HT-3 cells were shown to 
indicate the level of cell death that was induced in the cell lines per unit of arsenic taken 
up by the cells. Targeted liposomal ATO was more effective than the free drug in 
inducing cell death per unit of arsenic uptake in both receptor positive KB and HeLa 
cell lines, whereas free ATO was more effective in inducing response in HT-3 cells. 
Additionally, between KB and HeLa cells, the liposomal ATO treatment was more 




Fig 3.3.16: Ratios of cell death vs. uptake of targeted liposomal and free ATO for KB, HeLa and HT-3 
cells after 48 h treatment. Targeted liposomes induced highest cell death per unit arsenic uptake in HeLa 
cells. Targeted liposomes were more effective in inducing response than free ATO in FR+ KB and HeLa 





































We described in this chapter the synthesis of folate targeted ATO encapsulating 
liposomes and the effect of increasing the ligand spacer length on cellular uptake and 
inhibitory potency against FR positive cancer cells in vitro, with particular emphasis on 
HPV and FR positive cervical cancer cells. To prepare targeted liposomes against HPV 
positive HeLa cervical cancer cells, folic acid was the ligand of choice as its receptor 
was the most differentially expressed out of the three receptors investigated on cervical 
cancers with differing HPV status. In addition, folic acid is also inexpensive and stable 
with low molecular weight having simple conjugation chemistry with relative low 
immunogenicity (Byrne, Betancourt and Brannon-Peppas, 2008; Talekar et al., 2011; 
Yu et al., 2010). It has a very high affinity for the FR presented on tumour’s cell surface 
and is rapidly endocytosed (Talekar et al., 2011). Since folic acid is a vitamin required 
by the eukaryotic cells for the biosynthesis of nucleotide bases, any cargo attached to it 
remains within endosomes and then released into cytoplasm rather than being shuttled 
to the lysosome for destruction (Talekar et al., 2011; Byrne, Betancourt and Brannon-
Peppas, 2008).  Folate targeting of liposomal drug carriers have been reported to 
increase the therapeutic efficacy in a number of cases but it requires careful 
optimisation for effective therapeutic applications for selected tumours (Gabizon et al., 
2004; Stephenson, Low and Lee, 2004; Reddy, Allagadda and Leamon, 2005). 
The foremost necessity of synthesising an actively targeted nanoparticle was to design it 
so that it possessed extended circulation times, as mostly, an increased nanoparticles’ 
affinity for the target antigens could not compensate for the natural clearance processes 
(Bertrand et al., 2014).  Actively targeted nanoparticles without sufficient steric 
stabilisation from a PEG layer tend to lose their receptor binding ability due to non-
specific interactions with colloidal proteins (Salvati et al., 2013). Additionally, since the 
physical stability of the targeted liposomes without the PEG layer was also not very 
well explored, in the initial experiments, only the ligand conjugating PEG spacer was 
included in the liposomal mix to prepare a targeted ATO delivery system, without the 
addition of the brush forming PEG layer. It resulted in unstable liposomal formulations 
which aggregated during the drug loading itself, regardless of the length of the ligand 
PEG spacer. Adding mPEG2000-DSPE to the liposome mix stabilised the targeted 
176 
formulations and prevented them from aggregating. This might be due to the reason that 
surface grafted PEG chains, even at low concentrations, could provide sufficient steric 
barrier to prevent fusion of liposomal membranes (Holland et al., 1996). 
There was another parameter that required careful optimisation: the ligand density on 
the surface of the nanoparticle. Thermodynamically, the binding of a ligand to a 
receptor facilitates the binding of its neighbouring ligands; these multiple interactions 
lead to clustering of the receptors, wrapping of the membrane and eventual 
internalisation of the bound nanoparticle (Mammen, Choi and Whitesides, 1998). These 
multivalent interactions lead to an enhanced avidity of the nanoparticle towards the 
target cell and prevents its detachment from the cell surface.  However, in vitro, a higher 
ligand density does not necessarily translate to an enhanced cellular uptake (Weissleder 
et al., 2005). In some cases, it was shown that increasing the ligand density above a 
certain threshold resulted in saturation of the cooperative effects of the ligands, leading 
to unfavourable effects on cellular binding (Elias et al., 2013). Moreover, the presence 
of a dense ligand covering on the nanoparticles was also known to make them more 
prone to being recognised by the cells of MPS which consequently, led to a loss of their 
“stealth” surface characteristics (Kamaly et al., 2012). Hence, in order to bypass any 
such negative effects and to ensure high nanoparticle avidity to the surface receptors, it 
becomes necessary to optimise ligand density on the nanoparticles for every particular 
cancer type.  
There have been reports of ligand molar ratio to range from 0.03 to 0.5% in literature 
for folate targeting liposomes (Reddy et al., 2002; Saul et al., 2003; Gabizon et al., 
1999; Pan, Wang and Lee, 2002; Pan et al., 2002). In our experiments, it was observed 
that using 0.3mol% DSPE-PEG2000-FA and 1.7 mol% of mPEG2000-DSPE in the 
liposomal mixture formed stable L2 liposomes. However, the same (0.3 mol %) or 
higher amount of DSPE-PEG5000-FA could not be used to prepare stable L3 liposomes 
and it invariably led to the aggregation of liposomes as soon as they were synthesised, 
despite the presence of a stabilising PEG2000 brush layer. After adjusting molar ratios of 
components, employing 0.1 mol % of DSPE-PEG5000-FA and 1.9 mol% of mPEG2000-
DSPE gave stable L3 liposomal formulations. The same ratio was henceforth used for 
preparing L2 liposomes as well for comparison purpose. Cholesterol and soy PC were 
used in the same proportions as was detailed in the Chapter 3 (i) towards the formation 
of optimised neutral 100nm liposomes. The instability of L3 liposomes with higher 
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ligand density might be explained from studies where high folate density on the surface 
of nanoparticles were known to produce dimers, trimers and quartet self-assembled 
folate structures, causing aggregation of nanoparticles; with the longer ligand 
conjugating PEG spacer expediting the process (Ohguchi et al., 2008).   
At the molar ratio employed for synthesis of targeted liposomes, ligand conjugation had 
no effect on either the size of the nanoparticles, nor did it impair their loading efficiency 
and stability (Fig 3.3.3). All the formulations (L1, L2 and L3) had similar sizes, i.e. 
around 140nm and achieved high loading efficiency with arsenic to phospholipid of 
0.25 molar ratio. Our stability tests showed that all the liposomes, irrespective of ligand 
conjugation, were homogenous and stable with a loss of less than 10% of arsenic over 
four weeks storage at 4°C. 
Owing to a possibility that PEG brush might mask the targeting abilities of the ligand if 
it is conjugated to a PEG spacer of equal length, our first investigation was to assess 
whether folate targeting alone, without conjugating to a longer PEG spacer, could cause 
any enhancement in cellular uptake. For that purpose, we synthesised L2 liposomes 
having the ligand conjugating PEG spacer and surrounding PEG brush layer of equal 
length, i.e. 2000Da. We evaluated the differences in cellular uptake from four different 
techniques: confocal microscopy, flow cytometry, fluorescence reading via plate reader 
and cellular arsenic quantification via ICP-MS.   
Confocal microscopy studies indicated high liposomal binding of L2, though not of L1, 
to the surface of FR positive KB cells at 2 h (Fig 3.3.4). This surface receptor 
association of L2, was also present for HeLa cell line, albeit to a much lesser degree, but 
not for any other cell line. Increasing the incubation time to 24 h saw a widespread 
internalisation of targeted liposomes in KB cells, followed by HeLa and then HT-3 
cells. A549 cells did not show any liposomal uptake after conjugation. These results 
were in accordance to the hypothesis that folate targeted arsenic loaded liposomes 
would be efficiently and selectively taken up by FR positive cells and that since from 
the previous chapter it was incurred that the FR expression followed the trend in cell 
lines as KB>HeLa>> HT-3>A549, the cellular uptake of targeted liposomes would also 
follow the same behaviour. From the confocal images of KB and HeLa cells in 
particular, the cell surface association of targeted liposomes at 2 h and then subsequent 
internalisation and accumulation within the cytoplasm at 24 h was very obvious, 
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indicating to the process of endocytosis. Non-targeted liposomes L1 too were taken up 
by KB cells at the end of 24 h, although to a much lesser extent than targeted liposomes, 
showing a certain level of vulnerability of KB cell line towards the treatment. 
These results were corroborated by flow cytometric analysis of cellular uptake of 
fluorescent liposomes (Fig 3.3.5). Results showed that even in the first two hours, KB 
cells took up almost 50 times more L2 than L1. This drastic enhancement in liposomal 
uptake was however not reflected in other cell lines; however, HeLa did take up twice 
as much as L2 than L1.  HT-3 cells also took up more L2 than L1, albeit to a lesser 
extent that HeLa. A549 cells, as expected, showed no difference in liposomal uptake 
based on conjugation.  
The difference between the cellular uptake of conjugated and non-conjugated liposomes 
decreased with prolonging the exposure time, which might be due to two contributing 
factors: an increase in non-specific uptake of unconjugated liposomes and a subsequent 
decrease in the uptake of conjugated liposomes due to a possible saturation of the 
targeted receptors on the cell surface. For KB, this effect was very much pronounced; 
the difference between L2 and L1 went from 50 fold at 2 h to around 24 times in 24 h. 
HeLa, being less FR+ did not exhibit this drastic decrease in this difference, with L2 
still being taken up twice more than L1 at the end of 24 h. In HT-3 cells, the uptake of 
both targeted and non-targeted liposomes equalised within the first 6 h.  
From the plate reader results as well, KB cells displayed the maximum difference in 
cellular fluorescence arising between L2 and L1 uptake, followed by HeLa and HT-3 
(Fig 3.3.6). Additionally, as with the flow cytometry analysis, we saw a consistent 
decrease in the uptake difference between L2 and L1 with increasing incubation times. 
The reason for it, as hypothesised above, was further corroborated after quantifying 
cellular arsenic via ICP-MS (Fig 3.3.7). Results showed that after an initial high surge 
of liposomal L2 arsenic intake by FR+ cells, the rate at which L2 was taken up almost 
invariably slowed down in comparison with L1. This led to a bridging of the gap 
between L2 and L1 uptakes in cells. However, as seen from ICP-MS studies, the 
difference between L2 and L1 intake was considerable, almost three-fold for KB cells 
and 1.6 and 1.3 times for HeLa and HT-3 respectively. This, further confirmed by the 
above findings, established beyond doubt that folic acid conjugation to liposomes, even 
to a PEG spacer of similar length as the surrounding PEG brush, was able to effectively 
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target the FR positive cells with efficiency and selectivity. However, to be positive that 
the surrounding PEG layer was not masking the conjugation abilities of the ligand, even 
to a small extent, we decided to next conjugate folic acid to a PEG spacer of longer 
length and observe any further enhancement in uptake within FR+ cell lines. Since, the 
previous studies had employed FA-PEG3350 (Chen et al., 2009); we decided to use 
even longer PEG spacer length of 5000Da for making targeted liposomes and 
investigate any increase in cellular uptake along with any inherent toxicity that might 
arise from employing longer PEG spacers for ligand conjugation.   
Folic acid was subsequently conjugated to a PEG spacer having longer length (5000Da) 
than the surrounding PEG brush (2000Da). The above mentioned techniques including 
confocal microscopy, flow cytometry, plate reader analysis and ICP-MS arsenic 
quantification were once again employed to assess any enhancement in cellular 
targeting. Keeping all the settings and parameters same for comparative analysis, 
confocal microscopic images very distinctly showed the superiority of using a longer 
PEG spacer for ligand conjugation (Fig 3.3.8). At the end of the initial 2 h incubation, 
L3 liposomes clearly displayed strong cell surface attachment in around 80% of FR+ 
KB cells, in contrast to 10% of KB cells with L2 liposomes. Additionally, around 20% 
of HeLa cells showed membrane attachment with L3, but none with either L2 or L1. A 
little attachment (around 5%) was also seen with L3 in HT-3 cells. A549 showed no 
cellular association with L3, exhibiting the selectivity of the conjugated ligand. As the 
incubation period was increased to 4 h, 6 h and eventually 24 h, KB cells saw a 
widespread internalisation and accumulation of L3 in their cytosol. L3 was also taken 
up in almost all the HeLa cells and around 20% of HT-3 cells. In contrast, L2, albeit 
more effective that L1, was visibly less effective than L3 in being taken up by FR+ 
cells.    
Results from flow cytometry also established that L3 had a superior uptake in FR+ cells 
(Fig 3.3.10). It was taken up almost twice as much as L2 in the first 24 hours in HeLa; 
whereas in HT-3, its uptake was only 1.3 times more than L2.  Fluorescence reading 
from the plate reader showed that at the end of 24 h, KB cells incubated with L3 had 6.7 
times more fluorescence that L2 (Fig 3.3.11). Additionally, this value was 4, 1.5 and 0.9 
times for HeLa, HT-3 and A549 respectively, clearly displaying the superior targeting 
abilities of L3 liposomes than L2. ICP-MS studies also validated the findings and the 
results showed that the cellular arsenic content from L3 uptake was almost 3 times 
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higher than L2 uptake in KB cells and two times higher in HeLa cells at the end of 24 h 
(Fig 3.3.12). This enhanced uptake was however not very significant in the case of HT-
3 cells, clearly owing to the weak FR expression by its cells. FR- A549 cells displayed a 
similar uptake for all the liposomes, irrespective of conjugation or non-conjugation.  
From the above results, it was established beyond doubt that L3 instigated the highest 
uptake in FR+ cells while being very selective in its targeting abilities and therefore 
should be the logical choice for delivery vehicle of arsenic in FR rich HeLa and KB 
cells with HPV infection. However, for it to function as a successful delivery vehicle, it 
needed to test negative for any inherent cytotoxicity. Since we intended to elaborate our 
work on investigating the therapeutic potential of arsenic in HPV infected cervical 
cancers and the time period chosen for the our previous studies had been 48 h, all the 
liposomal formulations henceforth were tested for any intrinsic cytotoxicity to the cells 
by incubating the empty liposomes with HeLa and HT-3 cells, along with KB cells 
(owing to them being positive for HPV infection), for 48 h. The dilutions of liposomes 
tested for toxicity studies included the ones that corresponded with the liposomal 
concentration with encapsulated 5µM ATO that were typically used for treatment. All 
the liposomes, including L3, were non-toxic at the dilutions to be used for treatment. 
This finding was in agreement with the study by Peng et al. (2013) where they observed 
that the conjugated docetaxel delivery systems targeting prostrate specific membrane 
antigen with longer spacer length had no significant toxicity in vitro and in vivo, i.e. in 
major organs of the treated mice bearing C4-2 tumour xenograft.   
Consequently, the inherent non-cytotoxicity of L3 liposomes along with their superior 
targeting abilities led us to select them among the other formulations as the optimised 
design for the targeted ATO nano-carrier. Further in vitro analyses was henceforth 
carried out with L3 as the conjugated liposomes, L1 as their unconjugated counterparts 
and free ATO on HPV positive KB and HeLa and HPV negative HT-3 cells.  
Cellular uptake studies showed that usually arsenic was transported more readily within 
the cells when the free form was applied. However, owing to the very high FR 
expression of KB cells which render them most amenable towards folate targeting and 
consequent liposomal uptake, L3 liposomes transported twice more arsenic in the first 
six hours of treatment. This trend was also seen with HeLa, though to a lesser extent 
(1.3 times more than free ATO), again due to a high FR expression. As the treatment 
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time increases however, we reported an equalising of the cellular arsenic concentration 
from L3 and ATO treatment in KB cells while an increasing arsenic concentration with 
free ATO treatment in HeLa cells. In HT-3 cells however, free form of the drug was 
always taken up more than the liposomal forms, with not much difference between L1 
and L3 uptake.  
The cells were further incubated with free and liposomal ATO of 5µM concentration for 
a period of 24 h, 48 h and 72 h and their cytotoxicity assessed by MTT assay. As 
expected, KB cells displayed the maximum vulnerability towards L3 treatment, where 
L3 liposomes able to induce 1.5 times more cell death than the free drug itself at 24 h. 
L3 liposomes killed almost 35% of KB cells, as opposed to free ATO and L1 which 
killed 24% and 12% cells respectively. In contrast, free ATO generated higher cell 
death than either liposomal formulations for both HeLa and HT-3 cells. The difference 
between L3 and free ATO toxicity reduced for all the cell lines as the time of treatment 
increased. This might probably have arisen from the increasing non-specific cellular 
association of liposomes along with passive arsenic release contributing to the lessening 
of the differences between the cytotoxicities.   
The cell death–uptake ratio indicated the cell death induced per unit of arsenic uptake, 
and is an effective means of comparing the efficacy of a treatment on different cell 
populations. Our results indicated that for targeted liposomal treatment, this ratio was 
higher for HPV positive HeLa and KB cells than HPV negative HT-3 cells. Moreover, 
targeted liposomes were more efficient in inducing cell death than free ATO in FR 
positive cells per unit arsenic taken up, in contrast to HT-3 cells. Interestingly, targeted 
liposomal ATO was found to be most effective in inducing its response towards HeLa 
cells, which again point to a certain susceptibility of the cell line towards liposomal 









The success of a targeted drug delivery system, tailored to the specific cancer under 
investigation, depends on the thorough optimisation of the nano-carrier’s various 
parameters. From the previous chapters, we observed that for treating HPV positive 
cervical cancers, neutral 100nm liposomes were the most optimal formulation amongst 
different sizes and charges and folic acid was the best targeting ligand. Henceforth in 
this chapter, we synthesised folic acid conjugated, 100 nm neutral ATO encapsulating 
liposomes and examined the impact of varying spacer length on their targeting abilities 
for treating HPV positive cervical cancer. Folate targeting, particularly when the ligand 
was attached to a longer PEG spacer, led to an appreciable enhancement in cellular 
uptake by FR positive cancer cells. This formulation, along with being efficient and 
highly specific, had no inherent toxicity of its own at the dilutions used for the 
treatment, making it very suitable for it to be used as the delivery vehicle of ATO to 
HPV positive cervical cancer cells. Our next step would be to investigate the molecular 
mechanism behind the action of free and liposomal ATO with particular emphasis on 
the HPV’s E6 and E7 oncoproteins, apoptotic protein activated caspase-3 and tumour 













3.4 INVESTIGATING MECHANISM OF ACTION 
OF THE LIPOSOMAL AND FREE ARSENIC 









The HPV infection is reported to occur at some point in 75% of sexually active women, 
making it the most sexually transmitted infection in the world (Yim and Park, 2005). 
Through several epidemiological studies supported by molecular technology, HPV has 
been identified as the causal agent in cervical cancer development (Bosch et al., 2002). 
Despite the widespread infection, only 10% of infected women develop precancerous 
lesions of which 8% develop early cancer limited to the epithelial layer of the uterine 
cervix (Yim and Park, 2005). However, if left untreated, these precancerous lesions may 
develop into invasive cancer at a later stage (Yim and Park, 2005).  
 
The HPV family includes over 100 HPV types, of which 15 types are classified as high 
risk HPVs involved in over 95% of cervical cancer cases (Bosch et al., 2001). Of these, 
HPV-16 and HPV-18 are the two primary high risk types which are responsible for 50% 
and 10% of invasive cancer respectively (Munoz et al., 1992). Studies have indicated 
that persistent presence of high risk HPV infection is critical for development, 
maintenance and progression to CIN (Remmink et al., 1995). HPV infection are also 
indicated to play a crucial role in the pathogenesis of other carcinomas such as upper 
respiratory digestive tract cancers, urogenital tumours and cancers of different human 
organ types (NeufCoeur et al., 2009; Shukla et al., 2009; Sutcliffe et al., 2010). 
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The mechanism by which HPV induces cancer in humans has been investigated 
intensively and these investigations have highlighted the crucial roles of oncoproteins of 
HPV E6 and E7 in inducing cancer (Tommasino, 2013; Lazo, 1999; McGlennen, 2000). 
HPVs have double stranded, circular DNA genome, 8 kb in size, which encodes for 8 
proteins of which E6 and E7 oncoproteins are necessary for malignant transformation 
(Walboomers et al., 1999). Besides the transforming properties, E6 and E7 have 
additional functions including regulation of chromosomal stability and cell cycle, 
transmembrane signalling, immortalisation of primary cell lines and transformation of 
established cell lines (Yim and Park, 2005). Post HPV infection, de-regulation of viral 
E6 and E7 oncogenes expression drive cellular proliferation and stimulate host cells to 
re-enter the cell cycle (Doorbar, 2007). The carcinogenic potential of E6 and E7 viral 
proteins lies in their selectively degrading p53 and retinoblastoma RB gene products 
respectively, resulting in the inactivation of two crucial negative regulatory cellular 
proteins and the consequent cellular immortalisation and transformation (Fig 3.4.1) 






Fig 3.4.1: The role of HPV’s E6 and E7 oncoproteins in the inactivation of tumour suppressors’ p53 and 




E6 is an anti-apoptotic protein and its carcinogenesis lies with its ability to associate 
with p53, which promotes its ubiquitination and proteasome dependent degradation 
(Doorbar, 2007). E6 protein stimulates degradation of tumour suppressor p53 by 
forming a trimeric complex, consisting of E6, p53 and the cellular ubiquitination 
enzyme E6-AP (Yim and Park, 2005). This E6 stimulated degradation of p53 disrupts 
the control over cell cycle progression and apoptosis, compromising the effectiveness of 
cellular DNA damage response and causing accumulation of secondary mutations, 
collectively resulting in the growth of tumour cells (Doorbar, 2007; Um et al., 2002). 
Besides the abovementioned p53 degradation, E6 protein has oncogenic potential 
independent of p53 as well (Yim and Park, 2005). 
 
E7 associates with hypophosphorylated form of the cell cycle regulator pRb and 
consequently disrupts its binding with the E2F family of transcription factors (Doorbar, 
2007). These transcription factors are responsible for repressing the expressions of 
replication enzyme genes, forming a direct correlation with the tumour suppressor 
function of Rb (Lipinski and Jacks, 1999). The E2F on being released from the pRb-
E2F complex activates cellular genes promoting host cell and viral DNA replication 
(Doorbar, 2007). E7 and E6 have been known to work cooperatively as well as 
independently of each other in inhibiting apoptosis and mediating cell proliferation 
(Doorbar, 2007; Nguyen et al., 2003; Thomas et al., 2002). 
 
Therefore, since the oncogenic potential of HPV lies in the expression of E6 and E7 
genes and their product, they represent the logical targets for developing molecular 
therapies for cervical cancer and that the inhibitors should target the functions of both 
the oncoproteins (Horner et al., 2004; Lin et al., 2009; Soliman et al., 2004). Hence, a 
drug downregulating E6 and E7 oncogenes expression and disrupting the linkage of E6-
p53 and E7-pRb to liberate p53 and pRb in HPV infected cells may have the potential to 
restore the altered biological functions of the cells and allow them to carry on with the 
normal process of apoptosis. ATO has been reported to downregulate E6/ E7 oncogenes 
expression and reduces survival of HPV-18 infected HeLa cells (Um et al., 2002; Wang 
et al., 2016).  
 
ATO is being therapeutically used since 200BC, initially in traditional Chinese 
medicine (Ho et al., 2005). As an anti-cancer agent, it proved highly successful on 
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patients with APL, a subtype of acute myeloid leukaemia. The success following its 
clinical trials on APL patients as a single agent or in combination with conventional 
chemotherapy led to its approval by FDA as its frontline therapy (Antman, 2001). The 
same kind of clinical success was subsequently translated for other haematological 
malignancies (Swindell et al., 2013). Since then, ATO has been extensively studied as 
an anti-cancer drug with an effort to further extend its application to treat solid tumours. 
Studies indicate that ATO demonstrates significant anti-cancer activity on a variety of 
solid cancer lines and tumour models including lung, endometrium, skin, liver, 
colorectal, pancreas, breast, kidney, ovarian and cervical cancers, albeit without 
appreciable clinical success in human patients (Bornstein et al., 2005; Dilda and Hogg, 
2007; Kito et al., 2003; Lam et al., 2014; Maeda et al., 2001; Murgo, 2001; Park et al., 
2003; Wang et al., 2014; Zekri et al., 2013). Employing ATO to treat solid tumours has 
drawbacks as higher doses are required for their treatment in comparison to 
haematological malignancies (Liu et al., 2006). This is to overcome rapid clearance of 
arsenic and its products from the blood by reticuloendothelial system and allow further 
penetration into the solid tumour mass (Liu et al., 2006).  The higher dosages though, 
have been reported to cause systemic toxicities such as long term memory damage, liver 
failure, cardiac failure and peripheral neuropathy, limiting its clinical utility (Evens, 
Tallman and Gartenhaus, 2004). 
Moreover, even though the mechanism of action of ATO for blood cancers has been 
carefully elucidated and reviewed, it is not fully understood for solid tumours (Evens, 
Tallman and Gartenhaus, 2004).
 
Some of the mechanisms reported for its anti-cancer 
activity are induction of apoptosis (Emadi & Gore, 2010), mitochondrial toxicity 
(Larochette et al., 1999), generation and accumulation of ROS (Platanias, 2009), along 
with interference in telomerase activity (Zhou et al. 2007), tubulin polymerisation, DNA 
repair or cell cycle progression (Kroemer & de Thé, 1999). It has also been reported to 
inhibit proliferation of carcinogenic cells and angiogenesis by either down-regulating 
VEGF or inducing apoptosis in endothelial cells (Miller et al., 2002).
 
However, the 
exact mechanisms for treating specific tumours remain ambiguous.  
Our research team, with focus on HPV infected cervical cancers, had previously 
employed ATO as the treatment drug and shown it to be effective against the cancer 
cells (Wen et al., 2012). However, its efficacy was evident only when it was used at a 
low concentration (up to 2 μM), as concentrations higher than 2μM were toxic to 
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majority of the cells (Wen et al., 2012). Further study carried out by the same research 
group showed that ATO encapsulated in liposomes improved arsenic’s therapeutic 
index and observed that the liposomal formulation was effective in inducing apoptosis 
and reducing HPV E6 oncogene expression in HeLa (Wang et al., 2016). However, the 
impact on HPV E7 oncogene expression and the relationship between E6-p53 and E7-
pRb post treatment was not completely explored. Moreover, it was also not shown how 
ATO, if encapsulated in liposomes with ligands specifically targeting HPV positive 
cancer cells, would regulate the expressions of E6 and E7 oncogenes and whether there 
would be any differences in their mode of action from free ATO and unconjugated 
liposomal ATO. Therefore, in this study we first optimised the ATO carrying liposomal 
design (Akhtar et al., 2018) and conjugated them with ligands specifically tailored for 
HPV positive cervical cancer treatment. Using the optimized liposomes (100 nm 
neutral) and folic acid being the ligand of choice, an in vitro study was further carried 
out to investigate the mode of action of free ATO, liposomal-encapsulated ATO and 
folate conjugated liposomal ATO on HPV infected and non-infected cancer cells though 
evaluation of apoptosis induction and expression levels of apoptotic protein active 




3.4.1.2 Aims:  
 
The aims of this chapter are to investigate and compare the mode of action of ATO 
when it is delivered free or encapsulated in unconjugated and folate conjugated 
liposomes on HPV positive and negative cancer cells in vitro and to assess the best 










(i) To investigate whether active targeting approach using FA-conjugated liposomes 
(ATO-FA-L2) is better at inducing apoptosis in HPV positive cancers than non-targeted 
liposomes (ATO-L1). 
 
(ii) To compare the efficacy between ATO delivered free or through targeted liposomal 
approach for cervical cancer cell treatment. 
 
(iii) To assess the mechanisms of action of ATO delivered via the three disparate 
techniques by examining the downregulation of oncogenes E6 and E7 and upregulation 
of tumour suppressor proteins p53/ pRb and apoptotic protein activated caspase-3. 
(iv) To investigate which ATO delivery method is the most selective and effective for 

















The list of materials employed for the study, including Annexin V-FITC/PI apoptosis 
detection kit, antibodies for protein detection, reagents for Western blotting, confocal 
and flow cytometry analysis, have been enlisted in Chapter 2. The FA-targeted and non-
targeted liposomes were prepared and characterised as detailed in Chapter 3 (iii).  
 
3.4.2.2 Cell culture 
 
Two cervical cancer cell lines, HeLa and HT-3, and HPV positive HeLa derivative 
human nasopharyngeal epidermal carcinoma cells KB were employed in this study. 
HeLa and KB cells were cultured in RPMI1640 media with no folic acid and HT-3 cells 
in McCoy’s 5A (Modified) media containing 10 % foetal calf serum, 100 U/ml of 
penicillin and 100 mg/ml streptomycin in 75-cm
2
 flasks. The following experiments 
were then set up for further studies including Western blot, fluorescent staining and 
flow cytometry analysis. 
 
3.4.2.3 Analysis of Cell Apoptosis by Flow Cytometry
 
 
Cells from the three different cell lines were seeded at 5 × 10
5
/ml in six-well culture 
plates and grown overnight for cell attachment. After 48 h of treatment (media only, 
5µM ATO encapsulating ATO-L1 and ATO-FA-L2 liposomes and 5µM free ATO), the 
cells were analysed for apoptosis induction via flow cytometry according to the protocol 
described for Annexin V–FITC/PI apoptosis detection kit (Abcam, UK) used for this 






3.4.2.4 Western blot analysis 
 
Expression of active caspase-3, p53, pRb, E6 and E7 proteins in the cell lines were 
determined by Western blotting as detailed in Chapter 2. The treatment was arranged as 
follows: media only, 5µM ATO encapsulated liposomes ATO-L1 and ATO-FA-L2 and 
5µM free ATO for a period of 48 h. The primary antibodies used were rabbit 
monoclonal anti-active caspase-3, mouse monoclonal anti-p53 and mouse monoclonal 
anti-Rb antibodies in 1:500 dilutions, mouse monoclonal anti-HPV 18 E7 in 1:1000 
dilutions and mouse monoclonal anti-HPV 18 E6 in 1:100 dilutions. The secondary 
antibodies employed were goat anti-mouse and goat anti-rabbit IgG-HRP antibodies in 
1 in 3000 dilutions. Protein quantification was done using REVERT total protein stain 
technique on Licor Odyssey imaging system.  
 
3.4.2.5 Fluorescent staining analysis  
 
Single fluorescent staining for active caspase-3, p53, pRb, E6 and E7 proteins and 
double fluorescent staining for E6 and p53; and E7 and pRb proteins in the cell lines 
under investigation were carried out as per the protocol described in Chapter 2. The 
cells were treated with media only, 5µM ATO encapsulated ATO-L1 and ATO-FA-L2 
liposomes and 5µM free ATO for 48 h. The primary antibodies used were the same as 
those used in Western blotting experiments. The dilutions used however for single 
staining for all the antibodies were 1:100 in PBS. The signal was amplified using ABC 
kit and detected via TSA Fluorescein system or TSA Cys-5 system. In case of double 
staining of E6/p53 and E7/pRb, the first primary antibody used was mouse monoclonal 
anti-HPV 18 E6 (1:50) and mouse monoclonal anti-HPV 18 E7 (1:100) respectively 
which was detected with TSA-Cys-5 system. The second primary antibody was rabbit 
polyclonal anti-p53 antibody (1:100) and rabbit polyclonal to pRb (1:100) respectively 
detected by secondary antibody goat anti-rabbit IgG conjugated with FITC (1:100). The 
nuclei were counterstained and the slides mounted using Vectashield hard set mounting 
media with DAPI. A confocal microscope (Leica Microsystems, Wetzlar, Germany) 
was used to capture the images of single and double fluorescent staining using the 
antibodies as described above.  
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3.4.2.6 Flow cytometry analysis of intracellular antigen staining 
 
The cells were stained for active caspase-3, p53 and pRb proteins with primary 
antibodies rabbit monoclonal to Rb (1:100 dilution), rabbit monoclonal to active 
caspase-3 (1:200 dilution) and mouse monoclonal to p53 (1:100 dilution). The 
secondary antibodies employed were goat anti-rabbit IgG-FITC and goat anti-mouse 
IgG-FITC (1:500 dilution) and flow cytometry analysis of the protein expression was 
carried out as per the protocol described in Chapter 2.   
 
3.4.2.7 Statistical analysis 
 
Statistical analysis described in experimental sections was done with Minitab17. 
Statistical significance was determined by 2-sample t-test. P< 0.05 was considered 
significant. For results from Western blotting studies, the signals were normalised using 
Image J software and mean and SD were calculated. For immunostaining results, an 
average number from positively stained cells in a total of six fields of each sample were 
calculated and average percentages were recorded. For flow cytometry, statistical 














3.4.3.1 ATO encapsulated in targeted liposomes induce higher apoptosis 
for HPV positive cancer cells than non-targeted liposomes  
 
HPV positive HeLa and KB cells were exposed to the following treatments as follows: 
control (cells in RPMI media only) and 5µM ATO encapsulating ATO-L1 and ATO-
FA-L2 liposomes for 48 h. They were further labelled with FITC-conjugated Annexin-
V and PI for the detection of early and late apoptotic populations respectively. The 
fluorescence was detected by flow cytometer on its FL1 and FL3 channels respectively. 
The percentages of cell populations distributed in the different quadrants depicting live 
(lower left), early (lower right) and late apoptotic/necrotic cells (upper region) were 
calculated and the fold increase of apoptotic population (early + late) from various 




Fig 3.4.2: Flow cytometry analysis of apoptotic cells in KB and HeLa after treatment with only media, 
5µM ATO encapsulating ATO-L1 and ATO-FA-L2 after 48 h treatment. An unpaired t test was used to 
test for any significant difference in the apoptotic population in cells after treatment with ATO-L1 and 
ATO-FA-L2. Targeted liposomal ATO induced more apoptosis than non-targeted liposomal ATO. *p ≤ 











































Results showed that ATO-FA-L2 induced higher apoptosis in both KB and HeLa cells 
than non-targeted liposomes. This difference was more pronounced for KB cells with 
ATO-FA-L2 treatment producing 2.5 times more apoptotic cells than the ATO-L1 
treatment; whereas it was 1.4 times higher with ATO-FA-L2 than ATO-L1 in HeLa 
cells. The unconjugated liposomal treatment, however, induced higher apoptosis in 
HeLa cells with 1.8 times more apoptotic cells than the control as compared to the 1.4 
times more apoptotic cells in KB.  
To further characterise the apoptosis observed in the targeted and non-targeted 
liposomal ATO treated cells, the expression of activated caspase-3 was investigated via 
Western blotting, confocal microscopy and flow cytometry analysis. Western blotting 
results clearly showed a distinct band of active caspase-3 at around 17kDa for the 
treated cells for both KB and HeLa cell lines. The band was very prominent for ATO-
FA-L2 treatment, fainter for ATO-L1 treatment while being negligible for the control. 
The signal intensity for the bands obtained was normalised employing REVERT total 
protein stain (Fig 3.4.3). As expected, the activation of caspase-3 was most pronounced 
in ATO-FA-L2 treated KB cell line. Active caspase-3 expression was observed to be 1.6 

















   
 
 






   
 
 
       
 
 
Fig 3.4.3 (a): Comparative Western blot analysis of active caspase-3 expression in KB and HeLa cell 
lines after ATO-L1 and ATO-FA-L2 treatment for 48 h; (b) relative protein expression levels on the 
two cell lines after normalisation with REVERT total protein stain as determined via Western blot.  
Data shown is means ± standard deviation from 3 independent experiments. Active caspase-3 is 
expressed more after ATO-FA-L2 treatment than ATO-L1. * p ≤ 0.05; ** p≤ 0.01 
 
The results obtained from Western blot were further corroborated by fluorescent 
staining of active caspase-3 in KB and HeLa cells after 48 h treatment (Fig 3.4.4). As 
with the Western blot, the expression of active caspase-3 was more prominent with 
ATO-FA-L2 treatment than ATO-L1 in both cell lines, while being almost negligible 
for control. The analysis of its expression via flow cytometry also validated the previous 
findings in that the targeted liposomal treatment was more efficient in activating the 




















































































































































   
 
Fig 3.4.4: Confocal microscopic examination of active caspase-3 expression in KB and HeLa cells 
following ATO-L1 and ATO-FA-L2 treatment. Cells were counterstained with DAPI to reveal the 
nuclear/ DNA location. ATO-FA-L2 liposomes activated more caspase-3 than ATO-L1 liposomes in 




Fig 3.4.5: Flow cytometry analysis of active caspase-3 expression in KB and HeLa cells post ATO-
L1 and ATO-FA-L2 treatment. Data shown is means ± standard deviation from 3 independent 



















































































3.4.3.2 Targeted liposomes are more efficient in downregulating oncogenes 
expression and upregulating tumour suppressors than non-targeted 
liposomes in HPV positive cells  
 
 
Expression levels of E6 and E7 oncoproteins and their relationship with pRb and p53 
tumour suppressors were investigated though Western blotting and single and double 
immunostaining of E6 and E7 oncoproteins and p53 and pRb tumour suppressors.  
 
Western blotting results clearly showed that targeted liposomal ATO was significantly 
more efficient in downregulating both E6 and E7 oncoproteins in KB and HeLa cell 
lines than non-targeted liposomal ATO (Fig 3.4.6). Moreover, it was also observed that 
compared to ATO-L1, the downregulation of their expression was higher with ATO-
FA-L2 treatment for HeLa cells than KB cells for both E6 and E7 proteins. The tumour 
suppressors’ p53 and pRb also displayed a marked increase in their expression with 
ATO-FA-L2 treatment for both the cell lines. However, in this instance, the fold 
increase of tumour suppressors with ATO-FA-L2 treatment, compared to ATO-L1 









































































Fig 3.4.6: Comparative Western blot analysis of E6, p53, E7 and pRb expression in KB and HeLa cell 
lines and relative protein expression levels on the cell lines after normalisation with REVERT total 
protein stain as determined via Western blot.  Data shown were expressed as means ± standard 
deviation from 3 independent experiments. Targeted liposomes ATO-FA-L2 were more efficient in 
inducing response than ATO-L1 in both cell lines for all the proteins investigated. *p≤0.05; **p≤0.01 


























































































































































































































































































































































































































































































































KB and HeLa cells were stained for E6, E7, p53 and pRb proteins after a 48 h exposure 
to 5µM ATO encapsulating non-conjugated and FA-conjugated liposomes. The cell 
lines were examined under confocal microscopy (Fig 3.4.7). The results corroborated 
the above Western blot findings as the expression levels of E6 and E7 oncoproteins 
diminished significantly more after ATO-FA-L2 treatment than ATO-L1 for both the 
cell lines. The tumour suppressors’ p53 and pRb expression levels were elevated 
instead, more significantly by ATO-FA-L2 than ATO-L1, for both KB and HeLa cells. 
The oncoproteins were expressed in the cytoplasm around the DAPI stained nuclei 
whereas both the tumour suppressors were localised within the nucleus.  
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Fig 3.4.7:  Confocal microscopic examination of E6-p53 and E7-pRb in KB and HeLa cells following 
ATO-L1 and ATO-FA-L2 treatment via single immunostaining. Cells were counterstained with DAPI 
to reveal the nuclear/ DNA location. ATO-FA-L2 liposomes downregulated oncoproteins and 
upregulated tumour suppressors more than ATO-L1 liposomes in both the cells. 
199 
Since the main oncogenecity of E6 lies in stimulating the degradation of p53 and E7 
with interfering in the function of pRb, their relationship was investigated in KB and 
HeLa cells after 48 h-liposomal ATO exposure though double immunostaining of HPV 
18 E6-p53 and HPV 18 E7-pRb (Fig 3.4.8). Along with validating the above findings of 
higher efficiency of ATO-FA-L2 in downregulating oncogenes while upregulating 
tumour suppressors, confocal staining results showed a slight difference in the 
expression of the p53 between the two cell lines. In ATO-FA-L2 treated KB cells, 
whereas p53 staining is found to be sharp and seen in fewer cells, it is diffused but 
present in more cells in HeLa. This is also seen with pRb staining, where HeLa cells 
display diffused staining in more cells as compared to KB cells, where the expression is 
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Fig 3.4.8:  Double immunostaining of E6-p53 and E7-pRb in KB and HeLa cells following ATO-L1 and 
ATO-FA-L2 treatment. Cells were counterstained with DAPI to reveal the nuclear/ DNA location.  
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3.4.3.3 FA-conjugated liposomes are selective in their action by targeting 
HPV positive HeLa cells more than HPV negative HT-3 cells.  
 
After establishing that FA-conjugated liposomes are more efficient in inducing 
apoptosis, reducing oncogene levels and increasing tumour suppressors in HeLa cells 
and with a final goal of selectively targeting HPV positive cervical cancers, their 
selectivity was further investigated by comparing  their action on HPV negative cervical 
cancer cells. Towards this aim, HPV negative cervical cancer HT-3 cell line was 
introduced and was subjected to unconjugated and FA-conjugated liposomal ATO 
treatment for 48 h. It was further examined for the abovementioned mechanisms by 
conducting the following experiments including apoptosis induction, expression of 
apoptotic protein active caspase-3 and tumour suppressors’ p53 and pRb.    
Results from flow cytometry apoptosis assay clearly indicated that ATO-FA-L2 
liposomes were more efficient in inducing apoptosis in HeLa cells than HT-3 cells (Fig 
3.4.9). Compared to the control, ATO-FA-L2 induced 2.6 times more apoptotic cells in 
HeLa whereas only 1.4 times more apoptotic cells in HT-3. The expression of active 
caspase-3 in HT-3 was investigated via Western blotting, immunostaining and flow 
cytometry and compared with HeLa. Western blotting results clearly showed that 
compared to the control cells, active caspase-3 was expressed much more strongly in 
HeLa than HT-3 following ATO-FA-L2 treatment (Fig 3.4.10). This was also evident 
from both the flow cytometry analysis of the apoptotic protein (Fig 3.4.11) and confocal 
analysis where active caspase-3 stained more strongly for HeLa cells than HT-3 cells 





Fig 3.4.9: Flow cytometry analysis of apoptotic cells in HeLa and HT-3 after comparing treatments with 
only media and 5µM ATO encapsulating FA-conjugated liposomes (ATO-FA-L2) post 48 h treatment. 
Targeted liposomal ATO-FA-L2 induced higher apoptosis in HeLa than HT-3; *** p≤0.001. Data 






   






     
      
 
 
Fig 3.4.10 (a): Western blots of active caspase-3 expression in HeLa and HT-3 cells after ATO-L1 and 
ATO-FA-L2 treatments for 48 h; (b) relative protein expression levels on the two cell lines after 
normalisation with REVERT total protein stain as determined via Western blot; only control and ATO-
FA-L2 protein levels are shown for comparison purposes.  Data shown is means ± standard deviation 
from 3 independent experiments. * p≤0.05. Active caspase-3 was expressed more in HeLa after ATO-FA-








































































































































Fig 3.4.11: Confocal microscopic examination of active caspase-3 expression in HeLa and HT-3 cells 




Fig 3.4.12: Flow cytometry analysis of active caspase-3 expression in KB and HeLa cells post control and 












































Further exploring the cause of lower apoptosis induced in HT-3 cells, the tumour 
suppressors’ expression was investigated. Western blot results showed that for both the 
tumour suppressors, there was a significant difference in their expression between HeLa 
and HT-3 cells when treated with ATO-FA-L2 liposomes, with HeLa expressing almost 
2.3 times more p53 and 1.3 times more pRb than HT-3 from their respective controls 
(Fig 3.4.13). The confocal images also show a consistent higher expression of both the 
tumour suppressors in HeLa cells as compared to HT-3 cells from ATO-FA-L2 

















Fig 3.4.13: Western blots of pRb and p53 expression in HeLa and HT-3 cells after ATO-L1 and ATO-
FA-L2 treatments for 48 h; (b) relative protein expression levels on the two cell lines after normalisation 
with REVERT total protein stain as determined via Western blot; only control and ATO-FA-L2 protein 
levels are shown for comparison purposes.  Data shown is means ± standard deviation from 3 independent 
experiments. * p≤0.05, **p≤0.01. p53 and pRb proteins were expressed more in HeLa cells after ATO-
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Fig 3.4.14: Confocal microscopic examination of p53 and pRb expression in HeLa and HT-3 cells 












3.4.3.4 Comparative study for oncogenes and tumour suppressors’ 
expression from free and FA-liposomal ATO treatment in HPV positive 
cells. 
 
HPV positive KB and HeLa cells were treated with free ATO to compare the drug’s 
mode of action when it is delivered in its free form as opposed to when it is delivered 
liposomally (ATO-FA-L2). A comparative study was thereby drawn and the results 
from Western blotting showed that free drug was more effective than ATO-FA-L2 in 
reducing the expression of E6 in both cell lines and E7 in KB cells (Fig 3.4.15). The E7 
expression, however, was comparable from both treatments in HeLa cells. Moreover, 

















When the cells were immunostained to be viewed under confocal microscope, images 
unexpectedly, did not show any significant difference in the expression of E6 for KB 
 




   
 
 





















































Fig 3.4.15: Comparative western blot analysis of E6, p53, E7 and pRb expression in KB and HeLa cell 
lines and relative protein expression levels on the cell lines after normalisation with REVERT total 
protein stain as determined via Western blot after 48 h treatment.  Only protein expression levels from 
control, ATO-FA-L2 and ATO treatment are analysed for comparison purposes here. Data shown is 

























































































































































































































































































































































































































































































































































and HeLa cells treated with ATO-FA-L2 or ATO (Fig 3.4.16). With E7 protein 
however, the results were the same as Western blotting, with an elevated expression for 
KB cells with ATO-FA-L2 treatment while no significant difference in HeLa cells with 
either treatments. The expression of tumour suppressors’ p53 and pRB was comparable 
with both the treatments for KB and HeLa cells.  
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Fig 3.4.16:  Confocal microscopic examination of E6-p53 and E7-pRb in KB and HeLa cells following 
ATO-FA-L2 and ATO treatment via single immunostaining. Cells were counterstained with DAPI to reveal 
the nuclear/ DNA location. Staining was comparable for ATO-FA-L2 and ATO treatments for all proteins 
except in the case of E7, where KB stained more with ATO than ATO-FA-L2. 
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The expression of tumour suppressors were further analysed with flow cytometry and 
corroborating the above findings, no significant difference in both p53 and pRb 
expression was observed with either treatment (Fig 3.4.17).   
 









Fig 3.4.17: Flow cytometry analysis of p53 and pRb expression in KB and HeLa cells post ATO-FA-L2 
and ATO treatment. Data shown is means ± standard deviation from 3 independent experiments. 
































































































































































3.4.3.5 Targeted liposomal ATO are more selective in inducing HPV 
infected cancer cell apoptosis and down-regulating HPV oncogenes  
 
FA-liposomal ATO had demonstrated high selectivity in targeting HPV positive 
cancers. However, as free ATO marginally showed higher efficiency in downregulating 
oncogenes more despite being comparably effective for tumour suppressors’ expression, 
free ATO was also tested whether it was as selective towards HPV positive cancers as 
the targeted liposomal ATO was. HPV negative HT-3 cells, henceforth, were incubated 
with free ATO for 48 h and investigated for apoptosis induction and tumour 
suppressors’ upregulation.  
Apoptosis assay via flow cytometry revealed that free ATO was not selective in its 
action by inducing high apoptosis in both HeLa and HT-3 cells unlike ATO-FA-L2 
which induced higher apoptosis only in HeLa and not in HT-3 (Fig 3.4.18). ATO 
treatment resulted in a significantly higher apoptotic population from ATO treatment in 
HT-3 than ATO-FA-L2 liposomal treatment. The apoptosis induced in HeLa from free 
ATO and ATO-FA-L2 treatment was observed to be comparable.  
 
 
Fig 3.4.18: Flow cytometry analysis of apoptotic cells in HeLa and HT-3 after treatment with only media, 
5µM ATO encapsulating FA-conjugated liposomes (ATO-FA-L2) and 5µM free ATO after 48 h 
treatment. Free ATO induced high apoptosis in both cell lines; * p≤0.05. Data displayed is mean ± SD 




















































Investigations into the apoptotic protein active caspase-3 expression also revealed the 
same findings in Western blot that whereas ATO-FA-L2 resulted in a higher expression 
of the protein in only HeLa cells, ATO treatment elevated the protein’s expression in 
both HeLa and HT-3 (Fig 3.4.19); probing its expression though immunostaining and 
flow cytometry also validated the above findings (Fig 3.4.20; Fig 3.4.21). Whereas 
staining for activated caspase-3 was similar for ATO-FA-L2 and ATO in HeLa cells, 
HT-3 displayed an elevated expression of the protein from ATO treatment only. Flow 
cytometry investigation also yielded the same result with a significant difference in the 
protein expression in HT-3 cells between ATO-FA-L2 and ATO treatment while being 






   
 
 






     
 
    
 
 
Fig 3.4.19: Western blots of active caspase-3 expression in HeLa and HT-3 cells after ATO-L1, ATO-
FA-L2 and ATO treatments for 48 h; (b) relative protein expression levels on the two cell lines after 
normalisation with REVERT total protein stain as determined via Western blot; the analysis of 
normalised intensity is shown only for control , ATO-FA-L2 and ATO protein levels for comparison 










































































































   
 
Fig 3.4.20: Confocal microscopic examination of active caspase-3 expression in HeLa and HT-3 cells 




Fig 3.4.21: Flow cytometry analysis of active caspase-3 expression in HeLa and HT-3 cells post ATO-

















































To further characterise the apoptosis induced in the cells, ATO-FA-L2 and ATO treated 
HeLa and HT-3 cells were further investigated for any upregulation of tumour 
suppressors resulting from the treatment. As expected, ATO treatment resulted in 
upregulation of both pRb and p53 in KB and HeLa cells. However, ATO-FA-L2 was 
effective in upregulating these proteins only in HeLa and not for HT-3 cells. Western 
blot results showed a significant difference in p53 and pRb protein levels in HT-3 while 
none for HeLa cell line from both the treatments (Fig 3.4.22). The results were further 
confirmed with similar staining of the proteins in HeLa for ATO-FA-L2 and ATO, 
while a significantly elevated staining for ATO treated HT-3 cells than ATO-FA-L2 




















Fig 3.4.22: Western blots of pRb and p53 expression in HeLa and HT-3 cells after ATO-L1, ATO-FA-L2 
and ATO treatments for 48 h; (b) relative protein expression levels on the two cell lines after 
normalisation with REVERT total protein stain as determined via Western blot; only control, ATO-FA-L2 
and ATO protein levels are shown for comparison purposes.  Data shown is means ± standard deviation 


























































































































































      
Fig 3.4.23: Confocal microscopic examination of p53 and pRb expression in HeLa and HT-3 cells 


















This study shows that encapsulating anti-cancer drug ATO in folate tethered liposomes 
enhances the drug’s specificity in selectively targeting HPV positive cancers. In 
addition to improving the therapeutic index of the drug, liposomal encapsulation makes 
it more efficient than its free form in selectively inducing apoptosis, downregulating 
HPV oncogenes and increasing the tumour suppressors’ expression in HPV cancer cells. 
This presents a potential approach of significantly increasing the potency and specificity 
of ATO towards management of cervical cancers of HPV origin. 
HPV, typically the high risk types, have been confirmed as the causal agents of cervical 
cancer (NeufCoeur et al., 2009; Shukla et al., 2009; Sutcliffe et al., 2010). HPV’s E6 
and E7 oncoproteins are the key potentiators of the oncogenic process and crucial in 
bringing about the host cell immortalisation and transformation (Mansur and Androphy, 
1993; Um et al., 2002).  E6 operates by mediating the tumour suppressor protein p53 
degradation, whereas E7 binds to and inactivates another crucial regulatory molecule 
pRb (Barbosa and Schlegel, 1989).  
 
The p53 tumour suppressor gene product is a nuclear-DNA binding phosphoprotein 
which plays an important role in DNA damage recognition, DNA repair, triggering 
cellular apoptosis after identifying genetic injury and cell cycle regulation (Bellamy, 
1997). Since it limits the oncogenic potential of viral oncogenes, viruses such as HPV 
have evolved counterstrategies to evade induction of apoptosis by stimulating 
ubiquitination and proteasome dependent degradation of p53 (Um et al., 2002). 
Similarly, pRb exhibits significant tumour suppressive properties by regulating cell 
cycle progression (Berman et al., 2008). Its overexpression results in G1 cell cycle 
arrest whereas its acute extirpation causes quiescent cells to re-enter cell cycle (Sage et 
al., 2003). In order to perform its inhibitory function, the hypophosphorylated form of 
pRb binds to and inhibits the E2F family of transcription factors (Trimarchi and Lees, 
2002).  HPV’s E7 disrupts this pRb-E2F bond and the E2Fs released induce the 
transcription of cellular genes essential for S-phase entry and cell division (Doorbar, 
2007). 
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Owing to the crucial role of p53 and pRb in cell cycle regulation and apoptotic 
responses, any factors which inhibit p53 and pRb may cause apoptosis inhibition, 
unchecked cell proliferation and loss of epithelial cell adhesion, leading to development 
of cancer (Dyson, 1998; Howie, Katzenellenbogen and Galloway, 2009; Nevins, 1998). 
Therefore, any strategy that can inhibit E6 and E7 protein expression and upregulate 
tumour suppressors’ p53 and pRb levels would be desirable as a therapeutic agent for 
managing HPV related cancers, including cervical cancers. 
 
ATO has been reported to downregulate E6 and E7 oncogene expression and increase 
p53 protein (Um et al., 2002; Wen et al., 2012). When encapsulated in liposomes to 
improve its therapeutic index, ATO was observed to be effective in reducing HPV-E6 
protein levels and inducing apoptosis in HPV positive HeLa cells 43, (Wang et al., 
2016; Wen et al., 2012). Following the synthesis and optimisation of targeted ATO 
encapsulating liposomes specifically for HPV cancers, herein we studied the mechanism 
of action of ATO on HPV positive and negative cells and any differences that might 
arise when ATO is delivered in its free form, within unconjugated and conjugated 
liposomes.  
 
Stable nanoparticulate form of folic acid tethered liposomal ATO were synthesised as in 
the previous results chapter. HPV-positive HeLa cells were employed for investigating 
the mechanism of action of ATO on HPV infected cervical cancer when being delivered 
in the abovementioned three disparate forms. Another HPV positive HeLa derivative 
nasopharyngeal KB cells and HPV negative cervical cancer HT-3 cells were used as 
control cell lines. FR expression on these cells was also investigated in the previous 
chapter III (ii) and the receptor was found to be expressed on the cell surface in the 
order of KB>HeLa>>HT-3 cells.  
 
The first hypothesis to be investigated was that conjugating liposomes with folic acid 
would increase the liposomal efficiency in targeting HPV positive cells while inducing 
apoptosis in those cells. This was based on the fact that HPV positive KB and HeLa 
cells were FR positive while HPV negative HT-3 displayed minimal FR expression. 
This hypothesis proved to be true when investigation of rates of apoptosis measured via 
flow cytometry demonstrated an increased efficiency of FA-conjugated liposomes over 
non-conjugated liposomes in inducing apoptosis in HPV positive cells. For this part of 
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the analysis, both KB and HeLa cells were treated with non-targeted and targeted 
liposomal ATO for 48 h. Results showed that among the liposomal delivery methods, 
ATO delivered via targeted liposomes had a clear advantage of inducing higher 
apoptosis in the HPV positive cells than non-targeted liposomes (Fig 3.4.2). Predictably, 
the level of apoptosis induction was dependent on the cellular uptake of arsenic which 
in turn was dependent on the FR expression on the cell surface. Since KB cells had a 
higher FR expression than HeLa cells, FA-liposomal ATO generated higher apoptotic 
population in KB than HeLa cells. Non-targeted liposomes, on the other hand, induced 
more apoptosis in HeLa as compared to KB cells. This observation was striking as 
HeLa cells were also found to display this definite susceptibility towards ATO delivered 
in liposomal form when compared to HPV negative HT-3 cells as shown in the previous 
chapter III (i).  
 
To further characterise the apoptosis induced in the cells, the expression of active 
caspase-3 was investigated via Western Blotting, confocal microscopy and flow 
cytometry analysis. Caspases are a class of cysteine proteases that are crucial mediators 
of apoptosis by cleaving key cellular proteins resulting in morphological features 
characterised by nuclear condensation and fragmentation (Miller et al., 2002). Among 
them, caspase-3 is a frequently activated death protease and its activation is a crucial 
requirement for many typical hallmarks of apoptosis (Porter and Janicke, 1999).   
 
Western blotting results showed that the targeted liposomal ATO treatment resulted in a 
significantly higher activation of caspase-3 than the non-targeted liposomal ATO for 
both the cell lines (Fig 3.4.3). This finding was consistent with the confocal microscopy 
results which showed a considerably elevated staining of active capase-3 in KB and 
HeLa cells incubated with ATO-FA-L2 compared to ATO-L1 liposomes (Fig 3.4.4). 
Results from flow cytometry analysis (Fig 3.4.5) also confirmed the above results which 
are consistent with the higher apoptosis observed with targeted liposomal treatment for 
HPV associated cancers.  
 
To examine the potential pathways for apoptosis induction in HPV infected cancer cells 
following liposomal treatment, the expression of the key potentiators of HPV related 
cancers, E6 and E7 oncoproteins and the tumour suppressor proteins’ p53 and pRb were 
investigated in KB and HeLa cell lines. Predictably, targeted liposomes were more 
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efficient than non-targeted liposomes in downregulating oncogenes expression and 
upregulating the tumour suppressors in both cell lines. The Western blotting results 
showed that in both KB and HeLa, there was a significant difference between the 
protein levels resulting from the two treatments, with targeted liposomes more efficient 
at reducing the oncoproteins levels and increasing tumour suppressors (Fig 3.4.6).  
 
Results also showed that non-targeted liposomes, however, downregulated E6 and E7 
proteins more in HeLa, compared to KB cells. This is in accordance with the above 
results where non-conjugated liposomes induced higher apoptosis in HeLa. 
Surprisingly, even the downregulation of oncoproteins following ATO-FA-L2 treatment 
was more in HeLa cells, despite KB cells having higher FR expression and 
consequently higher cellular uptake of FA-lipo-ATO. This result again points to the 
possibility of HeLa cells possessing higher sensitivity for liposomal treatment.  
 
Confocal microscopy images corroborated the above findings with targeted liposomes 
visibly reducing E6 and E7 protein levels in both KB and HeLa while elevating the 
expression of p53 and pRb more than the non-targeted liposomes (Fig 3.4.7). In 
addition, from the confocal images it could also be seen that the downregulation of both 
the oncoproteins and upregulation of tumour suppressors resulting from ATO-FA-L2 
treatment was more pronounced in HeLa cells when compared to KB cells, validating 
the Western blot results.  
 
To further understand the relationship between E6-p53 and E7-pRb, the cells were 
double immunostained and the images displayed a reciprocal relationship between the 
oncoprotein and the tumour suppressor it inhibits (Fig 3.4.8). When the liposomal 
treatment reduced the oncoprotein, a corresponding increase in the tumour suppressor 
that the oncoprotein associates with and inactivates, is demonstrated. These findings are 
consistent with the expected consequences of specific inhibition of HPV early gene (E6 
and E7) expression: after viral integration, the HPV-E6 protein of high-risk types of 
HPV binds to and stimulates p53 degradation, whereas E7 protein inactivates pRb. By 
inhibiting constituently expressed E6 and E7, p53 and pRb accumulates, inducing 




As with the previous results, ATO-FA-L2 is observed to be more efficient than ATO-L1 
in both cell lines. Interestingly, in the double immunostained images, the pattern of the 
increased staining of both tumour suppressors was different for KB and HeLa. For KB, 
though fewer cells expressed the suppressor proteins, the staining in each cell was 
abundantly elevated; unlike in HeLa, where more cells stained for the protein, but the 
expression level remained lower than KB cells. One hypothesis explaining this 
observation might be that KB cells, despite having a higher FR expression, might have a 
more heterogeneous distribution of the receptor among its cell population, whereas 
HeLa might possess a more homogenous distribution of the receptor. Therefore, 
targeted liposomes would enter some KB cells in a much higher concentration than the 
remaining cells, whereas they would enter more uniformly in the HeLa cells. However, 
this hypothesis requires further investigation which remains outside the scope of this 
study. 
 
After establishing the superiority of conjugated liposomes over non-conjugated 
liposomes in targeting HPV positive cells, it was essential to test their selectivity 
towards these cells as our main aim is to design drug carriers for ATO specifically 
targeting HPV positive cervical cancers. Towards this goal, HPV negative HT-3 
cervical cancer cells were also exposed to targeted liposomes for 48 h and their 
apoptotic responses along with their expression levels of tumour suppressors were 
investigated and compared with HPV positive HeLa cervical cancer cells. Investigation 
into the rates of apoptosis via flow cytometry analysis revealed that targeted liposomes 
were selective in their action by inducing significantly higher apoptosis in HeLa cells 
compared to the HT-3 cells (Fig 3.4.9). This was reflected in the much lower expressed 
levels of activated caspase-3 in HT-3 cells following ATO-FA-L2 treatment than HeLa.  
Predictably, analysis of the tumour suppressors’ expression levels also revealed that 
ATO-FA-L2 did not show much efficacy in enhancing their accumulation in HT-3 cells, 
unlike HeLa.  
 
Ligand conjugated liposomal encapsulation of ATO alleviated the drug’s off-target 
toxicity and increased their uptake in the targeted cells, as was observed in the previous 
chapter. However, to establish any superiority of liposomal ATO over the drug in its 
free form, it was crucial to investigate and compare their mode of action and finally, 
their selectivity towards cancers of HPV origin.  
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As the first step, the mode of action of ATO delivered free and in targeted liposomal 
form was compared to assess which delivery method is more effective, specifically for 
HPV positive cells. For that, KB and HeLa cells were exposed to both 5µM free drug 
and FA-conjugated liposomes encapsulating 5µM ATO for 48 h. Western blotting 
results showed that free ATO downregulated both the oncoproteins more than ATO-FA-
L2 in KB cells (Fig 3.4.15). For HeLa cells however, the results were a bit different 
where though free ATO downregulated E6 protein more than ATO-FA-L2, there was no 
significant difference observed for the protein E7 with either treatment. Moreover, 
despite the apparent higher efficacy of free drug in reducing oncogene expression, the 
results further disclosed that the amount of tumour suppressor proteins upregulated was 
comparable for both the treatments in KB and HeLa cells. A possible explanation for 
the results can be that the oncogene downregulation and tumour suppressors’ 
upregulation is not a strictly reciprocal phenomenon. E6 and E7 proteins, apart from 
inactivating p53 and pRb, have also been reported to cause immortalisation of cells 
though other pathways as well (Yim and Park, 2005). 
 
Fluorescent immunostaining corroborated the Western blot findings by displaying a 
comparable increase in tumour suppressors’ staining from either treatment (Fig 3.4.16). 
Additionally, the downregulation of E7 oncogene from free ATO treatment was more 
prominent in KB cells while being comparable for HeLa cells. Surprisingly though, 
confocal images deviated from the above findings by not showing any appreciable 
difference in the E6 staining in KB and HeLa cells following either treatment. To settle 
this disparity, Western blot results were given preference over confocal microscopy due 
to the former being a more robust, quantitative technique. The tumour suppressors’ 
expression was also analysed via flow cytometry and the results validated the above 
findings (Fig 3.4.17).  
 
Since specificity towards the targeted cells remains one of the most crucial requirements 
of an effective therapeutic agent, it was essential to assess the specificity of free drug for 
HPV positive cancer cells in the light of the knowledge that free ATO did prove to be 
more effective in downregulating oncogenes despite the tumour suppressors’ 
accumulation being similar from both the treatments. Henceforth, HPV negative HT-3 
cells were also assessed for apoptosis induction and protein expression analysis to 
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evaluate which of the treatments (free ATO or targeted liposomal ATO) was more 
specific in its action towards HPV positive cells.  
 
Results clearly demonstrated that unlike targeted liposomal ATO, free drug was not 
selective in its action. Apoptosis assay via flow cytometry revealed that free ATO 
induced similarly high apoptosis in both HeLa and HT-3 cells unlike the targeted 
liposomal ATO, which specifically induced higher apoptotic population in HeLa cells 
(Fig 3.4.18). This result was further confirmed when the investigation into the activation 
of caspase-3 revealed that whereas free ATO did not distinguish between HeLa and HT-
3 cells in activating caspase-3, resulting in similar high expression levels; ATO 
delivered in targeted liposomal form induced its activation significantly more in HeLa 
cells than HT-3. Moreover, in accordance with the apoptosis findings, the investigation 
into the tumour suppressors’ expression re-instates the non-selective mode of action of 
free ATO, increasing the tumour suppressors in both HeLa and HT-3; unlike ATO-FA-



















ATO has been established as an effective anti-cancer drug which has the potential to 
induce apoptosis and inhibit proliferation of various human cancer cell lines. However, 
its lack of specificity and off-target toxicity has necessitated research into various 
delivery methods which could efficiently overcome the above mentioned barriers and 
target specific tumours. Herein, we have shown a promising strategy for targeting HPV 
infected cancer cells using FA conjugated liposomal ATO. This active targeting 
approach, in addition to alleviating ATO’s toxicity, has higher selectivity for HPV 
cancers in inducing apoptosis, reducing HPV-E6 and E7 oncogenes and increasing the 
expression of tumour suppressor proteins’ p53 and pRb. Further investigation of 
molecular mechanisms of ATO delivered liposomally, employing active targeting 



























Cervical cancer has been and continues to be a major worldwide health concern, mainly 
in developing countries (Soliman, Slomovitz and Wolf, 2004). In the past few decades, 
great advancements have been made in understanding the molecular basis of the disease 
and most importantly, HPV has been consistently identified as the causal agent in its 
development. The current treatment entailing invasive procedures of surgery and 
chemoradiotherapy with debilitating side effects has sparked an intensive research into 
therapies which can specifically target HPV (Downs, 2011). As HPV encodes for 8 
genes, out of which E6 and E7 are the primary oncoproteins, any strategy that can 
control or inhibit these oncoproteins would be desirable for use as a therapeutic tool to 
manage HPV associated cancers, such as cervical cancer (Wen et al., 2012).  
 
Among the potential anti-cancer drugs, previous work has demonstrated that ATO 
reduces the oncogene E6 expression and can be used as an effective agent to treat HPV-
infected cervical cancer cells (Wen et al., 2012). ATO is a potent clinical agent for the 
treatment of acute promyelocytic leukemia and has demonstrated significant clinical 
success for other haematological malignancies (Wang and Chen, 2008; Zhu et al., 
2002). Clinical response of solid tumours following ATO treatment has been 
compromised despite reported anti-cancer effects against a variety of solid tumour cell 
lines. This is due to a requirement of much higher dosages for the treatment, which are 
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often accompanied with severe side effects (Dilda and Hogg, 2007; Liu et al., 2006). 
The requirement for higher dosages might be owing to the low half-life of plasma 
arsenic, ~12 h after IV administration (Ni et al., 1997). The in vitro studies also 
indicated that ATO was selective in its action only when it was used in low 
concentrations (~2µM), inducing cellular apoptosis and increasing p53 expression in 
HPV positive cervical cancer cells (Wen et al., 2012).  When the dosage was increased 
to 5µM however, most of the cells were killed from drug-induced toxicity, irrespective 
of HPV status (Wen et al., 2012).  
 
Therefore, an effective delivery system was needed which could reduce ATO’s off-
target toxicity and expand its clinical utility by increasing its accumulation at tumour 
sites, extending its circulation time in blood and specifically targeting HPV infected 
cancer cells (Allen and Cullis, 2004). Encapsulating ATO in liposomes was one such 
strategy which had the potential to improve the drug’s therapeutic index by reducing its 
side effects and increasing drug concentration in tumours through the EPR effect. In 
addition, if the liposomes were conjugated with targeting ligands, the encapsulated drug 
could be directed to the target sites with minimal disturbance to the surrounding cells 
and tissues (Allen and Cullis, 2004). 
 
Therefore, our research team encapsulated ATO in liposomes and investigated their in 
vitro anti-cancer activity for HPV positive cervical cancer cells (Wang et al., 2016). 
Liposomal ATO was found to have the effect of reducing HPV E6 expression and 
inducing apoptosis in HeLa cell, while being less toxic to normal cells. These results 
gave us a good starting point to further design our liposomal construct to be a targeted, 
robust, pH responsive nano-carrier capable of selectively delivering ATO to HPV 
infected cervical cancer cells. We also explored the anti-cancer effects of the 
liposomally delivered ATO and the mode of action of the liposomal ATO in comparison 
to the free form ATO. 
 
As the first step towards the design of such a drug carrying liposomal construct, we 
optimised the physical parameters of liposomes, mainly in terms of best size and charge, 
specifically tailored for our target cells. These factors play a crucial role in drug loading 
efficiency, liposomal stability and cellular uptake, and as their effect is dependent on 
cell types, we examined the effect of these factors for cervical cancer cells with varying 
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HPV status (Akhtar et al., 2018). Consequently, ATO encapsulating liposomes of 
different sizes (100 nm, 200 nm, and 400 nm) and different charges (neutral, positive, 
and negative) were synthesised and tested on HPV positive HeLa cells. All the 
liposomes were stable at 4°C for a month and were pH sensitive, allowing them to 
unload the drug cargo when pH was lowered to 6 or 5, as found in endosomes or 
lysosomes (Ira, Renate and Ari, 1986).  
 
Among the differently charged liposomes, neutral liposomes were found to be the best 
formulation as they had the highest encapsulation efficiency whereas negative 
liposomes were found to be unstable at higher pH and positive liposomes displayed 
toxicity of their own when incubated with cells for more than 48 h. When size of 
liposomes was taken into consideration, 100nm liposomes were found to be the most 
stable at all the pH range tested and since smaller nanoparticles are more adept at 
evading MPS (Danhier, Feron and Preat, 2010), we chose 100nm liposomes among the 
different sizes. Consequently, 100 nm, neutral liposomes were finally chosen as the 
most optimal carrier for ATO delivery and were used for further in vitro studies (Akhtar 
et al., 2018). 
 
The ATO encapsulating liposomes were investigated for their selectivity towards 
targeting HPV positive cells by incubating them with HeLa cells and this was compared 
with HPV negative HT-3 cells. Additionally, as one of the main aims of employing 
nanotechnology in pharmaceutics is to deliver the drug specifically to the cancer cells 
while sparing the normal cells, liposomal ATO was also assessed for its toxicity 
towards cells and intracellular uptake response profile in non-cancerous control cells. 
Two control cell lines were chosen for this study, namely human keratinocytes (HK) 
and human colon (CRL-1790) cells.   
 
A ratio of cell death induced to the amount of arsenic taken up by the cells was 
calculated for all the cell lines as it is an effective means of comparing the efficacy of a 
treatment on different cell populations- cancerous cells and normal control cells. For an 
ideal treatment, the cell death–uptake ratio would be low for normal cells and high for 
the target cancer cell population. Our results indicated that this ratio was indeed lowest 
for the control cell populations and highest for HeLa cells. Moreover, liposomal ATO 
was 71 times more toxic to HeLa cells than HT-3 cells per unit of intracellular arsenic. 
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In contrast, free ATO was more efficient in inducing a toxic response in HT-3 cells per 
unit arsenic, demonstrating the selective nature of liposomal ATO for HPV positive 
HeLa cells. This selectivity might be attributed to a possibility that when liposomal-
encapsulated ATO reaches the cells, it results in bio-physical changes in the cell 
membrane, in turn affecting the cellular transport systems. As different types of cells 
may react to these changes in different ways, HeLa cells appear to be more vulnerable 
to this drug treatment, which could be relevant to HPV. These results were evidence of 
the potential of liposomal-encapsulated ATO as a promising strategy for treating HPV-
positive cervical cancers (Akhtar et al., 2018). 
 
In the tumour microenvironment, these long-circulating PEGylated nanocarriers can 
take advantage of the EPR effect in accumulating within the tumour interstitium 
(Danhier, Feron and Preat, 2010). But unless there is a specific affinity between the 
nanoparticles and the target cancer cells, the chemotherapeutic payload would either 
have to reach its target on its own or endanger itself diffusing back to the vasculature 
(Dreher et al., 2006).  This affinity could be achieved by active targeting strategies with 
ligands decorated on the surface of the nanoparticles capable of binding to the receptors 
overexpressed in diseased cells (Kamaly et al., 2012).  
 
Hence, after optimising the physical parameters of the liposomes, the next step was to 
find the most appropriate ligand which could be conjugated to these optimised ATO 
liposomes, and this entire system could act as “homing device” to actively target HPV 
positive cervical cancer cells. Towards that aim, both HPV positive HeLa and HPV 
negative HT-3 cells were screened for the three most widely employed surface markers, 
i.e. folate receptor, transferrin receptor and epidermal growth factor receptor. The ideal 
surface marker would be the one that was most differentially expressed between the two 
cell lines, for instance, overexpressed in HeLa cells while minimally expressed in HT-3 
cells.  
 
Out of the three surface markers investigated, folate receptor was the most differentially 
expressed receptor by being highly expressed in HeLa and negligibly expressed in HT-3 
cells. Both the cell lines expressed transferrin receptors and EGFR, but the difference in 
their expression between the two cell lines was not as distinct as the folate receptor 
expression. Consequently, folic acid was the ligand of choice for our attempt in 
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designing targeted ATO liposomes for HPV positive cells. Folic acid, as a ligand, also 
offered other advantages, such as small size, low immunogenicity and ease of 
conjugation to the liposomal surface (Low and Antony, 2004; Dancey, 2001). Further 
validation for using folic acid as the ligand of choice was carried out by including two 
control cells lines, KB as positive control (FR+) and A549 as negative control (FR-) 
(Chen et al., 2009; Nukolova et al., 2011). The results indicated that folate receptor 
expression was very high for KB cells and negligible for the negative control, A549, 
validating the accuracy of the experiments. 
 
Reiteratively, in order to design folate targeted, ATO encapsulating liposomes 
specifically tailored for our target cells, there were few parameters that needed careful 
consideration and optimisation. First, folic acid had to be tethered to the PEG terminus 
instead of being attached to the phospholipid headgroup, to avoid masking of the 
ligand’s binding affinity to the target antigens by the surrounding PEG brush layer 
(Klabinov et al., 1991). Second, the presence of an unconjugated PEG brush layer was 
essential to prevent aggregation of the nanoparticles as was seen in the study. Ligand 
density on the surface of the liposomes also needed to be optimised as high ligand 
density could increase cellular internalisation but on the other hand, also make the 
nanoparticles more prone for aggregation in vitro and for recognition by MPS in vivo 
(Kamaly et al., 2012). After several trial and errors, employing 1.9 mol % of brush layer 
forming PEG and 0.1mol% of ligand conjugating PEG was found to give stable FA-
conjugated ATO encapsulating liposomes. Therefore, this formulation of FA-
conjugated liposomal ATO was used for the subsequent studies. 
 
Another parameter that needed optimising was the ligand conjugating PEG spacer 
length. Since some studies indicated that employing ligand conjugating PEG spacers of 
the same length as the surrounding PEG brush layer might result in the masking of the 
targeting abilities of the ligand, our first investigation was to assess this aspect (Lee and 
Low, 1994). For that purpose, we synthesised targeted liposomes having the ligand 
conjugating PEG spacer and surrounding PEG brush layer of equal length, i.e. 2000Da. 
We then evaluated the differences in cellular uptake with increasing incubation times 
from four different techniques: confocal microscopy, flow cytometry, fluorescence 
reading via plate reader and cellular arsenic quantification via ICP-MS.   
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The results from the all the techniques were consistent and indicated that FA-conjugated 
liposomes were efficiently and selectively taken up by the cells according to the status 
of FR expression on their cell surface. As folate receptor expression follows the order of 
KB>HeLa>> HT-3>A549 in cell lines, the cellular uptake of targeted liposomes also 
displayed the same pattern. As the time of incubation increased, the cellular 
internalisation of targeted liposomes in FR+ KB and HeLa cells also increased. 
Accordingly, the difference between the cellular uptake of targeted and non-targeted 
liposomes was maximum in KB and none for FR- A549 cells. It was also observed that 
this difference between the cellular uptakes of conjugated and non-conjugated 
liposomes decreased with prolonging the exposure time, which might be due to two 
contributing factors: an increase in non-specific uptake of unconjugated liposomes and 
subsequent decrease in the uptake of conjugated liposomes due to a possible saturation 
of the targeted receptors on the cell surface. Indeed, quantifying cellular arsenic via 
ICP-MS gave results that after an initial high surge of targeted liposomal arsenic intake 
by FR+ cells, the rate at which it was taken up almost invariably slowed down in 
comparison with non-targeted liposomes. This led to a bridging of the gap between their 
uptakes in cells.  
 
These findings established that folic acid conjugation to liposomes, even to a PEG 
spacer of similar length as the surrounding PEG brush, was able to effectively target the 
FR+ cells with improved efficiency and selectivity in comparison to the untargeted 
liposomal ATO. However, to be positive that the surrounding PEG layer was not 
masking conjugation abilities of the ligand, even to a small extent, we decided to  
conjugate folic acid to a PEG spacer of longer length and observe any further 
enhancement in ATO cellular uptake from FR+ cell lines. Since the previous studies 
had employed 3350Da for the PEG spacer length (Chen et al., 2009), we decided to use 
even longer PEG spacer length of 5000Da for making targeted liposomes and 
investigate a possible increase in cellular uptake along with any inherent toxicity that 
might arise from employing longer PEG spacers for ligand conjugation.   
 
Targeted liposomes were prepared with folic acid conjugated to PEG spacer of 5000Da 
length. The results on improving cellular uptake were obvious. Longer PEG spacer for 
FA conjugation made liposomes much more efficient in being taken up by the FR+ cells 
than liposomes with FA-PEG spacer of equal length to the surrounding PEG brush. This 
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enhancement was not evident for HT-3 and A549 cells due to the weak/ absent 
expression of FR by those cells. The superior performance of targeted ATO liposomes 
with 5000Da FA-PEG spacer thus made them a logical choice as the delivery vehicle of 
ATO. Moreover, results also showed that the presence of the longer FA-PEG spacer did 
not increase the liposomal construct’s inherent toxicity for any of the cell lines tested. 
Consequently, targeted liposomes with FA-PEG5000 PEG spacer was chosen as the 
optimised design for the targeted ATO nano-carrier as they had low inherent 
cytotoxicity along with their superior targeting abilities. 
 
In order to assess the performance of targeted liposomal ATO over free form ATO as a 
treatment for HPV positive cells, once again we calculated the abovementioned ratio of 
cell death induced to the amount of arsenic taken up by the cells following the 48 h 
treatment. The results indicated that this cell death-uptake ratio was higher from 
liposomal ATO treatment for both HPV positive KB and HeLa cells than from free 
ATO treatment, whilst the ratio was lower for HPV negative HT-3 cells. This indicated 
that liposomal ATO was more effective in inducing cell death to KB and HeLa cells per 
unit arsenic taken up while free ATO was more effective for HT-3 cells. Moreover, the 
ratio was highest for HeLa cells indicating the superior efficacy of the liposomal ATO 
treatment for this cell line. As a final part of this study, the mode of action of ATO 
when delivered in its free form or encapsulated in non-conjugated and conjugated 
liposomes was investigated and compared between each other and the best delivery 
method was identified to target and treat HPV positive cervical cancer cells in vitro. 
 
As mentioned earlier, the key proteins responsible for oncogenecity of HPV are E6 and 
E7 proteins which operate by inactivating two crucial negative regulatory molecules 
p53 and pRb respectively (Barbosa and Schlegel, 1989). Therefore, to investigate the 
mode of action of ATO delivered via the three disparate routes, emphasis was given to 
study the changes in expression levels of oncoproteins E6 and E7 and tumour 
suppressor proteins’ p53 and pRb following the treatment. Since the oncoproteins 
inhibit cellular apoptosis, the treated cells were also investigated for apoptosis induction 
and the expression levels of apoptotic protein, active caspase-3. The techniques 
employed were Western blotting, flow cytometry and confocal microscopy for protein 
expression analysis and flow cytometry for apoptosis induction studies. 
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The results from mechanism studies clearly showed that targeted liposomes were far 
more superior to non-targeted liposomes in inducing apoptosis response in HPV 
positive KB and HeLa cells. They resulted in a significantly higher activation of 
caspase-3, a crucial requirement for many typical hallmarks of apoptosis (Porter and 
Janicke, 1999). Additionally, they were more efficient in downregulating oncoproteins 
and upregulating tumour suppressors than non-targeted liposomes in both cells.  This 
could be caused from a significantly higher uptake of conjugated liposomes in FR + 
HPV infected cells.  
 
An interesting observation was that among the two HPV positive cell lines KB and 
HeLa, the non-targeted liposomes were significantly more efficient in inducing 
apoptosis and downregulating E6 and E7 in HeLa cells than KB cells. This result again 
pointed to a certain susceptibility of HeLa cells towards ATO delivered in liposomal 
form, which was previously noted while comparing its toxicity vs uptake ratio with HT-
3 cells (Akhtar et al., 2018). Moreover, even the downregulation of E6 and E7 
oncoproteins following targeted liposomal treatment was surprisingly more in HeLa 
cells than KB, despite KB having higher FR expression and consequently higher 
cellular uptake of targeted liposomal ATO. All these results suggest a possibility of 
HeLa cells possessing higher sensitivity for liposomal encapsulated ATO treatment, an 
aspect that warrants further investigation. 
 
Immuno-double staining of treated cells for E6-p53 and E7-pRb revealed an expected 
reciprocal relationship between the oncoprotein and the tumour suppressor it inhibits. 
When the liposomal treatment reduced the oncoprotein, a corresponding increase in the 
tumour suppressor that the oncoprotein associates with and inactivates, is demonstrated. 
These finding were consistent with the expected consequence of inhibition of HPV 
oncoproteins’ E6 and E7, which would lead to accumulation of p53 and pRb, induction 
of apoptosis and activation of the most common death protease, caspase-3.  
 
After establishing the superiority of targeted liposomes over non-targeted liposomes, the 
next step was to compare the anti-cancer activity of targeted liposomal ATO with free 
ATO for HPV positive cells. Results indicated that free ATO was more efficient in 
downregulating E6 and E7 in KB cells than targeted liposomes. Free ATO also 
demonstrated higher efficacy than targeted liposomes in downregulating E6 in HeLa 
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cells, but the expression of E7 was comparable from both the treatments. Surprisingly, 
for both KB and HeLa, the upregulation of tumour suppressors was comparable from 
either treatment.  
 
Acknowledging that ATO delivered in its free form appeared to downregulate 
oncogenes more than the targeted liposomes, even though the tumour suppressors were 
comparably upregulated from either treatment, it was important to further investigate 
which of the two delivery methods was more selective for HPV positive cells. This 
aspect was important as selectivity towards the target cells remain one of the most 
crucial requirements of an effective therapeutic agent. Towards this goal, HPV negative 
HT-3 cervical cancer cells were also exposed to targeted liposomes and free ATO for 48 
h and the apoptotic responses along with the expression levels of tumour suppressors 
were investigated and compared with HPV positive HeLa cervical cancer cells. 
 
Results clearly indicated that while targeted liposomal ATO was selective in its action, 
free ATO was not. Targeted liposomes induced significantly higher apoptosis in HeLa 
than HT-3. The upregulation of tumour suppressors and activation of caspase-3 were 
also more pronounced in HeLa than HT-3 following targeted liposomal treatment. In 
contrast, free ATO induced similarly high apoptosis in both the cells. Moreover, the 
investigation into the tumour suppressors’ expression and activation of caspase-3 
reinstated the non-selective nature of free ATO as it induced similar levels in both the 
cell lines irrespective of HPV status. These findings emphasized the advantages of 
targeted liposomes over other delivery methods (including free form or in non-
conjugated liposomes) as a therapeutic system for HPV positive cancers, including 







4.2 FUTURE WORK 
 
The high biocompatibility and versatile nature of liposomes have made these 
nanoparticles an excellent choice for transporting drugs specifically to target cancer 
cells. In the current research, we have shown a promising strategy for targeting ATO to 
HPV positive cervical cancer cells using folate-tethered drug encapsulating liposomes.  
These targeted liposomes were more efficient than non-targeted liposomes and more 
selective than free ATO in their action towards the target HPV positive cervical cancer 
cells, which establish them as the best delivery method of ATO to our target cells. This 
was also supported by the calculated cell death to uptake ratio as a comparative measure 
of the efficacy of a treatment for different cell populations, where FA-conjugated 
liposomal ATO induced higher toxicity in HPV positive HeLa and KB cells per unit 
arsenic taken up than free ATO.  
Investigations on the mechanism of actions of both liposomal delivered ATO and ATO 
in free form, however, demonstrated that free ATO downregulated oncogenes more 
efficiently than the targeted liposomes, even though the upregulation of tumour 
suppressors and apoptosis induction was comparable from either treatment. This brings 
us to a conclusion that the higher anti-cancer activity of ATO delivered through targeted 
liposomes maybe attributed to the activation of different or additional pathways. Some 
factors which warrant further investigations include mitochondrial toxicity, reactive 
oxygen species generation and accumulation, inhibition of transcription of hTERT gene 
(Chen et al., 2015). These investigations could provide an important basis for future 
attempts to co-encapsulate synergistic agents or alter liposomal composition in further 
improving the therapeutic potential of ATO. This could be important at understanding 
how we can design/synthesize better therapeutic vaccines for HPV infections and their 
associated cancers as most currently available HPV vaccines are for prevention 
purposes rather than therapeutics (Chabeda et al., 2018). 
Results from the current in vitro study is promising with targeted liposomal ATO as a 
potential therapy for cervical cancer, as the first stage in evaluating the therapeutic 
potential of a drug or drug delivery platform in cancer therapy is to test it on human 
cancer cell lines. In vitro studies, as demonstrated above, can be very useful in assessing 
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features such as nanoparticle uptake, subcellular localization, intracellular drug delivery 
and cytotoxic killing among others. In this study, human cancer cell lines such as HPV 
positive HeLa and HPV negative HT-3 served as the fundamental model in a monolayer 
culture in vitro. To substantiate this study further, it will be essential to include other 
cervical cancer cell lines, including HPV-16 SiHa and CaSki, HPV-18 ME-180 and 
HPV negative C33-A cells (Ordikhani et al., 2016).  
 
Acknowledging the fact that as tumour models, these two dimensional (2D) cell cultures 
have limited efficacy, the three dimensional (3D) in vitro models could be employed as 
they have been reported to indicate higher malignancy, invasiveness and drug 
resistance, characteristic of the in vivo tumour environment than cell cultures (Ordikhani 
et al., 2016). In vivo testing on xenograft models in athymic nude or severe combined 
immunodeficient mice and orthotopically implanted tumours with relevant 
microenvironments may further be employed to investigate crucial information about 
absorption, metabolism, distribution, toxicity, efficacy and excretion of nanoparticles in 
rodent models as appropriate (Zamboni et al., 2012). Once the formulation proves 
efficacious for experimental models, it then has to go through clinical trials to 


















4.3 CONCLUSION  
 
 
In conclusion, we have shown a promising strategy for targeting ATO to HPV positive 
cervical cancer cells using folate-tethered liposomes in vitro. In the initial step, 
liposomes were loaded with ATO and optimised in terms of best size and charge for the 
target cells. 100nm, neutral liposomes were observed to be the best formulation as they 
showed highest ATO encapsulation, maximum stability and least intrinsic toxicity. In 
the following in vitro studies, they displayed higher anti-cancer activity towards HeLa 
cells than either non-HPV cervical cancer cells or non-cancerous normal cells. The 
therapeutic efficacy of liposomes towards HPV positive cells was further enhanced by 
conjugating folic acid to the liposomes as the cells were found to overexpress folate 
receptor on their cellular surface. The resulting folate liposomal drug showed higher 
anti-cancer activity against HPV positive cancer cells and was more selective than free 
ATO by inducing higher apoptosis, downregulating oncogenes and upregulating tumour 
suppressors in HPV positive HeLa cells than other cell lines.  Future preclinical studies 
will elucidate the role of EPR passive targeting and folate-directed active targeting in 
vivo. Our results provide a rationale for ATO therapy in further animal studies through 
the folate-targeted liposomal delivery system. This targeting system can be extended to 
treatments of other HPV associated cancers, including urogenital cancer, upper 
respiratory tract cancers and other epithelial cancers associating with HPV infections in 
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